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I Introduction 
I.1 Recombinant vaccines 
Since Edward Jenner’s time (1798), comprehensive vaccination programs have prodigiously 
influenced human and animal health, saved millions of lives and billions of dollars worldwide. 
Immunization is the most effective, convenient and economical method for prevention of many 
diseases especially contagious infections. Conventional vaccines consist of attenuated or killed 
viruses, bacteria or inactivated bacterial toxins (toxoid), which are mostly administered 
parenterally. Although these types of vaccines are very effective, their production and 
administration are costly. Additionally, application may accompanied by side effects such as 
reversion of virulence due to imperfect attenuation or inactivation or even recombination or 
mutagenesis that could lead to generation of pathogens with higher contagious strength during 
production. 
Using attenuated or killed pathogens in vaccines eliminates the need to identify distinct protective 
antigens. Still safety and efficacy raise concerns. This could be alleviated by identification of 
protective antigens. By using the protective antigens, the safety of a vaccine combines with the 
advantages of focusing the immune response on an optimal target. Development in purification 
techniques refined previous production methods and provided large-scale manufacturing of 
extremely pure antigens. This led to the development of “purified subunit vaccines”. In this 
vaccination method, only the antigenic part of the pathogen is being extracted and, with or without 
modification, applied as vaccine. Hereby many previous hazardous contaminants are prevented 
(Ulmer et al., 2006). 
The emerging recombinant technologies provided a very safe and economical way for large-scale 
production of subunit vaccines (Farchaus et al., 1998; Ribot et al., 2006). The technology 
facilitates identification, extraction, amplification and modification of DNA/RNA fragments 
encoding the antigenic part of a pathogen for recombinant expression. To conquer a disease with a 
subunit vaccine, the first step is the identification of a suitable antigen with the ability to elicit a 
protective, long lasting immune response. The new generation of vaccines exploiting recombinant 
DNA technology is being called recombinant vaccines. They can be divided into two major 
groups: DNA and antigen-based vaccines. 
 DNA-based vaccine I.1.1
The use of DNA as vaccine is a new and promising approach in vaccination since it is safe (no 
infectious antigen is involved), specific, easy and economical. The term refers to induction of 
immune response against a protein(s) expressed in vivo (vaccine recipient) subsequent to the 
injection of plasmid DNA, therefore mimicking the live pathogen in immune system induction. 
The plasmid DNA is carrying an antigen-coding sequence under a host-specific promoter. This 
method is attractive due to its simplicity. It only requires plasmid construction, proliferation and 
extraction (Dertzbaugh, 1998).  
DNA vaccines are able to induce both humoral and cellular immunity (Chang et al., 2001). 
Cytotoxic T lymphocyte (CTL) response is usually efficiently induced when the antigen is 
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expressed by the host cells (Ulmer et al., 2006). Especially when the antigen is expressed in 
antigen-presenting cells (APCs), it most likely leads to major histocompatibility complex (MHC) 
class II as well as class I presentation (Condon et al., 1996; Casares et al., 1997). It was shown that 
DNA vaccines also have the potential to induce a potent systemic immune response (Donnelly et 
al., 1997; Davis and McCluskie, 1999). DNA vaccines are mostly administered parenterally by 
intramuscular or interadermal injection (named “naked DNA”). So far, they show moderate 
immune response stimulation in human but two veterinary vaccines, one for horse and one for 
farm-raised salmon, have already been licensed (Brun et al., 2011). Therefore, an optimal delivery 
strategy should be found to increase DNA vaccine potency (Ulmer et al., 2006). To induce 
mucosal immunity mucosal administration of DNA vaccines has also been accomplished 
(McCluskie and Davis, 1999). The main drawbacks of DNA vaccines are the need for large 
amounts of DNA to achieve protective immune response in large animals and human and the slow 
development of a strong immunity (which limits the application in disease outbreaks where quick 
control in required). Last but not least, DNA vaccines can trigger disease exacerbation instead of 
protection if a non-proper antigen and administration pathway is chosen (Brun et al., 2011). 
Improvement in immune response induction has been tried by realizing enhanced plasmid uptake 
by exploring various administration routes such as electroporation or gene-gun, delivery of 
vaccines in association with cytokines (Littel-van den Hurk et al., 2004) and by co-delivery of 
DNA vaccines, adjuvant and cytokines to exploit different local subsets of antigen presenting cells 
(APCs) (McKay et al., 2004). Although the risk of DNA integration into the host genome is one of 
the main concerns, it was shown that the frequency is less than the frequency of spontaneous 
mutation (Gravier et al., 2007; Donnelly et al., 2005).  
Alternatively, live viral vectors have been introduced instead of plasmid DNA. These vectors have 
been derived from adenovirus, poxviruses or alpha viruses, which have been investigated so far for 
carrying the gene of interest for vaccine application. Although manufacturing viral vector-based 
vaccines are more complicated, they are more immunogenic than naked DNA vaccines 
(McConkey et al., 2003). Vector design, genetic stability, producer cell lines, virus propagation 
and purifications and product characterization are the main challenges to ensure the safety and 
quality of vector-based vaccines. 
 Antigen-based vaccine (subunit vaccine) I.1.2
Known protective antigens are expressed recombinantly in a heterologous expression system and 
formulated for further vaccine application. Using a specific protective antigen guaranties the 
induction of specific and focused immune response. Such antigen-based or subunit vaccines raise 
less concern than conventional vaccination methods since administration of live or killed 
organisms to the recipient is not required. Also, recipients are not transiently transformed with 
foreign genetic materials as is essential in DNA vaccination. Moreover, the chemical composition 
and the processes used for production of subunit vaccines should be thoroughly defined. Using 
well-characterized organisms as expression hosts may reduce the risk of contamination of the 
target antigen with harmful agents. However, most of the recombinant systems have certain 
limitations in synthesizing the antigen in proper immunogenic form. With respect to post-
translational modifications, lack of glycosylation in prokaryotic organisms and hyperglacosylation 
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in yeasts are the major concerns. Other issues in developing subunit vaccines are related to the 
high cost for production and downstream processing based on the need for expensive fermentation 
systems, manufacturing, purification and the procedure required to adjust the dosage. Thus, finding 
new expression systems with high expression level, easy purification procedure is crucial in 
reducing the costs.  
In contrast to live attenuated pathogens which attack and replicate in the host body in natural 
manner and normally elicit strong immune responses, recombinant subunit vaccines lack this 
characteristic and are inherently less immunogenic. To enhance immunogenicity to a protective 
level it is necessary to adapt the vaccine formulation and vaccination regime by using a strong 
adjuvant and several boosts, respectively (O’Hagan, 1998; Brun et al., 2011). Recently, virus-like 
particles (VLPs) and subviral particles (SVPs) have received great attention due to their potential 
application in vaccine development as well as in drug targeting and gene therapy (Zhao et al., 
2011). VLPs are composed of one or more recombinantly expressed viral proteins, which 
spontaneously assemble into supermolecular structure. VLPs have the same size and morphology 
as the parent virus, whereas SVPs are smaller in size or possessing a lesser degree of organization 
than a comparable intact viral particle because the parent virus comprises several different coat 
protein subunits while SVPs are homomeric (Tsoka et al., 2000; Brumfield et al., 2004; Allnutt et 
al., 2007; Brown et al., 2009; Manzenrieder et al., 2011). VLPs and SVPs, like the viral particles 
of their origin, are robust, symmetrical uniform nano-scale structures, but in contrast to them, are 
devoid of the genome. Therefore, they mimic the structure of the native virus but provide a non-
replicative but immunogenic form, which provides a safe tool for a vaccine approach (Roy and 
Noad, 2008). Moreover, lacking the genome prevents any risk associated with virus replication, 
mutation, reversion and reassortment (Jennings and Bachmann, 2008). Both VLPs and SVPs have 
shown strong immunogenicity due to their strong stability and multivalency of antigen 
presentation. Their strong immunogenicity in stimulation of humoral and cellular responses may 
compensate for the need for an adjuvant to induce a strong immune response in vaccination 
(Grgacic and Anderson, 2006). In addition, antigenic particles are efficiently taken up by M cells 
and dendritic cells (DCs) in the small intestine when orally administered and consequently lead to 
an improved stimulation of immune cells. So far, only two kinds of VLPs have been licensed as 
commercial vaccines for application in humans, which are only administered through injection: the 
human papillomavirus and Hepatitis B vaccines are the first VLP-based vaccines approved by the 
Food and Drug Administration (FDA), but many others are still in preclinical trials (Brun et al., 
2011). Also, in veterinary vaccination some VLP and SVP-based vaccines have been generated 
such as Porcine parvovirus, equine Rhinitia A virus, Bluetongue virus, Chicken anemia virus and 
Infectious bursal disease virus (IBDV) (Crisci et al., 2012). But among them, only the Porcine 
parvovirus type2 (PCV2) VLP-based vaccine found the way to the market under two brands name 
Ingelvac CircoFLEX (Boehringer Ingelheim, Germany) and Porcilis PCV (Intervet International, 
he Netherlands). 
In the last decades, plants have been investigated as alternative systems for production of subunit 
vaccines (Tiwari et al., 2009). Even though sometimes low expression levels due to poor protein 
folding and low stability in plants create a bottleneck (Fischer et al., 2004), the excellent scalability 
(Kusnadi et al., 1998; Yonekura-Sakakibara, 2006) and cost efficiency (Hood et al., 2002) as well 
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as their potential use in direct oral delivery of vaccines make them very attractive compared to 
conventional microbial and mammalian production systems. In addition, plants are free of human 
and animal pathogens (safety). Finally, a major advantage of using plants for animal vaccines is 
that the plant constituents such as pigments, alkaloids and polyphenols as well as plant sugar 
structures are able to stimulate both innate and acquired immunity (Bae et al., 2003; Paul and Ma, 
2010; Bosch et al., 2010; Malabadi et al., 2011). 
However, the vast majority of recombinant proteins, especially therapeutics including vaccines are 
still successfully produced in microbial systems (Allnut et al., 2007; Lin et al., 2012) or 
mammalian cell cultures. For example, Pichia pastoris has many of the advantages of higher 
eukaryotic expression systems such as protein processing, protein folding, and posttranslational 
modification, while being as easy to manipulate as Escherichia coli or Saccharomyces cerevisiae. 
It is faster, easier, and less expensive to use than other eukaryotic expression systems and generally 
gives higher expression levels. It shares the advantages of molecular and genetic manipulations 
with Saccharomyces, and it has the extra advantage of 10- to 100-fold higher heterologous protein 
expression levels. Both S. cerevisiae and P. pastoris have a majority of N-linked glycosylation of 
the high-mannose type; however, the length of the oligosaccharide chains added post-
translationally to proteins in Pichia (average 8-14 mannose residues per side chain) is much shorter 
than those in S. cerevisiae (50-150 mannose residues) (Grinna and Tschopp, 1989; Tschopp et al., 
1987b). Very little O-linked glycosylation has been observed in Pichia. These features make Pichia 
very useful as a protein expression system especially for vaccine production. Presently, P. pastoris 
is one of the most heterologous systems being extensively used for commercial production of high 
valuable proteins such as pharmaceuticals (Li et al., 2012), enzymes (Wongwisansri et al., 2012; 
Soares-Costa et al., 2012) as well as vaccines (Jha et al., 2007). Pichia system like plant cells is 
free of pathogenic and toxic hazards. 
I.2 Vaccine administration  
 Parenteral immunization I.2.1
Parenteral immunization (injection or shot-based vaccination) is the most common method of 
vaccine administration. There are various ways of administration (e.g. subcutaneous, intravenous, 
interadermal, intramascular). By these methods, the quantity of vaccine can be easily controlled 
resulting in a measurable antibody and lymphoid response in the blood. This procedure quite 
efficaciously elicits protective immunity. But there are also some objections, for example the need 
to cold chain transportation and trained medical personnel, needles and syringes requirement, 
which increases the cost of administration and restricts the accessibility to mass endangered 
populations. Moreover, using needle and syringe imposes fear and stress, which has a negative 
effect on vaccination efficiency and increases the risk of infectious transmission. Due to the 
mentioned concerns, immunization without needles and syringes has been received great interest 
(Aziz et al., 2007).  
 Mucosal immunization I.2.2
In contrast to parenteral immunization, mucosal immunization is inexpensive, more safe and 
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acceptable. It provides rapid immunization of a population with less concern. Moreover, mucosal 
immunization stimulates the mucosal immune system as a first frontier line in preventing many 
pathogens to enter the body, the event which is absent in parenteral immunization. Many 
pathogens enter the body via mucous membranes either orally, nasally or genitally. In conjunction 
with skin, these membranes make a comprehensive anatomical barrier that constitutes the first line 
of defense against pathogens. These mucosal membranes are defended by an underlying well-
organized mucosal lymphoid tissue (MALT). The MALT can be divided into tissues such as 
GALT (gut-associated lymphoid tissue), BALT or NALT (bronchus/nasal- associated lymphoid 
tissue), RALT (rectal associated lymphoid tissue), genitourinary tract, etc. Secretory 
immunoglobulin A (SIgA or S-IgA) is the main part of the mucosal immune system. Moreover, 
mucosal immunization also leads to the generation of systemic immunity by producing serum 
immunoglobulin G (IgG). Thus, SIgA is of primary importance for the host defense not only 
against mucosal pathogens but also pathogens causing systemic diseases. Therefore, SIgA provide 
two layers of defense against mucosal pathogens (Salyaev et al., 2010).  
To mimic the effect of the pathogen on the immune system and to induce immunity in the same 
manner by vaccination, choosing the mucosal route for delivery of the vaccine is crucial. The gut-
associated lymphoid tissues (GALT) are the primary targets for the oral delivery of vaccination. In 
the oral immune system, antigens are delivered via the gastrointestinal tract to inductive sites of the 
mucosal system named Payer’s patches, a large cluster of lymphoid follicles. The surface of 
epithelia in Payer’s patches regions constitutes of a single layer of cells known as follicle-
associated epithelium (FAE). These regions contain dispersed microfold cells (M cells) in the 
structure underlying the FAE. M cells provide transportation of intact macromolecules and 
microorganisms across the epithelial barrier to sub-epithelial dendritic cells (DCs), which are 
subsequently being presented in the adjacent mucosal T-cell area (Neutra and Kozlowski, 2006).  
The abundance of M cells is quite low but it was shown that the FAE can alternate its epithelial 
and lymphoid cell populations in response to antigen stimulation (Kerneis et al., 1997). The 
epithelial layer has a crucial role in the immune system by constant delivery of antigens from the 
intestinal lumen to underlying GALT via M cells. Beneath the M cells, highly compartmentalized 
follicles are settled. This region is rich in B cells as well as T cells, macrophages and DCs (figure 
I.1). M cells are physiologically and morphologically different from epithelial cells and are 
specialized to uptake particulate antigens. They lack brush microvilli and have a thin layer of 
glycocalyx. Besides, they have relatively smaller vesicles and less lysosome, which contribute to 
the relative intact delivery of antigens to APCs (Aziz et al., 2007). This characteristic opens a 
gateway for some pathogens such as Salmonella and Vibrio cholera to enter the body via M cells 
and cause disease. A positive aspect is that M cells facilitate an entranceway for micro/nano 
particle and mucosal vaccines to stimulate mucosal immune response (Neutra et al., 1996).  
M cells also have deep invagination in the plasma membrane, which facilitates a strong contact 
with lymphocytes. When antigens are taken up and transcytosed through M cells, they are mainly 
digested and presented by DCs (Kelsall et al., 1996). The antigen-loaded DCs migrate to local 
lymph nodes where they present the antigen to naïve lymphocytes, which originate from the blood. 
This interaction leads to lymphocyte maturation. Thus, they were subjected to clonal selection, 
class switching and expansion under the effect of presented antigen by activated APCs and 
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cytokines. These antigen-specific B cells along with T cells including helper T cells (Th1/Th2) and 
cytotoxic T lymphocytes (CTLs) migrate to mesenteric lymph nodes (MLNs) and travel to 
mucosal effector sites such as intestinal mucosal respiratory and genital tract. MLNs serve as a 
connector between peripheral lymph nodes and mucosal recirculating pathway. 
 
 
Figure I.1 The schematic feature of mucosal immune system in the gut. Inductive sites of mucosal 
immunity are constituted by MALT (mucosa-associated lymphoid tissue) with their B-cell follicles and M 
cells that pass the antigen from the lumen to antigen presenting cells (APCs) including follicular dendritic 
cells (FDCs), macrophages and B cells. In addition, dendritic cells (DCs) may receive the antigen at the 
effector sites. APCs move to local lymph nodes, become active and stimulate naïve T and B cells. APCs 
also move to mesenteric lymph nodes via lymphatic vessels and stimulate Naïve T and B cells reside there. 
Stimulated lymphocytes proliferate and migrate from lymph nodes, distribute to peripheral blood and finally 
localize at mucosal effector sites. Differentiations of SIgA B cells take place during their dispersion to the 
effector sites. At effector site, e.g. gut lamina propria, many T helper cells (CD4+) and B cells reside. B cells 
start to secrete J-chain expressing IgA (dimmers/polymers) and IgM (pentamers). The generated secretory 
IgA (SIgA) and secretory IgM (SIgM) interact with pIgR (polymeric Ig receptor or secretory component 
(SC)-mediated epithelial transport) on the surface of epithelial cells and transferred by transcytosis to the 
other side of the cell and into the lumen. The secretory component (SC), which is part of pIgR, is added to 
the antibody polymer to protect it from enzymatic degradation. Finally, the expression of memory/effector 
T cells can take place within the surface epithelium. The small picture in the left down corner shows an M 
cell and its “pocket” containing different cell types. Figure reference is Brandtzaeg et al. (2008). 
 
Activated lymphocytes enter to the blood stream and leave it when they reach to the effector sites 
such as lamina proporia. In lamina proporia, IgA-committed B cells interact with T cells 
moderated by cytokines, TGF-β (transforming growth factor-β) and IL-10 (Interleukin-10), which 
are produced by T cells, subsequently leading to the production of SIgA (Guy-Grand et al., 1974; 
Brandtzaeg et al., 2008). A large number of activated B cells (IgA plasma cells) reside in these 
sites and start to secrete IgA. Polymeric forms of the IgA produced by mucosal plasma cells bind 
to a glycoprotein named polymeric Ig receptor (pIgR) on the surface of epithelial cells. This 
receptor mediates external transport of dimeric and polymeric forms of IgA and is cleaved from it 
on the luminal epithelial face. Thus, the polymeric form of SIgA secretes to the lumen while 
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carrying a part of pIgR, which is known as secretory component (SC). In this manner the local 
mucosal immunity is induced and by producing memory/effector B and T cells and secretion of 
IgA, inhibits the pathogen to interact with receptors on the mucosal cell surface and consequently 
stops the pathogen in the preliminary stage of entrance. Thus, the long-term mucosal as well as 
systemic immunity is generated as a result of cooperation between epithelial cells, B and T cells 
and stimuli elicited by Th1, Th2 and cytokines. This explains why mucosal vaccination is essential 
to protect against mucosal pathogens. Interestingly, stimulated lymphocytes in the GALT mainly 
tend to return and reside in the mucosa of their origin (gut: their inductive site) and differentiate 
into effector/memory cells. This process that directs and recruits certain lymphocytes to become 
activated in order to remove mucosal antigens in certain parts and as a result limits their presence 
in specific organ, is called “homing”. This compartmentalization within the mucosal immune 
system has a great impact on choosing the proper vaccination route to induce effective immune 
responses in the target sites (Holmgren and Czerkinsky, 2005). Accordingly, oral immunization 
induces antibody response in small intestine, ascending colon, mammary and salivary glands. 
Nasal vaccination in human elicits immunity in upper airway mucosa, regional secretions (saliva 
and nasal secretions) and vaginal organs. Conversely, rectal and vaginal vaccinations lead to just 
local immune response (Holmgren and Czerkinsky, 2005).  
 Challenges in mucosal immunization I.2.2.1
Exploiting attenuated bacterial or viruses either for immune-stimulation against their own antigens 
or recombinant antigens, which are carried and presented by them has been accomplished as 
vaccine application (Yin et al., 2010; Brennan et al., 2001; Hwang, 2010; Schoen et al., 2004; 
Vajdy et al., 2004). Despite the advantages of mucosal vaccines, just few vaccines of this type are 
approved for human use. Examples are Poliovirus, rotavirus, Vibrio cholera, Salmonella typhi 
Ty21 (against Typhoid), Vibrio cholera, Rotavirus and attenuated and nasal influenza vaccines, 
which are licensed for human use (McCluskie and Davis, 1999; Holmgren & Czerkinsky, 2005; 
Salyaev et al., 2010).  
Oral delivery of subunit vaccines is an attractive option due to its safety, cost-effectiveness and 
easy handling properties. The main concerns of mucosal vaccine delivery are: (1) the vaccine 
should be protected from low pH and enzymatic digestion, (2) proper targeting to mucosal 
inductive sites or M cells (3) proper stimulation of the innate immune response to generate 
effective adaptive immunity. 
During the relatively long journey of the oral vaccine from the mouth to the inductive site (small 
intestine) through the gastrointestinal tract, it encounters to obstacles such as acidic pH and 
proteolytic environment. These obstacles may partly degrade the vaccine before reaching the 
inductive sites and consequently decrease the efficacy of the vaccination. Therefore, in contrast to 
parenteral immunization, it is difficult to measure the actual dose of mucosally delivered vaccine 
reaching the inductive sites resulting in the stimulation of the immune system. To achieve 
immunogenicity, either a large amount of vaccine should be administered or the antigen should be 
protected from acidic pH and proteolysis through encapsulation. In addition, the majority of 
vaccine is not immunogenic when delivered mucosally and need to be co-administered with strong 
oral adjuvants (Salyaev et al., 2010) and/or efficiently being targeted to the M cells.  
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Using lipid-based structures with entrapped antigen (Copland et al., 2005), various types of 
biodegradable complexes (Rieger et al., 2009; Mishra et al., 2010; Garg et al., 2010; Demento et 
al., 2010), different mucosa-binding proteins including either classical plant lectin or bacterial 
proteins such as the binding subunit protein of cholera toxin or E. coli heat labile enterotoxin, 
which are linked either chemically or as gene fusion protein to antigens, have been addressed 
(Holmgren and Czerkinsky, 2005). In addition, synthetic oligodeoxynucleotides (ODNs) such as 
CpG motifs (CpG ODN), which resembles genomic DNA extracted from E. coli (poephogus 
grunniens strain) (McCluskie et al., 2000; Dar et al., 2009) and co-administration of cytokines and 
chemokines (Staats et al., 2001; Eo et al., 2001; Lillard et al., 2001) have been introduced as 
promising methods for increasing the vaccine efficiency. 
In the late 1990’s, a novel approach known as “edible plant vaccines” received great interest 
(Mason et al., 1996; Yu et al., 2001). Transgenic plants that produce the target antigen are 
promising tools for mucosal delivery of large amounts of protective antigens in a plant cell-
encapsulated form. Plant cell walls protect the antigen from harsh environmental condition and 
enable it to reach the inductive sites (Streatfield, 2006). Transgenic plants such as tobacco, potato, 
lettuce, spinach, tomato, carrot, pea, alfalfa and soybean have been used for plant-produced 
vaccines (Fischer and Schillberg, 2004). Plant-made mucosal vaccine have several advantageous 
including, low cost of production due to elimination of downstream processing of traditional 
vaccines such as purification, sterilization and cold chain transport. Plant systems are free of 
human and animal pathogens. In addition, plant expression system facilitates post-translational 
modifications, which may be essential for antigen folding into the immunogenic form. Plants are 
the majority part of human and animal’s diet therefore can carry a large amount of vaccine with 
less concern about inducing allergic and autoimmune diseases.  
Mucosal delivery of plant-produced antigen has been accomplished in several cases and led to the 
generation of antigen-specific antibodies in mice and humans such as in vaccination against 
cholera (Davoodi-Semiromi et al., 2009), rabies (Yusibov et al., 2008), Norwalk virus (Zhang et 
al., 2006), diarrhea (Tacket, 2007) and hepatitis B (Thanavala et al., 2005). Some of the plant-
produced antigens are currently in preclinical and clinical trials (Davoodi-Semiromi et al., 2009). 
Despite the great appeal of plant-derived vaccines, up to now only one animal vaccine against 
Newcastle disease in chicken has achieved approval by the USDA, but due to a strategic decision 
of the responsible company, Dow AgroSciences (Indianapolis, USA), the vaccine has not been 
introduced into the market although the plant-produced product was compatible to others produced 
in alternative production hosts.  
A major challenge in oral vaccine delivery is that a 1000-fold dose needs to be administered orally 
in comparison with parenteral delivery. However, the normal yield range in plant expression is 
0.01-0.4% of total soluble protein (TSP) (Salyaev et al., 2010) which is often too low to provide 
sufficient amounts for immunization.  
The yeast expression system P. pastoris has also been widely used for the expression of viral and 
bacterial antigens (Lin et al., 2012). Pichia is also not pathogenic for human and most of the 
animals. Expression of recombinant proteins in Pichia is faster, more simple and less expensive 
compare to other eukaryotic expression systems (Ruth et al., 2010).  
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Until 2009, about 20% of the produced recombinant biopharmaceuticals on the market were 
produced in yeast systems, nearly all in S. cerevisiae. In 2009 the first biopharmaceutical protein, 
Kallikrein inhibitor (Kalbitor by Dynax Inc.), produced in P. pastoris was approved by the FDA 
(Mattanovich et al., 2012). Shanvac-B, antigen of hepatitis B virus (HBsAg) produced in Pichia 
was also approved in Indian market (Chakma et al., 2011). 
 Oral tolerance I.2.2.2
The mucosal immune system should protect the individual from attacking pathogens while being 
tolerant against innocuous substances found in food. Accordingly, oral immunization has the 
potential to induce either protection or oral tolerance corresponding to the administered antigen. As 
a consequence the immune system is paralyzed in response to the relevant pathogen. It was shown 
that the induction of oral tolerance is related to the route of antigen internalization. Passing through 
intestinal epithelial cells instead of lamina proporia and transport through blood vessels to the liver 
induce oral tolerance (Mayer and Shao, 2004). In other words, inefficient transport of the antigen 
from the gut lumen to the GALT may induce system immune tolerance. Orally delivered subunit 
vaccines that are composed of soluble, nonparticulate antigens are inherently less immunogenic 
and can induce oral tolerance. The effectiveness of mucosal vaccines dramatically increases when 
the antigens are multimeric and/or in particulate form. From this aspect, VLPs and SVPs are 
promising mucosal vaccines due to their size and subsequent uptake by M cells and DCs (Huang et 
al., 2005; Neutra and Kozlowski, 2006).  
Alternatively, administration of a single high dose of the antigen or repeated low doses induce 
tolerance. These types of tolerance are called high and low-dose tolerance, respectively, and they 
are mediated through different mechanisms. T cells have a crucial role in the induction of 
tolerance. The mechanism of oral tolerance is not well understood. As a result of oral tolerance, 
when DCs encounter the antigen, they behave differently and secrete IL-10 and TGF-β. This leads 
to the deletion of antigen specific T cells as well as the generation of regulatory T cells (Tr). Tr 
suppress the systemic immune response (Aziz et al., 2007).    
I.3 The chicken immune system 
Bird’s immune system is very similar to vertebrates. Whether or not a bird develops a disease 
depends on bird’s condition, level of immunity, number of invading pathogens and their virulence 
strength. Innate immunity is affected by genetic factors (ability to develop required receptor 
against pathogens), body temperature (higher body temperature prevents some bacteria to survive) 
as well as the health of the anatomical barriers like skin, the mucous and the respiratory tract cilia. 
Other factors like nutrition, age, stress, inflammatory processes and metabolic factors have great 
impact on the effectiveness of the immune response. A specific immune response in birds could be 
generated via two ways. First, passive immunity is achieved when antibodies are transferred to the 
individual either maternal or orally/through injection. Second, active immunity is the production of 
antibodies by individuals against a pathogen as a result of vaccine application or recovery from 
disease, which eventually leads to the generation of memory cells. Birds lack lymph nodes, but 
they have an avian-specific primary lymphoid organ, the bursa of Fabricius (BF), which is the 
organ for development of their B-cell repertoire (Kaiser, 2007). When a pathogen enters the body, 
it is engulfed by APCs and exposed through T cells to B cells. B cells are produced in the liver of 
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the chicken embryo, the yolk sac and the bone marrow. They move to BF for maturation when an 
antigen is encountered, the BF programs these cells to attack the antigen. The programmed cells 
then move to the blood, spleen, cecal tonsil, bone marrow, Harderian gland and thymus. It takes 
five days for B cells to be programmed and to go through clonal expansion resulting in the 
production of specific antibodies. Antibodies attach to antigens and neutralize them. On the other 
hand, the antibody-antigen immune complex triggers macrophages to remove the antigens.  
There are three classes of antibodies found in chickens when they are exposed to antigens: IgM, 
IgY (or chicken IgG) and IgA. IgM appears after 4-5 days following exposure to an antigen and 
then disappears by day 10-12. IgY is detectable after 5 days following exposure, peaks at 3 to 3.5 
weeks, and then slowly decreases. IgY instead of IgG in mammals is the most important protective 
antibody in chickens and can be measured by most serological test systems. IgA appears after 5 
days following exposure. This antibody isotype is found primarily in the mucus system of the eyes, 
gut and respiratory tract and provides local mucosal protection to these tissues (Tizard, 2002). T 
cells in chickens like mammals are programmed and maturated in the thymus. Like mammals, 
some T cells producing cytokines; some T cells are facilitated to directly destroy the contaminated 
cells (CTLs); T helpers enhance the activity of B cell, macrophages and other T cells.   
 Chicken diseases and vaccination I.3.1
Innate immune system seems to be fully functional in the newly hatched chickens whereas the 
optimal adaptive immune responses only develop following the first weeks after hatch.  
Consequently, they are not able to develop a fast immune response, which makes them susceptible 
to various diseases in early days. To compensate this deficiency, they receive maternal antibodies 
via the egg (Davison et al., 2008). These antibodies are specific against all pathogens that the 
mother has encountered or has been vaccinated against. This antibody reservoir lifetime is long 
enough to donate immunity until the chicken’s immune system becomes active. Knowing the 
maternal antibody level is critical for managing vaccination schedules. If chickens receive a 
vaccine at the time when the maternal antibody level is still high, the vaccine may be inactivated 
violently by maternal antibodies, which leads to a weak immune response. In contrast, if 
vaccination takes place long after the decline of maternal antibody levels, chickens would be 
susceptible to diseases prior to be immunized (Hair-Bejo et al., 2004). Damages to the BF due to 
late immunization of chickens at early susceptible days of age by IBDV or Marek’s disease 
inhibits proper B cell maturation and programming. This leads to immune susceptibility so that 
affected chickens will neither be able to raise immune response against attacking pathogens nor 
respond to immunization programs, adequately. As a consequence, the right time for vaccination 
and boosting the immune system is critical for the poultry industry. Newcastle, Influenza and 
infectious bronchitis as well as infectious bursal disease (IBD) are the most important poultry 
disease worldwide which need to be controlled by proper vaccination programs (Tao et al., 2009).  
The majority of currently used vaccines is against systemic pathogens or their toxins and 
administered parenterally (Zhang et al., 2008). Although parenteral route of vaccination is very 
effective in stimulation of the systemic immune response, this response does not extend to mucosal 
interfaces. To stimulate mucosal immunity, the pathogen or vaccine should be delivered via the 
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mucosal route. By this way, mucosal as well as systemic immunity are being generated (Boyaka et 
al., 2003).   
I.4 Infectious bursal disease virus (IBDV) 
Infectious bursal disease virus (IBDV) is an acute, highly contagious pathogen, which causes 
intensive irreparable immunosuppression or often death in young chickens, often at an age of 3-6 
weeks when the B lymphocytes are developing, and as a result imposes severe losses to the poultry 
industry annually worldwide. Younger chickens are passively protected by maternal antibodies 
transmitted via egg yolk and older ones are able to produce antibodies against the virus, therefore 
rarely develop clinical signs of the disease (Macreadie et al., 1990). Since the first outbreaks 
occurred in Gumboro, Delaware, “Gumboro disease” became a synonym for IBD (Cosgrove, 
1962).  
 Virus classification I.4.1
IBDV belongs to the genus Avibirnavirus of the family Birnaviridae. The virion is composed of a 
non-enveloped icosahedral capsid with a bi-segmented double strand RNA genome. It has two 
distinct serotypes (I and II) but only serotype I is virulent for chickens. An intrinsic characteristic 
of RNA viruses is the high variability of their genome due to the low proofreading activity of their 
viral replicases. Accordingly, many strains have been generated. Based on the pathotype detectable 
IBDV in the field can be divided to classical, antigenic variant and very virulent strains. Classical 
strains cause inflammation and severe lymphoid necrosis, immunosuppression and up to 30% 
mortality. Variant strains cause bursal atrophy and immunosuppression, with very low mortality 
whereas very virulent IBDV (vvIBDV) may cause acute clinical disease with 60-100% mortality 
(Snyder et al., 1988; Jackwood and Jackwood., 1994; Brown and Skinner, 1996). vvIBDV strains 
have emerged in Europe in 1987 and spread to Latin America, South-East Asia, Africa and the 
Middle East since the last three decades. One reason for the worldwide distribution of the virus is 
that it is extremely resistant in the environment. The Office of International des Epizooties (OIE) 
estimates that IBD is present in more than 95% of the 117 member countries. The acute clinical 
form of IBD caused by vvIBDV isolates has been observed in over 80% of these countries. It has 
been reported in Europe, Asia, Africa, South America and Central America.  
 Route of infection and pathology I.4.2
The route of IBDV infection is usually oral (from contaminated food, water or excrements), but 
may be via the eye or respiratory tract, with an incubation period of 2-3 days. Following oral 
infection, the virus replicates in gut-associated macrophages as well as lymphoid cells (Mahgoub, 
2012). The virus attacks the immature IgM-bearing B-lymphocytes in the BF and destructs the 
tissue resulting in the immunodeficiency of its host (Shaarma et al., 2000). Depression, anorexia, 
ruffled feathers, unsteady gait, trembling, huddling under equipment, watery diarrhea and the most 
prominent lesion, hemorrhage and necrosis of bursa of Fabricius, followed by bursal atrophy are 
some clinical symptoms of this disease (Chang et al., 2001). If chickens are infected within 1-3 
weeks of hatch, they show immunodeficiency without symptoms whereas infection within 3-6 
weeks of hatch accompanying symptoms leading to death; but no influence on older chickens has 
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been observed. Immunodeficient chickens are susceptible to other disease and show no adequate 
response to vaccination.  
 Virus detection, classification and diagnostic tests  I.4.3
To distinguish between classical, antigenic variant, very virulent and non-virulent strains, it is 
important to identify the IBDV serotype in order to be able to choose the best strategy for 
vaccination. Since the distinction between different strains is not possible through serological 
techniques like agar-gel precipitation test (AGPT) or enzyme linked immunosorbent assay 
(ELISA), reverse transcription-polymerase chain reaction (RT-PCR) has been used as rapid, 
sensitive and specific method for detection of IBDV in clinical samples and for phylogenetic 
studies (Lee et al., 1992; Li et al., 2009). Some laboratories utilized joined RT-PCR/RFLP (Juneja 
et al., 2008; Bahmaninejad et al., 2008), RT-PCR and nucleotide sequencing (Stoute et al., 2009; 
Li et al., 2009) and SYBR green I based one-step real-time RT-PCR (Kong et al., 2009) for 
diagnostic and classifications. Recently, the more sensitive method called reverse-transcription 
loop-mediated isothermal amplification (RT-LAMP) has been established for rapid diagnostics 
(Xu et al., 2009). 
 Treatment and prevention I.4.4
No specific treatment is available for IBD. The use of vitamin E and arginine supplements (Ruiz-
Feria and Abdukalykova, 2009) and facilitating access to water may help to increase the resistance 
of chickens against the disease. Antibiotic medication may be recommended if secondary bacterial 
infection occurs. Therefore, prevention is the best method of choice. Passive immunity protects 
against IBDV, as does previous infection with avirulent strains. In broiler farms, breeder flocks 
were immunized against IBD and maternal immunity via protective antibodies passed to their 
offspring. In each farm region, vaccination should be done according to prevalent strains. 
Accordingly, determination of virus serotype is very important in choosing the kind of vaccination. 
Previously, it has been shown that attenuated vaccines were efficient to cope with IBDV (Wyeth 
and Cullen, 1979). By outbreak of variant strains in the US and vvIBDV strains in Europe, 
traditional attenuated strain vaccines are not totally effective against new strains. Therefore new 
vaccines based on vvIBDV strains are being developed. Despite of vaccination, outbreaks of IBD 
are still reported for many countries (Li et al., 2009). 
 IBDV structure I.4.5
The IBDV genome has two segments of double-stranded RNA, named A and B (Azad et al., 1985; 
Muller et al., 1979), which are packed in a non-enveloped icosahedral (T=13) shell with 60 nm in 
diameter (Böttcher et al., 1997). The smaller segment B (~2.8 kb) encodes the protein VP1 (97 
kDa), which is an RNA-dependant polymerase. The segment A (~3.3 kb) contains two partially 
overlapping open reading frames. The smaller ORF encodes the non-structural protein VP5, which 
is not essential for virus replication neither in vitro nor in vivo (Mundt et al., 1997) but has a role in 
virus release (Gariiga et al., 2006; Wu et al., 2009). The larger ORF encodes a precursor 110 kDa 
polyprotein (VP2-VP4-VP3) that is post-translationally cleaved into three distinct proteins: pre-
VP2 (54 kDa), VP4 (25 kDa) and VP3 (28 kDa). Processing of the precursor protein is done by the 
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auto-catalytic activity of VP4 which is a viral protease (Azad et al., 1987; Jagadish et al., 1988). 
Pre-VP2 (pVP2 or VPX) is a precursor and truncates at its C-terminal in four steps into VP2 (441 
amino acid and 48 kDa), through the proteolytic activity of VP4 in three Ala-Ala bond positions 
(487, 494 and 501) and one unknown cleavage between residues 441- 442 (Luque et al., 2007). 
The whole cleavage sites have been determined through deletion mutants (Caston et al., 2001; Da 
Costa et al., 2002). The pVP2 processing to VP2 is essential for correct assembly of the viral 
capsid. VP2 (major protein with ~51% frequency in a virus) assembles into trimers, the structural 
unit of the virus capsid and forms the external surface of the virion while VP3 trimers form the 
interior face. VP3 is a multifunctional protein, which reacts with itself (Casanas et al., 2008), VP2 
(Saugar et al., 2005), VP1 (Maraver et al., 2003; Garriga et al., 2007) and the viral genome 
(Hjalmarsson et al., 1999). Briefly, VP3 has a key role in interacting with pVP2 for correct 
assembly into the capsid format (Chevalear et al., 2002; Chevalier et al., 2004; Ona et al., 2004; 
Saugar et al., 2005; Luque et al., 2007). It interacts with VP1 by its carboxyl terminal ten amino 
acids. It also binds to both segments of the dsRNA by positively charged domain immediately 
upstream of the VP1 binding domain (Tacken et al., 2002; Kochan et al., 2003; Luque et al., 
2007). As a result, VP3 is essential for proper assembly and virus morphogenesis (Martinez-
Torrecuadrada et al., 2000). In addition, VP3 seems to be involved in initial virus attachment 
(Reddy et al., 1992). After expressions and maturations of all viral proteins, the full-size capsid 
including the genome and viral proteins including VP1, VP2, VP3, VP4 and VP5 proteins is 
formed (figure I.2).   
 
 
 
Figure I.2 Schematic configuration of IBDV and its genome. Segment A of the viral genome encodes 
two overlapping ORFs: ORF1 encodes VP5 with a role in virus release (Gariiga et al., 2006; Wu et al., 
2009) and ORF2 encodes a polyprotein. The polyprotein is cleaved by the proteolytic activity of VP4 into 
three separate proteins. VPX or pVP2 is truncated to VP2 via proteolytic cleavage. VP2 is the capsid 
protein of virus, which is the main antigenic protein containing major epitopes responsible for eliciting 
immunogenic responses (Becht et al., 1988; Azad et al., 1991; Heine et al., 1991): Picture taken from the 
viralZone website (www.http://viralzone.expasy.org/viralzone/all_by_species/572.html). 
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Native IBDV has an icosahedral symmetry with triangulation number (T) of 13 and 60 nm 
diameter made of 12 pentamers and 120 hexamers according to trimers decoration (Luque et al., 
2007). Structural studies indicated that the virus capsid is composed of 780 VP2 molecules in form 
of 260 structural trimer subunits (figure I.3), which stand on the outer face of the particle (Böttcher 
et al., 1997). On the inner side, 600 (or ~ 450 (Luque et al., 2007)) copies of VP3 in Y-shaped 
trimers make a scaffold responsible for the stability of the particle. VP4 is located on 60 positions 
next to 5-fold axes of icosahedrons (Böttcher et al., 1997; Hu et al., 1999). The RNA genome is in 
contact with positively charged C-terminus of VP3 inside the particles (Böttcher et al., 1997; 
Hudson et al., 1986).  
 
 
 
Figure I.3 Three VP2 proteins assemble together and form a trimer, the structural unit of the virus. 
Virus particles obtained by assembly of trimers (VP2 trimers outside and VP3 trimers inside of the 
particles) and engulfment of VP1, VP4, VP5 and bi-segmental genome. (A) The conformation of the trimer 
(VP2 proteins were shown in orange, red and blue) structural unit in spike-like form on the surface of the 
viral particle. (B) Electron micrograph of IBDV particles with about 60 nm in diameter. Figure A and B 
references are http://www.igs.cnrs-mrs.fr/elnemo/NORMA/ibdv_vp2_fit.12modes.gif and http://www.uni-
leipzig.de/forsch98/vetmed/virolo.htm, respectively.  
 
 Structure and characteristics of the viral antigen IBD-VP2 I.4.6
Sequence comparison between corresponding regions of genomes in different IBDV strains 
revealed that generally all viruses are very closely related but they show a hyper variable (hv) 
region (amino acid 206-350) in VP2, which is responsible for the antigenic variation observed in 
different viruses (Bayliss et al., 1990; Heine et al., 1991). In other word, although there are more 
than 93% similarity between sequences of proteins of known IBD-VP2 described all over the 
world (this number is more than 98% between Asian and European vvIBDV strains), this virus has 
been classified into different strains with different pathogenesis according to their diversity in the 
hypervariable region of VP2 (Liu et al., 2002; Kasanga et al., 2007). 
The hyper variable region is the most interested region in most epidemiology and phylogenetic 
studies. In spite of high frequency of mutation in this region, this part of the genome also contains 
relatively conserved sequence regions unique for vvIBDV strains (Jackwood et al., 2005; Parede et 
al., 2003; Hoque et al., 2001). On the other hand, this variable region with frequent mutations 
provides greater discrimination between closely related genomes and consequently is more 
important in evolutionary tracking and categorization than the constant regions (Levin et al., 1999; 
Li et al., 2009)    
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VP2, which makes 51% of the total IBDV protein content (Böttcher et al., 1997), is the main 
antigenic protein containing major epitopes responsible for eliciting immunity (Becht et al., 1988; 
Azad et al., 1991; Heine et al., 1991). The hv region involves two major hydrophilic regions 
(figure I.4) (Kasanga et al., 2007). Nevertheless, the whole VP2 is characterized as a hydrophobic 
protein (Wu et al., 2004; figure 1.4). Each major hydrophilic region (amino acid 210-225 and 312-
324) carries one part of the neutralizing epitope and altogether provides the conformational epitope 
of the virion (Yamaguchi et al., 1996; Cui et al., 2003).  
 
 
Figure I.4 Hydrophobicity plot of IBD-VP2 provided by CLC Main workbench 6.5 using Kyte-
Doolittle hydrophobicity scale. Two major hydrophilic regions (amino acids 210-225 and 312-324), which 
are also carrying the virus neutralizing epitopic regions have been circled in orange. As illustrated in this 
graph, VP2 is a hydrophobic protein.  
 
Since disulfide bond formation, glycosylation or phosphorylation has not been reported in VP2, 
oligomerization is known as the main factor providing conformational epitopes (Yamaguchi et al., 
1996). The atomic structure of intact virions was solved by X-ray crystallography (Coulibaly et al., 
2005). Further studies were performed with higher resolution (2.6 Aº) on the VP2 structure 
(Garriga et al., 2006; Lee et al., 2006a). These studies revealed that the VP2 subunit is folded into 
three domains termed the projectin (P), shell (S) and base (B) domains (figure 1.5). The P and S 
domains are β-barrels, which are in radial and tangential format to the particle surface, 
respectively. The P domain carries the neutralizing conformational epitope region. This region 
involves 210-222 amino acids and 312-324 amino acid sequences, matching with two major 
hydrophobic regions. The N and C terminal VP2 regions are involved in the formation of the α-
sheet structure (figure I.5) (Letzel et al., 2007; Luque et al., 2007). 
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Figure I.5 (A) Protein structure of VP2; which is composed of three domains named P (brown), S (blue) 
and B (green). Domain P carries the virus neutralizing epitope region (comprising amino acids 210-222, 
shown in red and amino acids 312-324, shown in yellow). The figure reference is Saugar et al. (2010). (B) 
The trimeric VP2 structure from the top view. The conformational epitope is shown in red (comprising 
amino acids 210-222) and yellow (comprising amino acids 312-324). The figure was rendered using the 
program PyMOL using the file with PDB code 2DF7 (Lee et al., 2006a). 
 
As described above, VP2 is the most frequent protein and the major host protective immunogen of 
the virion, which contains the antigenic regions of the virion (conformational epitope) responsible 
for inducing neutralizing antibodies against the parent virus in the host (Azad et al., 1987; Becht et 
al., 1988). It has been proven that VP2 alone is able to stimulate an immune response and 
eventually triggers antibody generation in the same way as the intact virus (Fahey et al., 1989). 
Immunodominant epitopes in VP2 region converts it to a target for designing subunit vaccines and 
diagnostic tests (Sedighzadeh et al., 2012). 
On the other hand, it was shown that recombinant expression of capsid proteins of non-enveloped 
viruses led to different grades of assembly with variable efficiencies (Chevalier et al., 2004). 
Recombinant expression of VP2 in combination with other IBD viral proteins and alone with 
different length, has led to various forms of assembly. Different types of assembly are also seen in 
IBDV infected cells in nature; In addition to IBD virions, tubular forms with a diameter of 55 nm 
(type I), and 24-26 nm (type II) are also formed during infection. Tubes type I is made only by 
pVP2 while type II contains VP4 (Chevalier et al., 2004).   
The expression of VP2 in companion with VP3 and VP4 in the whole polyprotein A (VP2-VP4-
VP3) in different heterologous system resulted in the formation of VLPs with icosahedral 
symmetry based on T= 13 lattice and 60 nm in diameter. Production of IBD-VLPs has been 
observed in E. coli (Rogel et al., 2003), yeasts such as S. cerevisiae (Macreadie et al., 1990; 
Jagadish et al., 1990), baculovirus and insect cell lines e.g. Sf9 and Hi-5 (Vakharia et al., 1993; 
Kibenge et al., 1999; Hu et al., 1999; Lee et al., 2006b) as well as mammalian cell lines like the 
African green monkey kidney epithelial BSC-1 (Fernandez-Arias et al., 1998). As previously 
mentioned, an interesting trait of VP2 is its ability of self-assembly. In fact, different sizes of VP2 
ranging from 512 amino acids (pVP2) to 441 amino acids (mature VP2) have been recombinantly 
expressed and led to different conformations (Saugar et al, 2005). While expression of mature VP2 
resulted in the formation of dodecahedral T= 1 subviral particles (SVP), pVP2 expression led to 
the assembly of tubular structures with hexagonal lattice (Luque et al., 2007). T= 1 IBD-SVPs are 
composed of 20 VP2 trimers as subunits (Caston et al., 2001) and made of only the first 441 amino 
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acids of VP2 (Coulibaly et al., 2005). Production of IBD-SVPs has been reported in different hosts 
like E. coli (Chen et al., 2005), S. cerevisiae (Garriga et al., 2006; Dey et al., 2009), SF9 and H5 
insect cell lines (Dybing and Jackwood, 1997; Wang et al., 2000; Caston et al., 2001; Lin et al., 
2007; Luque et al., 2007). The ability of self-assembly along with carrying the virus neutralizing 
epitope, make VP2 a promising subunit vaccine candidate. 
I.5 Vaccine development against IBDV 
Control of IBD has been initially achieved by maternal-derived antibodies (MDA) induced by live 
or attenuated vaccines applied to breeder progenies and by active immunization of chickens with 
inactivated viruses. During outbreaks of very virulent strains, traditional vaccines lost their 
effectiveness since they were not able to stimulate a strong immune response and are risky to apply 
due to their potential exacerbation of the disease. To cope with vvIBDV strains, new vaccines are 
being developed but they evoke only a moderate immune response and therefore are not able to 
fully prevent virus pathogenesis. Generation of genetically engineered IBDV using reverse 
genetics was afforded based on the introduction of mutation in hv region of VP2 to create 
attenuated IBDV with the potential application as vaccine. IBDV immune complex vaccines, 
which consist of a mixture of certain amount of VP2-specific antibodies extracted from the sera of 
hyper-immunized chickens and infectious virus was also introduced with in ovo application 
(Müller et al., 2012). Extraction of virus from infected BF of the chickens is one of the major 
sources for generation of most effective vaccines but to obtain large quantities of this antigen a 
large number of contaminated chickens has to be sacrificed (Pitcovski et al., 2003). Virus 
proliferation in cell culture and subsequent extraction, purification and attenuation or inactivation 
is a common but expensive and laborious method in vaccine production. It was shown that 
transferring anti-VP2 antibodies to susceptible chickens can passively protect them from IBDV 
(Fahey et al., 1989; Macreadie et al., 1990; Vakharia et al., 1993). It was also shown that VP2 is 
essential and adequate for stimulation of the immune system in chickens and as a result could be a 
powerful candidate for antigen-based vaccines either in oral or parenteral vaccination strategies 
(Wu et al., 2007, Rong et al., 2007).  
By development of recombinant DNA technology, many recombinant vaccines including DNA-
based and antigen-based have been revealed. In previous years, several IBD vaccines have been 
introduced but still need time to be improved. There is a need to improve safety, tolerability and 
potency. Besides, decreasing the cost and speeding up the rate and scale of vaccine production to 
meet daily increasing demands are global aims. Recombinant expression of IBDV polyproteins in 
several heterologous systems has been extensively reported (Chevalier et al., 2002). Among those, 
some have shown the formation of virus-like particles (VLPs) (Fernandez-Arias et al., 1998; 
Kibenge et al., 1999). In this type of vaccine, VP2 protein as a major host protective antigen has 
been attracted the most attention in vaccine development (Bentley et al., 1994). Several 
recombinant expression systems have been successfully afforded for the production of 
immunogenic and protective VP2 (in table I.I some of them are summarized). Self-assembly has 
also been reported in some of the heterologous expression systems. Oral delivery is preferred over 
parenteral immunization due to less stress for the vaccine recipient, the possibility to induce 
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mucosal immunity and the low cost and ease of administration. VP2, which was produced in plant 
systems such as Arabidopsis thaliana (Wu et al., 2004) and rice (Wu et al., 2007) was able to 
induce protective immune response when administered orally but no assembly to VLPs was 
reported. Due to the low accumulation of the recombinant vaccine in the plant cells, high volumes 
of plant materials with several repetitions should administered to reach the adequate immune-
stimulating dosage. An ideal oral subunit vaccine for production in transgenic plants is the primary 
antigen of the infectious pathogen that accumulates in high levels and also aggregates in forms that 
are recognized at mucosal sites where an immune response is triggered. These include viral coat 
proteins such as IBD-VP2 that co-assemble to form VLPs or SVPs.  
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I.6 Application of VLPs and SVPs in nanotechnology  
Other than common vaccination approaches, VLP and SVP-based structures have also been 
exploited for drug targeting (Wang et al., 2002c; Remond et al., 2009; Dhart et al., 2010; Zhao et 
al., 2011) and for displaying of inserted foreign immunogenic epitope (chimer particles) to the 
immune system of the host for induction of immune response against the inserted epitopes 
(Veremeiko et al., 2007; Fraile et al., 2012; Remond et al., 2009). In the latter case, IBD-SVPs 
were successfully used in displaying foot and mouth disease virus (FMDV) epitopes (Remond et 
al., 2009). However, generation of chimeric VLP/SVP is empirical and there is always a chance 
that inserted peptides interrupt in VLP assembly or in case of assembly are not immunogenic. An 
important limitation for chimeric particles is the limited size and nature of the epitope that can be 
inserted (Trovato et al., 2012).  
In the nanotechnology field, viral nanoparticles (VNPs) are defined as nanoscale devices based on 
natural viruses (Singh et al., 2007; Destito et al., 2007; Steinmetz et al., 2007a, 2008 and 2009). 
They offer advantages over synthetic nanoparticles such as carbon nanotubes and quantum dots 
(Steinmetz et al., 2010) because they are biocompatible, biodegradable and non-toxic. They 
provide a robust and symmetrical structure, amenable to both genetic and chemical modifications 
(Lee et al., 2009); can be used for the development of novel nanoscale formulations and as 
nanotemplates, nanoprobes and nanoreactors (Bronstein, 2011). Importantly, VNPs are stable, 
symmetrical, monodisperse particles with a distinct size, atomic precision and uniform 
multivalency; they are also easy to prepare in large quantities (Grasso and Santi, 2010). VNPs 
derived from mammalian viruses are already widely used, but concerns about their potential 
toxicity and pathogenicity have led to the more recent development of plant VNPs (Singh et al., 
2007; Rae et al., 2005; McCormick and Plamer, 2008), which are safer and can be prepared in 
gram quantities from a few kilograms of infected leaves (Steinmetz et al., 2007a; Nichols et al., 
2002; Barnhill et al., 2007a). Spherical VNPs based on Cowpea mosaic virus (CPMV) (Wang et 
al., 2002a,b,c; Wang et al., 2003; Raja et al., 2003), Cowpea chlorotic mottle virus (CCMV) 
(Gillitzer et al., 2002) and Turnip yellow mosaic virus (TYMV) (Barnhill et al., 2007a), as well as 
rod-shaped VNPs based on Tobacco mosaic virus (TMV) (Schlick et al., 2005) have been 
investigated for this purpose. The majority of research has focused on CPMV making this virus the 
gold standard for stability, addressability and functionalization (Miermont et al., 2008; Kaltgrad et 
al., 2008; Sapsford et al., 2006; Destito et al., 2007). As an alternative to VNPs, VLPs and SVPs 
can be produced recombinantly in higher amount that lack the virus genome, thus providing further 
safety (Mason et al., 1992; Remond et al., 2009). The absence of genomic nucleic acid leaves 
spaces for the encapsidation of small useful molecules, e.g. drugs, imaging reagents or nucleic 
acids (Yamada et al., 2003; Caston et al., 2001). Furthermore, the structure of the particles can be 
modified by genetic engineering e.g. to make the surface more favorable for the nucleation of a 
specific mineral or alloy (Shah et al., 2009; Reiss et al., 2004), or to introduce one or more 
chemically modified amino acids to display a specific chemical group for structural stabilization or 
conjugation (Steinmetz et al., 2007b; Peabody, 2003; Strable et al., 2008). Modification also 
provides an opportunity to optimize the physicochemical properties of the particle, which must be 
tailored for specific applications. For example, nanoparticles designed as contrast agents for 
Chapter I                                                                                                                            Introduction 
  
21 
 
magnetic resonance imaging (MRI) should encourage mineralization whereas those used for 
electronics applications need to be stable in acid, ethanol and at high temperatures. VNPs used for 
biomedical applications such as imaging or drug delivery often need to be bioconjugated in the 
presence of dimethylsulfoxide (DMSO), so the particles must be stable in this organic solvent 
(Steinmetz et al. 2008). The potential application of either IBD-VLPs or IBD-SVPs has not yet 
been reported.  
I.7 Aim of this thesis 
Infectious bursal disease virus (IBDV) serotype I is a worldwide distributed, highly contagious 
immunosuppressive agent for young chickens, which causes high morbidity and mortality. IBDV 
is stable in the environment and survives strict hygiene management and disinfection. No specific 
treatment is known for infectious bursal disease (IBD) and vaccination is the only adequate way of 
disease control (Müller et al., 2012). Currently, IBD vaccines are composed of either live 
attenuated or inactivated (killed) virus. Live vaccines are usually administered orally, by addition 
to drinking water whereas killed vaccines administered intramuscularly. Due to the emergence of 
variant strains in the Unites States and very virulent strains in Europe, which are speculated as a 
result of selection pressure from the live administered vaccines (Synder, 1990), conventional 
vaccines lost their efficiency to provide full protection (Rong et al., 2005). In addition, their 
application is accompanied with a risk of reversion of virulence. 
Over the last three decades, several reports have been published on recombinant expression of 
IBD-VP2 as the major protective IBDV antigen, responsible for induction of virus neutralizing 
antibodies in chicken. With the produced vaccines partial to full protection was achieved. But 
except the ones that are expressed in plant systems, the requirement for parenteral administration is 
still the limiting factor that increases the cost of administration and needs for protein purification. 
In contrast, oral delivery of vaccines is an attractive alternative due to the ease of administration 
and low costs. Also, oral delivery of the recombinant protein could reduce the production costs by 
almost 90% due to elimination of downstream processing (Chebolu and Daniell, 2009).  
The aim of the first part of this study was the development of an oral subunit vaccine for chickens 
against IBDV. Therefore the VP2, the coat protein of IBD virus, which carries the major host 
protective antigen and has self-assembly capability, was expressed in tobacco and Pichia pastoris. 
In this context, increasing the VP2 accumulation level through targeting to different organelles in 
both production systems was investigated. In addition, the self-assembly of the produced VP2 in 
both expression systems in vivo and in vitro was studied. The immunogenicity of the produced 
VP2 and its ability in induction of a protective immune response was studied when the vaccine was 
administered through either parenteral or oral route to the chickens. 
 
In the second part the potential application of the generated IBD sub-viral particles (IBD-SVPs) 
derived from self-assembly of the recombinantly produced VP2 as a nanotechnology platform was 
investigated. The tolerance window of these nano-particles concerning heat, pH and organic 
solvent stability was studied. Moreover, the addressability of solvent-exposed amine and 
carboxylic groups on the surface of IBD-SVPs was tested via traditional bioconjugation methods. 
A schematic overview of this PhD thesis is represented in the figure below. 
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Figure I.6 Schematic overview of the work presented in this dissertation. 
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II Materials and Methods 
II.1 Materials 
 Chemicals and consumables II.1.1
All chemicals were supplied by following companies: Amersham Pharmacia Biotech (Freiburg), 
BioRad (München), Duchefa (Haarlem, Netherlands), Fluka (Steinheim), Gerbu (Gaiberg), Merck 
(Darmstadt), MWG-Biotech (Ebersberg), New England Biolabs (Schwalbach), Pharmacia 
(Uppsala), Pierce (Germany), Roche (Mannheim), Roth (Karlsruhe) and Sigma-Aldrich 
(Steinheim). The consumables were provided from: Amicon (Witten), Biozym (Oldendorf), 
Calbiochem (Darmstadt), Corning Inc. (Hamburg), Eppendorf (Hamburg), Gentaur (Aachen), 
Greiner (Solingen), Millipore (Eschborn), Pall (Dreieich), Qiagen (Hilden), Sarstedt (Nümbrecht), 
Sartoriusstedim (Göttingen), Schott Glaswerke (Mainz), Serva (Heidelberg), USB/Amersham 
(Braunschweig) and Whatman (Dassel).  
 Buffers, media and solutions II.1.2
All standard buffers, media and stock solutions were prepared according to Sambrook and Russell 
standard protocols (2001) using deionized water. Compositions of non-standard solutions or 
buffers are listed at the end of respective method section. All media and some solutions were 
prepared and sterilized by autoclaving (25min/121°C/2bar). Heat-sensitive components, such as 
antibiotics, were prepared as stock solutions, filter-sterilized (pore size: 0.2 μm) and added to the 
medium after autoclaving following cooling down to 50°C. RPMI-1640 medium (Sigma) was used 
in hybridoma cell culture. Sabouraud agar medium (Heipha Dr Müller GmbH, Eppelheim 
Germany) was used as a yeast selection medium to test cell vitality. 
 Matrices and membranes II.1.3
Ni-NTA superflow matrix (Qiagen) was used for purification of His-tag fused recombinant 
proteins by immobilized metal ion affinity chromatography (IMAC, II.2.2.4). Nanosep columns 
(Pall) with different cut-off membranes were used for ultra-filtration assays and protein 
concentrating (300, 100, 50, 10 kDa cut-off). Protran® nitrocellulose membrane from Whatman, 
HybondTM-C-nitrocellulose membrane (0.45 µm) from GE healthcare (Freiburg) and Whatman 
no.1 paper from Whatman were used in immunoblot analysis (II.2.3.3, II.2.3.4). Rotilabo syringe 
filters (0.45 and 0.22 μm) (Roth) were utilized for clearance and sterilization, respectively, in small 
volumes and PES bottle top filter (Sartoriusstedim) for big volumes. Vivaspin 20 ml centrifugal 
concentrators (Sartorius Stedim biotech) were used to concentrate the protein of interest. 
Analytical and preparative gel filtration matrices (Sephacryl and superdex) (GE healthcare) with 
different separation range were used for protein purification and analysis (II.2.2.5, II.2.3.5).  
 Enzymes and reaction kits II.1.4
The restriction enzymes from New England Biolabs (NEB) (Schwalbach) were used for DNA 
digestion. Home-made Taq polymerase was used in colony-PCRs (II.2.1.20). 
In addition, the following kits were used:   
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• Expanded high fidelity PCR system (Roche) 
• Nucleospin Plasmid kit (Machery-Nagel, Düren) for mini-preparation of plasmids 
• NucleoSpin
 
Extract II Kit (Machery-Nagel) for DNA fragment purification 
• CloneJETTM PCR cloning Kit (Fermentas, St. Leon-Rot) for fast and direct PCR product 
cloning  
• BCA protein assay kit Pierce (Rockford, IL, USA) for protein concentration measurement 
• EzWayTM PAG protein elution kit (Koma Biotech, Seoul, South Korea) 
• Y-PER Yeast protein extraction reagent (Pierce)  
• DyLight 488 antibody labelling kit (Pierce) for fluorescent labelling of protein 
• AviPro Gumboro vac (Lohmann Animal Health GmbH & Co. KG, Cuxhaven) as 
commercial IBD vaccine used as positive control 
• IDEXX IBD-XR Ab test (IDEXX, Westbrook, ME, USA) for antibody titer determination 
in chickens 
 Antibodies and substrates II.1.5
Rabbit anti-His polyclonal antibody (BioMol, Hamburg), mouse anti-IBD-VP2 (15F5 mAb) 
monoclonal antibody (Ingenasa, Madrid, Spain) and rabbit anti-IBD-VP2 polyclonal antibodies, 
kindly provided by prof. Wang (National Chung Hsing University, Taichung, Taiwan) and prof. 
Rodriguez (CNB, Spain), respectively, have been used as primary antibody in immunoassays 
including immunoblot (II.2.3.3, II.2.3.4), ELISA (II.2.3.1) or antibody-labelled electron 
microscopy (II.2.3.6). Goat anti-mouse Fc (GAM) and goat anti-rabbit Fc (GAR) antibodies, 
conjugated either to alkaline phosphatase (AP) or horseradish peroxidase (HRP) (Dianova, 
Hamburg) were used as a secondary antibody in immunoblotting and ELISA, respectively. Rabbit 
anti-chicken IgY (Fc)-HRP conjugate, goat anti-chicken IgA-HRP conjugate and goat anti-chicken 
IgM-HRP conjugate (Gentaur, Aachen) were used to study the chicken immune response (II.2.6.2). 
NBT/BCIP (BioRad) and ABTS (Roche) were used as substrate for detection of target 
immobilized proteins in immunoblot and ELISA, respectively. Goat anti-biotin gold (5nm in 
diameter)-labelled antibodies (Aurion, Wageningen, The Netherlands) were exploited in 
conjugation studies via electron microscopy (II.2.3.6). Alkaline phosphatase conjugated rabbit 
anti-xylose antibodies (Faye et al., 1993) was used in immunoblot for glycan analysis of proteins 
expressed in plants (II.2.4.1). 
 Special chemicals II.1.6
Alkaline phosphatase conjugated Galanthus nivalis lectin (EY laboratories Inc., CA, USA) was 
used for glycan chain detection of the proteins expressed in yeast (II.2.4.1).  
Adjuvants, MM and 100 (Gerbu, Wieblingen) were used in parenteral immunization of mice and 
chicken, respectively. Sodium fluoride (NaF) from Sigma was also used in oral adjuvant mixture 
for chicken immunization.   
 Oligonucleotides II.1.7
Oligonucleotides used for DNA amplification using polymerase chain reaction (PCR) (II.2.1.20), 
splicing by overlapping extension PCR (SOE-PCR) (II.2.1.20) and sequence analysis (II.2.1.21) 
are listed in the following tables. All oligonucleotides were synthesized by MWG (Ebersberg). In 
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addition, an oligodeoxynucleotide (ODN) containing an unmethylated CpG dinucleotide with 
phosphorothioate backbone synthesized by Biolegio (Nijmegen, the Netherlands) was used as oral 
adjuvant in chicken immunization experiments (II.2.6).   
 
Table  II.1 Primers used for generation of DNA fragments by PCR.  
 
 
Table  II.2 SOE-PCR primers for introducing extra DNA fragments into constructs or joining two 
separate constructs. 
Primer name Restriction site at 5’ Primer sequence (5’→3’) 
VP2-forward  BspHI CCGTCATGACAAACCTGCAAGATC 
VP2-reverse-withHis6  XbaI GCTCTAGATTTAGTGATGGTGATGGTGATGT
GCTCCTGCAATCTTCAG 
Solulin-for5´UT  EcoRI CGCGAATTCACAACACAAATCAGATTTATAG
AGAGATTTATAAAAAAAAAAAAAAC 
VP2-reverse - ATTAGACTCGACCGCTCCTGCAATCTTCAG 
CytB5memAnch.-for - 
CTGAAGATTGCAGGAGCGGTCGAGTCTAATT
CC 
vIL-10_XbaI-bw XbaI GCTCTAGACGGTTTAATCTTCTGC 
Primer name Overhang region (5’→3’) 
Restriction 
site at 5’ 
Primer sequence (5’→3’) 
including overhang 
region 
CHS-elongation5’ 
TTTATAAAAAAAAAA
AAAAC 
- 
TTTATAAAAAAAAAA
AAAACAATGACAAAC
CTG CAAGATCA 
Solulin-for5´UT 
TTTATAAAAAAAAAA
AAAAC 
EcoRI 
CGCGAATTCACAACA
CAAATCAGATTTATAG
AGAGATTTATAAAAA
AAAAAAAAAC 
CHS-elongation5’primer-
withHis6 
TTTATAAAAAAAAAA 
AAAACAATG 
- 
TTTATAAAAAAAAAA 
AAAACAATGCATCAC 
CATCACCATCACACA 
AACCTGCAAGATCA 
VP2-reverse 
ATTAGACTCGACCGCT
CCTGCAATCTTCAG 
- 
ATTAGACTCGACCGCT
CCTGCAATCTTCAG 
CytB5memAnch.-for CTGAAGATTGCAGGA
GCGGTCGAGTCTAAT 
- 
CTGAAGATTGCAGGA
GCGGTCGAGTCTAATT
CC 
vIL-10_XbaI-bw - XbaI 
GCTCTAGACGGTTTAA
TCTTCTGC 
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Table  II.3 Primers used for DNA sequencing. 
 
Table II.4 Phosphorothioate CpG ODN used as adjuvant in oral immunization of chickens. 
 Vectors  II.1.8
Schematic maps of all plasmids used for tobacco and Pichia transformation are shown in Appendix 
VII-2.  
pUC19 (Invitrogen) was used for E. coli efficiency of transformation. 
The vector pJET1.2 from Fermentas was used as an intermediate vector for all sub-cloning 
purposes prior to sequencing. The vector contains a beta-lactamase (bla) gene for selection with 
ampicillin. 
The pPICZ_B vector (Invitrogen) was used for expression of recombinant proteins in Pichia 
pastoris. This vector contains a methanol inducible AOX1 promoter for high-level expression in P. 
pastoris, a c-myc epitope tag for detection of target proteins with an anti-myc antibody, a C-
terminal poly-histidine (His6 or in brief H6) tag for rapid purification with nickel-chelating resin 
and/or detection with an anti-His antibody and a Zeocin™ resistance gene (Sh ble) under both 
EM7 (synthetic prokaryotic promoter) for positive selection of recombinant E. coli and TEF1 
(Transcription elongation factor 1 gene) promoter for positive selection of yeast. 
The vector pTRAkc (Sack et al., 2007) was used for transformation of the tobacco plants via 
Agrobacterium-mediated transformation (II.2.2.3, II.2.2.4). pTRAkc is an optimized plant 
expression vector which in this case contains the Cauliflower mosaic virus 35S promoter, the 5’ 
untranslated region of the  Chalcone synthase gene from Petrosinella and the 3’ pA35S 
untranslated region from CaMV. Scaffold attachment regions (SAR) were introduced next to the 
right and left border of T-DNA to improve gene expression. On the T-DNA part of this vector the 
kanamycin (nptII) resistance gene as a plant selection marker and on the vector backbone 
ampicillin (bla) resistance gene as a bacterial selection marker are present. 
 Bacterial, yeast and virus strains II.1.9
E. coli strains DH5α and XL1-Blue were used as host cells for all intermediate cloning constructs 
(Table II.5).  
P. pastoris X-33 cell line (wild type, Mut+) from Invitrogen was used for expression of 
recombinant IBD-VP2. 
Primer name Primer sequence (5’→3’) 
VP2Primer1_forward TGGTAGCAACATGTGACA   
VP2Primer1_reverse TTGAAACACGAGTTCTCC   
pSS5′ ATCCTTCGCAAGACCCTTCCTCT 
pSS3′ AGAGAGAGATAGATTTGTAGAGA 
pJET1.2Forward CGACTCACTATAGGGAGAGCGGC 
pJET1.2Reverse AAGAACATCGATTTTCCATGGCAG 
Name sequence (5’→3’) 
CpG ODN TCGTCGTTGTCGTTTTGTCGTT 
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A. tumefaciens GV3101 (pMP90RK GmR, KmR, RifR (Koncz and Schell, 1986) was used for 
Agrobacterium-mediated gene transfer.  
For the challenge, a classical IBDV strain, MB3, from a recent outbreak in Germany was used.  
 
Table  II.5 Names, suppliers and genotypes of E. coli strains used throughout the work. 
 Plants and animals II.1.10
Nicotiana tabacum L. cv. Petite Havana SR1 was used for transient and stable protein expression 
(II.2.2.2, II.2.2.3) of IBD-VP2 after vacuum infiltration with recombinant agrobacteria.  
Six to eight week-old female BALB/c mice were used for immunogenicity studies (II.2.5). 
Two-week old chickens hatched from specific pathogen free eggs (Lohmann Tierzucht, Cuxhaven) 
were used for vaccine analysis (II.2.6). 
 Equipment and applications II.1.11
Cameras: MP4 (Polaroid, Cambridge, MA, USA). E.A.S.Y 429K camera (Herolab, Wiesloch).  
Cell counter: Cell counter CASY 1 TT (Roche Innovatis) 
Centrifuges: Avanti
TM 
30 and Avanti
TM
J-25 from Beckman (California, USA), Biofuge A from 
Heraeus (Hanau), Eppendorf 5415D. Rotors: F0650, F2402H, JLA 10.500 and JA 25.50 from 
Beckman, #1140 and #11222 from Sigma, RLA-300, SS-34 and GS-3 from DuPont Instruments 
(Bad Homburg).  
Clean bench: Kojair (Nideggen). 
Chromatography equipment: ÄKTA explorer 10xT (Amersham Pharmacia Biotech), Gel 
filtration HiPrep 26/60 (column 26 mm inside diameter, 20 cm length) Superdex 200 and 
Sephacryl S-400 HR (GE healthcare, Freiburg, Germany) and UNICORN control, evaluation and 
documentation software (GE healthcare, Freiburg, Germany). 
DNA-sequencing machine: 3700 DNA analyzer and BigDye
TM 
cycle-sequencing terminator 
chemistry (V 3.0) from Applied Biosystems.  
DNA gel electrophoresis apparatus: Wide mini and mini cells for DNA agarose electrophoresis 
from BioRad, and the power suppliers from BioRad.  
Dynamic light scattering apparatus: Koheras (Kleinostheim)  
Electron microscopy: 400T electron microscope (Philips, Eindhoven, The Netherlands) 
Electroporation apparatus: Multiporator from Eppendorf and 0.2 cm or 0.4 cm cuvettes from 
BioRad.  
ELISA reader: Synergy HT from Bio-Tek Instruments (Bad Friedrichshall). 
ELISA washer: Elx405 from Bio-Tek Instruments. 
Strain Source Genotype 
DH5α Invitrogen 
F- (f80d Lac 2ΔM15) Δ(LacZYA-argF) U169end A1 rec1hsdR17(rk- 
mk+) deoR thi-1 supE44 gyrA96 relA1 λ- 
XL1-Blue Stratagene 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F′ proAB laclIq 
ZΔM15 Tn10 (Tetr)] 
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Freeze-drying machine (Lyophilizer): Alpha 1-4 LSC (Company Christ, Osterode) combined 
with vacuum pump RZ6 (Vacuubrand, Wertheim). 
Incubators: CO2 Incubator CB Series (Binder, Tuttlingen)  
Innova
TM 
4340 incubator shaker: New Brunswick scientific (Nürtingen).  
Microfluidizer: M-110L from Microfluidics (Newton, MA, USA).  
Micromass Q-TOF micro Mass spectrometer equipped with a standard electrospray unit with 
variable in-source pressure, MALDI source, connected to an Ultimate 3000 Cap-LC system 
(Biobasic HPLC C18 column, Dionex).  
Microscopes: Leica (Wetzlar). 
PCR Thermocyclers: Primus and Primus 96 plus from MWG-Biotech, Mastercycler Personal 
from Eppendorff, DNA Engine from MJ Research Inc (Watertown, USA).  
Photometers: Spectrophotometer Uvikon 930 from Kontron (Neufahrn) and Cuvettes # 67.742 
from Sarstedt (Nümbrecht). NanoDrop, ND1000 from Thermo Scientific. 
Probe sonicator: Braun Biotech (Melsungen).  
Protein gel electrophoresis equipment: Mini PROTEAN II
TM 
from Bio-Rad.  
Software: Windows XP operating system (Microsoft); Microsoft Office 2010 (Microsoft); Adobe 
Photoshop CS2 (Adobe); Clone manager suite 8; Vector NTI advance 10; AIDA image analyzer 
v.4.14; MassLynx 4.0 SP4 Software (Waters Micromass), CLC Main workbench 6.5, EndNote X1; 
PyMOL v 0.99 and Chemdraw 12. 
UV-Transilluminators: Wavelength 302nm and UVT-20M from Herolab (Wiesloch). UV-
chamber from BioRad.  
Vacuum filtration unit: Sartorius (Göttingen). 
II.2 Methods 
 Recombinant DNA technologies II.2.1
All experiments related to genetic engineering were performed according to the regulations of “S1-
Richtlinien” General recombinant DNA techniques, i.e. DNA precipitation, restriction enzyme 
digestion, DNA ligation, DNA agarose gel electrophoresis, were performed according to the 
standard protocols described in Sambrook and Russell (2001).  
 Preparation of heat-shock competent E. coli II.2.1.1
A single colony of E. coli strain of either DH5α or XL1-Blue grown on LB-agar plate was 
inoculated into 5 ml LB medium in 15 ml falcon tube and incubated overnight (o/n) at 37ºC. Two 
ml of the o/n culture was transferred into 200 ml of LB medium. The cells were cultured at 37°C 
for 3-4 hours until the OD600 nm reached 0.4-0.5 and then transferred to an ice-cold tube. After 
placing on ice for 10 min, the cells were recovered by centrifugation (3500 ×g/4°C/3 min). The 
supernatants were decanted and the pellets were resuspended gently in 10 ml ice-cold 0.1 M CaCl2 
and kept on ice for 20 min. The cells were recovered by centrifugation as described above and 
resuspended in 3 ml ice-cold 0.1 M CaCl2 /15% (v/v) glycerol. One hundred μl-aliquots of the 
suspension were dispensed into pre-chilled 1.5 ml microcentrifuge tubes, frozen immediately in 
liquid nitrogen and stored at -80°C. 
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 Transformation of E. coli by heat-shock II.2.1.2
Frozen aliquots (100 µl) of the heat-shock competent E. coli cells (II.2.1.1) were thawed on ice for 
5-10 min and mixed gently either with plasmid DNA (up to 200 ng) (II.2.1.12) or ligation products 
(II.2.1.19) as described by Sambrook and Russell (2001). Together with DNA, the cells were 
stored on ice for 30 min. The cells were then suddenly exposed to 42°C for 90 seconds and 
immediately placed on ice for further 2 min. Then, 800 μl of pre-warmed (37°C) LB medium were 
added to the tubes and incubated at 37°C for 1 h. After incubation 200 μl of cells were plated onto 
a LB-agar plate supplemented with appropriate antibiotics and were incubated at 37°C over night. 
 Preparation of electrocompetent E. coli II.2.1.3
Electrocompetent E. coli were prepared from strains DH5α and XL1-blue as described by Dower 
et al. (1988). A single bacterial colony from an LB plate was inoculated in 5 ml LB-medium and 
cultured at 37°C o/n. Five ml of fresh o/n culture was transferred into 500 ml of LB medium. The 
cells were incubated at 37°C for 3-4 hours until the mid-log phase (OD600 nm= 0.5-0.6). Then the 
cells were placed on ice for 15-20 min and harvested by centrifugation (3000 ×g/4°C/10 min). 
Cells were washed three times with sterile cold water while the water amount was reduced to half 
in each washing time and resuspended in ice-cold 10% (v/v) glycerol to a 300-fold concentration 
from the original culture volume (at >1010 cells/ml). Sixty μl aliquots were frozen directly in liquid 
nitrogen and stored at -80°C. 
 Transformation of E. coli by electroporation II.2.1.4
Transformation via electroporation was accomplished according to the protocol provided by 
Stratagene. Frozen aliquots of electrocompetent E. coli cells (II.2.1.3) were thawed on ice for 5-
10 min and were mixed with either 100 pg of plasmid DNA or 100-200 ng of desalted ligation 
product (desalting was performed using desalting membrane). The cell/DNA mixture was 
transferred into a prechilled sterile electroporation cuvette (0.2 cm or 0.1 cm gap) and put into a 
safety chamber. After application of a 5 ms electric pulse (2.5 kV for 0.2 cm and 1.7 kV for 0.1 cm 
gap electrocuvette) the cells were immediately diluted with 900 µl of pre-warmed (37°C) SOC 
medium and incubated at 37°C with shaking for 1 h. Finally, 200 μl of the cells were plated onto 
LB-agar plates containing appropriate antibiotics and incubated at 37°C for o/n. 
 Preparation of electrocompetent A. tumefaciens II.2.1.5
A single colony of A. tumefaciens strain GV3101 grown on a YEB-agar plate containing 25 µg/ml 
rifampicin (Rif) and 25 µg/ml kanamycin (Km) (YEB-Rif-Km) was used to inoculate 10 ml of 
YEB-Rif-Km medium in a 100 ml Erlenmeyer flask and incubated at 28°C for two days with 
shaking (160 rpm). One ml of the culture was transferred into 100 ml of YEB-Rif-Km medium and 
cultivated at 28°C for 15-20 h with shaking (160 rpm) until the OD600 nm reached 1-1.5. After that 
the cells were kept on ice for 15 min and harvested by centrifugation (4000 ×g/4°C/5 min). The 
culture medium was decanted and the cells were sequentially washed three times with 100 ml of 
ice-cold ddH2O and one time with 100 ml of ice-cold sterile 10% (v/v) glycerol. After each 
washing step the cells were spun down by centrifugation (4000 g/4°C/5 min) and finally were 
resuspended in 500 µl of sterile 10% (v/v) glycerol. Around 50 µl aliquots of the suspension were 
Chapter II                                                                                                           Material and methods      
 
30 
 
dispensed into prechilled 1.5 ml microcentrifuge tubes, frozen immediately in liquid nitrogen and 
stored at -80°C. 
 
YEB-Rif-Km medium: 
Nutrient broth  0.5% (w/v) 
Yeast extract 0.1% (w/v) 
Peptone 0.5% (w/v) 
Sucrose 0.5% (w/v) 
The following compounds were added after autoclaving and cooling to 55°C: 2 mM MgSO4, 25 
µg/ml rifampicin and 25 µg/ml kanamycin. 
 Transformation of A. tumefaciens by electroporation II.2.1.6
About 0.2-0.4 µg of plasmid DNA (II.2.1.12) in sterile ddH2O was added to a thawed aliquot of 
electrocompetent agrobacteria cells (II.2.1.5) and placed on ice for 5 min. The cell/DNA mixture 
was transferred into a prechilled electroporation cuvette (0.2 cm) and put into a safety chamber. 
After application of the pulse (2.5 kV, 5ms), the cells were diluted in 900 µl of SOC medium in a 
15 ml falcon tube and incubated at 28°C for 1 h with shaking (160 rpm). Finally, 1-10 µl of the 
cells were plated on YEB-agar containing 25 µg/ml rifampicin (Rif), 25 µg/ml kanamycin (Km) 
and 50 µg/ml carbenicillin (Carb) (YEB-Rif-Km-Carb) and incubated at 28°C for 2-3 days. As a 
negative control, transformation of Agrobacterium cells with H2O was performed. 
 Determination of the transformation efficiency of competent bacteria  II.2.1.7
The efficiency of transformation for each new batch of competent cells was assessed by test 
transformations with known concentrations (100 pg) of supercoiled plasmid pUC19 for E. coli and 
pTRAkc for A. tumefaciens cells. The following equation was used to calculate the transformation 
efficiency (CFU/µg): 
 
CFU on control plate × 1 × 106 pg × volume of transformants × dilution factor 
   pg plasmid DNA              μg                 volume plated      
 
CFU: Colony forming unit. 
 
The transformation rates were obtained; for heat-shock competent E. coli >106/µg pUC19, 
electrocompetent E. coli >108/µg pUC19 and A. tumefaciens >103/µg pTRAkc.   
 Transformation of P. pastoris by electroporation II.2.1.8
Transformation of P. pastoris was accomplished according to the method published by Wu and 
Letchworth (2004) with some modifications. A single colony of wild type P. pastoris strain X-33 
grown on YPD-agar plate was selected to inoculate 20 ml YPD medium in a 100 ml Erlenmeyer 
flask and incubated at 28°C for 24 h with shaking (160 rpm). Around 20 µl of yeast culture were 
transferred to 100 ml of fresh YPD medium and incubated at 28°C until the cell density reached 
OD600 nm = 1-2. The cells were collected by centrifugation (1500 ×g/4°C/5 min). The number of the 
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cells was calculated according to the equation of 1 OD600 nm = 5 × 10
7 cells/ml (EasySelectTM 
Pichia expression kit user manual, Invitrogen). For each transformation, 8 × 108 cells were 
suspended at room temperature for 30 min in 8 ml of 10 mM Tris-HCl containing 100 mM LiAc, 
10 mM DTT, 0.6 M sorbitol, pH 7.5. The cells were then pelleted by centrifugation 
(1500 ×g/4°C/5 min), resuspended in 1.5 ml of ice-cold 1 M sorbitol and were transferred to a 2 ml 
microcentrifuge tube. Then, the cells were washed three times with 1.5 ml ice-cold 1 M sorbitol 
and resuspended in 1 M ice-cold sorbitol at a final concentration of about 1010 cells/ml. After that 
100 µl of those cells were mixed with 3-5 µg of linearized plasmid DNA (II.2.1.15, digested by 
SacI) in 1-10 μl of water, transferred to a prechilled electroporation cuvette (0.2 cm gap) and 
stored on ice for 5 min. Then the electroporation pulse (1.5 kV, 5 ms) was applied and the cells 
were immediately diluted in 1 ml of ice-cold 1 M sorbitol. The cells were incubated at 28ºC for 1-
2 h without shaking. Finally, 50-200 μl aliquots were spread on YPDS plates containing 100 μg/ml 
of Zeocin™. The plates were then incubated at 28°C for 3–6 days until colonies formed. The 
growing colonies from the Zeocin™ containing plates were streaked on both MD (minimal 
dextrose) and MM (minimal methanol) plates to screen for Mut+ (methanol utilization plus) strains 
as described (EasySelectTM Pichia expression kit user manual, Invitrogen). 
 
YPD: 
Yeast extract 1% (w/v) 
Peptone 2% (w/v) 
Dextrose (D-glucose) 2% (w/v) 
YPDS:               
Yeast extract 1% (w/v) 
Peptone 2% (w/v) 
Dextrose 2% (w/v) 
Sorbitol 1 M 
MD:                                     
YNB 1.34% (w/v) 
Biotin 4×10–5% (w/v) 
Dextrose 2% (w/v) 
MM:                    
YNB 1.34% (w/v) 
Biotin 4×10–5% (w/v) 
Dextrose 2% (w/v) 
Methanol 0.5% (v/v) 
  
 Culturing of E. coli and glycerol stock preparation II.2.1.9
Individual colonies of all strains were obtained by plating the corresponding strain on LB agar 
plates. For recombinant bacterial selection, LB agar containing 100 µg/ml ampicillin were used. 
Incubation was performed at 37°C. The plates were stored at 4oC for short periods (less than 2 
weeks). For long term storage, 5 ml LB medium containing the suitable antibiotics and 2% (w/v) 
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glucose was inoculated with a single recombinant colony and grown overnight at 37°C with 
vigorous shaking (160 rpm). Glycerol stocks were prepared by mixing 800 µl of a fresh overnight 
culture with 200 µl of 80% (v/v) sterile glycerol in water. Bacteria glycerol stocks were stored at -
80°C.  
 Culturing of recombinant A. tumefaciens and glycerol stock preparation II.2.1.10
Positive recombinant Agrobacterium colonies containing the plasmid of interest were inoculated in 
10 ml of YEB-Rif-Km-Carb medium and cultivated at 28°C for 2 days with vigorous shaking (160 
rpm). The culture was transferred to 15 ml falcon tubes and cells were collected by centrifugation 
at 4,000 g for 10 min at 15°C. The cells were resuspended in a 1:1 volume of fresh YEB Rif-Km-
Carb medium and glycerol stock media (GSM). The suspension was stored at -80°C in 500 µl 
aliquots and used for further experiments. 
 
Glycerol stock medium (GSM): 
Glycerol 50% (v/v) 
MgSO4 100 mM 
Tris-HCl, pH 7.4 25 mM 
  
 Culturing of recombinant P. pastoris and glycerol stock preparation II.2.1.11
A single colony of each recombinant strain was cultured in 20 ml YPD containing 100 µg/ml 
ZeocinTM for 2 days at 28°C with vigorous shaking (160 rpm). Then 1 ml of that culture was used 
to inoculate 100 ml of YPD containing 100 µg/ml ZeocinTM and cultivated for o/n at 28°C with 
shaking (160 rpm). Next day the cells were harvested by centrifugation (1500 g/4°C/5 min) and 
resuspended in fresh YPD containing 15% (v/v) glycerol with a final cell concentration OD600 nm of 
50–100 (1 OD600 nm = 5 × 10
7 cells/ml). Finally, 1 ml of cell aliquots were frozen in liquid nitrogen 
and then stored at -80°C for further experiments. 
 Isolation of plasmid from recombinant E. coli II.2.1.12
Plasmids were isolated in high quality from relevant recombinant E. .coli based on the alkaline 
lyses method (Sambrook and Russell, 2001) using Nucleospin Plasmid kit Mini and Midi 
(Machery-Nagel) according to the manufacturers’ instructions. Purity and yield of plasmid DNA 
was checked by reading the UV absorbance at 260 and 280 nm via NanoDrop spectrophotometer 
according to Sambrook and Russel (2001) or by analytical agarose gel electrophoresis (II.2.1.13). 
Isolated DNA samples were stored at -20°C and used for cloning and sequencing purposes. 
 Analytical agarose gel electrophoresis of DNA II.2.1.13
Plasmid DNA (II.1.8), PCR fragments (II.2.1.18) and enzymatically digested DNA (II.2.1.15) were 
electrophoretically separated on 0.8-1.2% (w/v) agarose gels prepared in TBE buffer containing 
0.1 μg/ml ethidium bromide as described by Sambrook and Russel (2001). Known amount of the 
DNA molecular marker such as 1 kb (Fermentas) or 100 bp (Roth) DNA ladder were used for 
evaluation of sample size, integrity and determination of DNA concentration. The DNA was 
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visualized on an UV transilluminator by illumination at 302 nm. The gel pictures were documented 
by using a universal hood II for Gel Doc XR (BioRad). 
 
10X TBE electrophoresis buffer (pH 8.3):                                      
Tris-base 900 mM 
Boric acid 900 mM 
EDTA 25 mM 
 Preparative agarose gel electrophoresis of DNA II.2.1.14
Preparative gel electrophoresis was used for isolation of DNA fragments after restriction enzyme 
digestion (II.2.1.15) or PCR-amplified DNA (II.2.1.18) prior to cloning into an appropriate vector. 
After electrophoresis, the desired DNA fragments were excised from the gel and purified using the 
“NucleoSpin
 
Extract II Kit l” (Machery-Nagel) according to the manufacturers’ protocol. 
 Restriction digest of DNA and preparative agarose gel electrophoresis II.2.1.15
Restriction endonucleases, appropriate buffers and BSA solution were obtained from New England 
Biolabs. Single or double restrictions of DNA fragments were performed at suitable buffer and 
temperature according to the manufacturers’ instruction. 
 Quantification of DNA II.2.1.16
The concentration of plasmids and DNA fragments were quantified using NanoDrop 
spectrophotometer according to the manufacturers’ instruction. In order to know the proper amount 
of DNA in ligation mixture, analytical agarose gel electrophoresis (II.2.1.13) followed by 
measurement of band intensity using AIDA software (according to the manufacturers’ instruction) 
was performed.  
 Ligation of the DNA fragments II.2.1.17
Digested DNA fragments (II.2.1.15) including insert and vector were ligated together in 3:1 ratio 
in order to obtain the desired vector by using 80 U of T4 DNA ligase or 1 µl Quick T4 DNA ligase 
(NEB) in buffer systems recommended in the manufacturers’ protocol. The final volume of 
ligation mixture was adjusted to 20 µl. Sticky and blunt end ligations were carried out at 22°C for 
30 min or longer (up to overnight). Ligation product was used for E. coli transformation (II.2.1.2, 
II.2.1.4). 
 PCR amplification II.2.1.18
Polymerase chain reaction (PCR) was used for amplification of IBD-VP2 from the TA-IBD-VP2 
kindly provided by Dr. Haleh Hashemi (National institute of genetic engineering and 
biotechnology, Tehran, Iran). The vector containing the cDNA sequence of IBDV-VP2 (NCBI 
code: AY704912). The PCR product containing the gene encoding the mature VP2 (441 aa) was 
used as a template in PCR for generation of other derived cDNA constructs. The DNA fragments 
encoding the cytochrome b5 membrane anchor was generated using pTRAkc-Cyt-m/vIL-10 
(Bortesi et al., 2009) as template in PCR. DNA amplification was carried out based on the protocol 
of Sambrook and Russell (2001), using ExpandTM high fidelity PCR system (Roche). The reactions 
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were performed in 0.2 ml PCR reaction tubes using a DNA thermal cycler (MWG-Biotech). The 
cycler contained a heated lid to prevent evaporation of the reaction mixture. 
For screening of recombinant E. coli and agrobacteria, colony-PCR was performed to detect 
plasmids as described by Jesnowski et al. (1995). Isolated colonies were picked using sterile tips 
and suspended in 20 µl of sterile distilled water in PCR tubes. The suspension was boiled for 
10 min and cell debris was spun down by centrifugation (13000 g/RT/5 min). Finally, 10 µl of the 
supernatant was used for PCR reactions in a total volume of 25 µl.  
The optimal annealing temperature (Tm) of the primers was experimentally optimized or calculated 
based on the empirical formula of Wu et al. (1991): 
 
Tm = {22 + 1.46 [2× (G + C) + (A + T)]} 
PCR reactions were performed in a total volume of 25 µl as described below: 
 
Table  II.6 PCR master mix. 
 
Amplification was performed under the following conditions: 
                                                          Step 1: 5 min 95°C 
                                                          Step 2: 1 min 95°C 
                                                          Step 3: 1 min 54°C    
                                                          Step 4: 1 min 72°C 
                                                          Step 5: 10 min 72°C 
 
The annealing temperature (step 3) and the time for extension (step 4) were changed according to 
Tm value of primers and the length of the target gene respectively. 
 
SOE-PCR (Horton et al., 1989) was exploited to introduce either extra sequence to a DNA 
fragment or to fuse two DNA fragments together. In the first case, a primer (forward) containing a 
matching sequence at the 3’ end with the template DNA fragment together with the backward 
primer was used to amplify the template for 5 cycles as mentioned above. The forward primer had 
an extra sequence at the 5’ end. By this way the extra sequence was introduced to the PCR 
Components Volume Final concentration 
10x PCR buffer 2.5 µl 1X 
50 mM MgCl2 1.0 µl 1.5 mM 
10 mM dNTPs 0.5 µl 0.2 mM each 
1.5 pmol forward Primer 2.0 µl 0.12 pmol 
1.5 pmol backward primer 2.0 µl 0.12 pmol 
Template DNA 2.0 µl 0.1-10 ng 
Taq DNA polymerase (5U/ml) 0.25 µl 1.25 units 
dd H2O to 25 µl  
30 X 
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products. Then the next primer was added to the PCR mixture. This primer had a matching 
sequence at the 3’ end with the forward primer and could also carry an extra sequence at the 5’ end 
which again leads to the introduction of extra sequences to the primary PCR product. Performing 
PCR using this primer and the backward primer elongated the PCR product and led to introduction 
of the desired sequence. For fusion of two sequences, initially two separate PCR were performed. 
Then, the SOE-PCR was carried out by mixing equimolar amounts of two overlapping PCR 
fragments in a total reaction volume of 25 µl (2.5 µl 10x PCR buffer, 1.75 mM MgCl2, 20 pmol of 
each dNTP, and 0.2 units ExpandTM high fidelity DNA polymerase mix) under the following 
conditions: an initial denaturation for 5 min at 95°C followed by 4 cycles of 95°C for 1 min, 37°C 
for 1 min and 72°C for 1 min. Then the reaction mixture from the SOE-PCR was mixed with 25 µl 
of PCR cocktails containing 2.5 µl 10x PCR buffer, 1.75 mM MgCl2, 20 pmol of each dNTP, 10 
pmol of forward and backward terminal primers, 0.2 units ExpandTM high fidelity DNA 
polymerase mix and again another normal PCR was performed as mentioned above. The 
performance of each PCR reaction was checked by running 5 μl of each reaction on agarose gels 
(II.2.1.13) with appropriate DNA markers. 
 DNA sequencing II.2.1.19
Dye termination sequencing based on chain termination method described by Sanger et al. (1977 
was performed using the Applied Biosystems 3700 DNA analyzer and BigDyeTM terminator 
sequencing kit. Chromas software package (Technelysium Pty Ltd) was used for displaying the 
chromatogram files. For evaluation of sequencing data the Vector NTI advance10 software 
package and Clone manager software professional suit version 8 (Sci-Ed software) were used. 
 Expression and purification of recombinant protein II.2.2
Recombinant proteins were transiently expressed in tobacco leaves (II.2.2.3). They were also 
stably expressed in tobacco (II.2.2.4) and yeast cells (II.2.2.6). Recombinant proteins were 
extracted, purified and characterized (II.2.2.5, II.2.3).  
 Growth and maintenance of tobacco plants II.2.2.1
Tobacco seed plants were cultured and grown in a greenhouse in ED73 standard soil (Patzer, 
Sinntal-Jossa) with 0-30% (v/v) sand under supplementary illumination of 10000 Lux (plus the sun 
light), 70-90% humidity and 16 h light/ 8 h darkness photoperiod at 24°C. To prevent pollination 
from other plants, flowers were covered with plastic bags with micropores. Mature, dried seeds 
were stored in paper bags at RT. 
 Preparation of recombinant A. tumefaciens II.2.2.2
Recombinant A. tumefaciens (II.2.1.10) were grown followed by vacuum infiltration of tobacco 
leaves according to Kapila et al. (1997) and Vaquero et al. (1999) with minor modifications. 
Inoculation of recombinant agrobacteria was initiated by taking 50 µl of frozen cells from the 
glycerol stock (II.2.1.10) into 5 ml of liquid YEB-Km-Rif-Carb medium in a 15 ml falcon tube. 
The culture then incubated at 28°C o/n with shaking at 160 rpm. Next day, a fraction of the culture 
was inoculated 1:100 into fresh YEB-Km-Rif-Carb medium in a 250 ml Erlenmeyer flask. The 
culture was incubated o/n as described above. The day after, filter sterile acetosyringone (200 
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mM), 1 M glucose and 1 M MES (pH 5.6) were added to the culture to a final concentration of 
20 µM, 10 mM and 10 mM, respectively. The incubation was continued o/n. Next day, the OD600nm  
was measured; calculated amount of cells were harvested by centrifugation (4000 ×g/RT/15 min) 
and resuspended in infiltration medium until the OD600 nm reach 1.0. The culture was incubated at 
RT for 2 h. The cell suspension was used for vacuum infiltration of cultivated tobacco plant leaves 
(II.2.2.2). 
 
YEB-Km-Rif-Carb:                                  
Nutrient broth                  0.5% (w/v)   
Yeast extract                 0.1% (w/v)   
Peptone                 0.5% (w/v)   
Sucrose                 0.5% (w/v)   
 
2 mM MgSO4, 25 µg/ml kanamycin, 25 µg/ml rifampicin and 50 µg/ml carbenicillin were added 
after autoclaving and cooling to 55°C. 
 
Infiltration medium:                             
MS basic salt mixture 0.43% (w/v) 
Glucose 20 mM 
Sucrose 
Acetosyringone                 
                    10% (w/v) 
                      200 µM 
 Vacuum infiltration and/or injection of tobacco leaves with recombinant II.2.2.3
agrobacteria 
N. tabacum cv. Petite Havana SR1 plants were cultivated in the greenhouse (II.2.2.1). Top leaves 
from young plants were harvested and placed into a stainless steel beaker with 200 ml of 
agrobacteria cell suspension (II.2.2.2) and fixed with a mortar to allow complete covering of the 
leaves with the cell suspension. A continuous vacuum (60-80 mbar) was applied for 25 min. After 
removing the vacuum, the leaves were briefly rinsed in tap water and kept on wet Whatman paper 
no.1 with adaxial side upwards. The plastic tray was sealed with saran wrap and placed at 22°C 
with a 16 h photoperiod (7500 lux) for 3-4 days. Leaves were weighed, frozen in liquid nitrogen 
and stored at -80°C until use. As a negative control, tobacco leaves were infiltrated with 
agrobacteria suspension, which harbor a pTRAkc plasmid but lack the gene of interest (empty 
vector control). As an alternative for small-scale expression and comparisons, agro-injection was 
employed. Briefly, agrobacterium suspension was applied directly into mesophyll space of leaf 
cells by injection through an invented spot wound using a syringe without needle. This method 
provides rapid expression analysis in natural form without separating leaves from plant and for 
longer investigation period. The injected plants were placed at 22°C with a 16 h photoperiod for 3 
days.    
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 Recombinant Agrobacterium-mediated stable transformation of Nicotiana tabacum II.2.2.4
Wild type seeds of N. tabacum L. cv. Petite Havana SR1 were grown on MS I medium in weck 
glasses. The youngest leaves were harvested and used for transformation. They were cut into small 
pieces (0.5-1 cm2) after removal of the central vein. Then, they were transferred into sterile glasses 
containing 100 ml of recombinant Agrobacterium suspension (OD600 nm = 1.0) and incubated at 
room temperature (RT) for 10-15 minutes. The leaf pieces were then transferred onto sterile water-
wetted Whatman papers in Petri dishes. They were incubated at 23-25 °C in dark for 2 days. 
Afterwards, they were moved onto MS II plates and incubated at 23-25 °C in 16 h light and 8 h 
darkness photoperiod for 3-4 weeks. After shooting, shoots were cut and moved onto MS III plates 
and incubated at the same condition like before for 10-14 days until roots emerged. The transgenic 
plantlets (T0) were transferred into weck glasses containing MS III medium and incubated at the 
same conditions. Two weeks later, they were ready to transfer to soil. They were grown in standard 
cultivation soil, ED73 (Patzer KG, Sinntal-Jossa) with 0-30% (v/v) sand under the following 
conditions: 16 h artificial light, 25°C (or higher depending on the outside temperature), 10,000 lux 
(plus the sun light) and 70-90% humidity. Young leaves of regenerated plants were used for 
screening analysis as previously described (II.2.2.4, II.2.2.5). To prevent pollination from other 
plants, flowers of designated plants were covered with plastic bags with micro pores to induce self-
pollination. Mature, dried seeds (T1) were stored in the seed bank in paper bags at RT. 
 
MS I medium:                              
MS basic salt mixture  0.44% (w/v) 
Sucrose 2.0% (w/v) 
Thiamine-HCl 0.2 mg/l 
 
The pH was adjusted to 5.8 with 1 N NaOH (for preparation of solid medium, 0.8% (w/v) agar was 
added). The medium was autoclaved and 500 μl of vitamin solution I were added upon cooling to 
55 °C. 
 
MS II medium:   
MS medium supplemented with:     
BAP  1 mg/l 
NAA 0.1 mg/l 
Kanamycin 
Claforan 
Betabactyl  
Agar 
100 mg/l 
             100 mg/ml 
              200 mg/ml 
             0.8% (w/v) 
MS III medium:     
MS medium supplemented with:                              
Kanamycin  100 mg/l 
Claforan 
Betabactyl 
Agar 
200-250 mg/l 
200-250 mg/l 
0.8% (w/v) 
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Vitamin solution I:     
Glycine  0.4% (w/v) Nicotinic acid Pyridoxine 0.1% (w/v) 0.1% (w/v) 
 
Filter sterilized and stored at 4°C. 
 Expression and purification of IBD-VP2 from tobacco leaves II.2.2.5
Extraction of either transiently produced IBD-VP2 from vacuum infiltrated tobacco leaves 
(II.2.2.3) or transgenic tobacco plants (II.2.2.4) were performed by grinding the leaves in a kitchen 
blender in companion with 2 ml of extraction buffer per gram leaf material. Cell debris was 
removed by centrifugation (15000 ×g/4°C/20 min) and the supernatant was used in SDS-PAA gel 
electrophoresis followed by either Coomassie staining (II.2.3.2) or immunoblot (II.2.3.3 and 
II.2.3.4).  
For purification, the leaves were grinded as above in companion with purification buffer with pH 
4.0. After centrifugation as above, the clarified extract was passed through double layer of 
miracloth filter. Then the pH was adjusted to 8.0 and NaCl was applied up to a final concentration 
of 1 M. Following gently stirring at 4°C for 1 h, one more round of centrifugation was performed 
as above. Then the supernatant was used for purification of IBD-VP2 via IMAC. The clarified 
extract was loaded on a pre-equilibrated Ni-NTA resin column. Pre-equilibration of the column 
resin was performed by washing 1 ml of resin with 20 column volumes of PBS (phosphate buffer 
saline). The clarified extract was passed through the column with 1 ml/min flow rate. The resin 
was washed with 20-30 column volumes of PBS and the protein was eluted by 2-3 ml of elution 
buffer (PBS) containing 250 mM imidazole. The elution fractions were mixed and separated 12% 
(w/v) SDS-PAA gel. The target band for the protein of interest was excised from the gel and the 
protein content was recovered using EzWayTM PAG protein elution kit (Koma Biotech.) according 
to the manufacture’s instruction.  
 
Protein extraction buffer: 
NaPO4 pH 7.0 50 mM 
NaCl 500 mM 
Na2S2O5 
Tween 20 
10 mM 
0.5% (v/v) 
 
Purification buffer (pH 4.0):                              
Acetate buffer                         100 mM 
Ascorbic acid 50 mM 
β-mercaptoethanol 5 mM 
Tween 20 0.5% (v/v) 
 
As an alternative purification method, ultracentrifugation was exploited. About 15 gram transiently 
transformed tobacco leaves were grinded while mixed with 45 ml (1:3 ratios) extraction buffer (25 
mM NaPO4 pH 7.0, 100 mM NaCl, 50 mM ascorbic acid, pH 5.3). The extract was passed through 
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two layers of Mira-cloth filter. Two tablets of complete EDTA-free protease inhibitor cocktail 
(Roche) were added for each 45 ml of extract. The sample were incubated at RT for 1 hour and 
then centrifuged at 27,261 ×g for 30 min to remove the plant debris. To concentrate the extracts, 
40% ammonium sulphate (226 g/l) was gradually added to dissolve rapidly avoiding accumulation 
of undesirable high local salt concentrations. Then centrifugation at 50000 ×g for 30 min at 4°C 
was carried out. The pellet were resuspended in 4 ml buffer (25 mM NaPo4 pH 7.0, 100 mM NaCl, 
pH 6.8) and loaded on prepared sucrose gradient tubes. The sucrose gradient was generated by 
tandem layering of 4.7 ml from 60, 50, 40, 30, 20 and 10% (w/v) sucrose dissolved in extraction 
buffer (25 mM NaPo4 pH 7.0, 100 mM NaCl pH 6.8). Tubes were incubated for 2 h at 4°C to allow 
diffusion and generation of 10-60% (w/v) continuous sucrose gradient column. Three ml of 
extracts were layered on the top of the column. Centrifugation was performed at 100000 ×g for 3 h 
at 4°C. Thirty-three fractions were generated by carefully removing 1 ml from the top to the 
bottom of the tube and analysed by ELISA (II.2.3.1), Coomassie staining (II.2.3.2) and 
immunoblot (II.2.3.3). 
 Expression and purification of IBD-VP2 from P. pastoris II.2.2.6
The yeast P. pastoris was used as an alternative system for production of IBD-VP2. After 
transformation, ten recombinant P. pastoris (X-33) colonies were selected from YPDS plates 
(II.2.1.8) for each construct and the production level of IBD-VP2 was compared at small scale 
(10 ml of culture medium) between various colonies by extracting the cellular soluble protein 
content using Y-PER yeast protein extraction reagent (Pierce) according to the manufactures’ 
instruction followed by performing an immunoblot (II.2.4.3). A colony which produced relatively 
more amount of protein (IBD-VP2) was designated for glycerol stock preparation (II.2.1.11).  
For medium-scale expression and purification, 20 ml of YPD medium containing 20 µl of Zeocin 
was inoculated with the glycerol stock and was cultured for 2 days at 28°C with vigorous shaking. 
The day after, 2 ml of the main culture was transferred to 200 ml of YPD containing 200 µl 
Zeocin™ and incubated at the same condition up to the following day. Then the OD600 nm was 
measured, the cells were harvested by centrifuge (3000 ×g/RT/5 min) and resuspended in 1 L of 
BMMY medium containing 0.5% (v/v) methanol and the OD600 nm was adjusted to ~ 1.0. The 
culture was incubated in baffled Fernbach flasks for overnight at 28°C with vigorous shaking and 
then the methanol concentration was gradually increased from 0.5%-1% (v/v) during additional 3 
days of growth. The cell-free medium was collected following centrifugation of the 1 L culture at 
3000 ×g for 10 min at 4°C and was concentrated to 50 ml by passing through a 30 kDa cut off 
membrane (Schleicher & Schuell) with the help of the cross-flow technique. For protein extraction, 
the harvested cells were resuspended in breaking buffer and disrupted by five passes in a 
microfluidizer (Newton, MA, USA). The supernatant was collected after centrifugation at 13,000 
×g for 30 min at 4°C.  For purification, the IBD-VP2 content of the cell extract and concentrated 
medium was precipitated by addition of 50% ammonium sulfate and resuspended in 5 ml 
phosphate-buffered saline (PBS). The extract was purified by size exclusion chromatography 
(SEC) on a Hiprep 26/60 Sephacryl S-400 HR column (GE HealthCare, Freiburg) and the SVP 
elution fractions were concentrated using a Vivaspin 20 spin column with a 300-kDa cut-off 
membrane (Sartoriusstedim). As a negative control, 500 ml of wild type X-33 cell culture was 
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processed as the transformed cells (without Zeocin™) and the medium and cell extract was 
extracted and concentrated as explained. The purity of IBD-SVPs was determined by densitometric 
analysis of gels stained with Coomassie brilliant blue using the AIDA software (Raytest isotope 
mass devices GmbH).  
 
BMMY medium (pH 6.0): 
Potassium phosphate 0.1 M 
YNB 1.34% (w/v) 
Biotin                   0.4% (w/v) 
Methanol  0.5% (v/v) 
Yeast extract 1% (w/v) 
Peptone 2% (w/v) 
YNB is yeast nitrogen base without amino acids. 
 
Breaking buffer (pH 4.0): 
Sodium acetate pH 4.0 0.1 M 
PMSF 1 mM 
EDTA                   1 mM 
Glycerol                         5% (v/v) 
 Protein analysis II.2.3
 Quantification of proteins II.2.3.1
The concentration of purified protein was determined by BCA assays. Concentration 
measurements were performed in duplicate according to the manufacturer’s instructions, using 
BSA as standard in low binding plate. 
To measure the concentration of IBD-VP2 in tobacco leaves, two leaf disks were cut out, weighted 
and mixed and grinded together with 2 µl of extraction buffer (II.2.2.5) per milligram leaf material. 
Cell debris was removed by centrifugation (13,000 g/4°C/20 min) and the supernatant was 
analyzed in an ELISA. Briefly, cell extracts were coated on polyvinyl chloride 96-well ELISA 
plates serially diluted two-fold with starting dilution factor of 1:50 in PBS and incubated o/n at 4°C 
(wild type tobacco leaf extract and 2 µg of purified IBD-VP2 in wild type tobacco leaf extract 
were used as negative and positive control, respectively). The plates were washed three times with 
PBST and blocked with 2.5% (w/v) skim milk in PBST for 1 h at RT. After washing as above, 
rabbit anti-IBD-VP2 (1:10000 in PBS) was added. Following 1 h incubation at RT and wash, 
horseradish peroxidase-conjugated goat anti-rabbit (final concentration: 0.12 µg/ml in PBS) was 
added. The plates were incubated at RT for 1 h. After washing the plate, the color was developed 
by adding ABTS substrate solution. OD405 nm was measured using a microtiter plate reader. IBD-
VP2 content was calculated according to the ratio of mean of OD405 nm at the saturation point of the 
sample to the mean of OD405 nm of the positive control (known concentration) at the saturation 
point.  
To measure the concentration of IBD-VP2 in Pichia cell cultures, the cells were harvested from 
1 ml of the culture by centrifugation (3000 g/4°C/5 min) and the total soluble protein was extracted 
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using Y-PER yeast protein extraction reagent (Pierce) according to the manufacturer’s instruction. 
Cell debris was removed and the quantification was performed as described above for tobacco 
leaves using ELISA. Wild type X-33 culture was treated in the same manner and used as negative 
control. 
 SDS-PAA gel electrophoresis and Coomassie brilliant blue staining II.2.3.2
Following protein extraction and purification (II.2.2), and quantity of the recombinant proteins 
were studied by discontinuous SDS-polyacrylamide gels (for the stacking gel: T = 4%, C = 2.6%, 
pH 6.8; for the separating gel: T = 12%, C = 2.6%, pH 8.8) (Ausubel et al., 1995) under reducing 
and/or non-reducing conditions (Laemmli, 1970) using a BioRad minicell II apparatus. Before 
loading onto the gel, protein samples were mixed with appropriate 5x sample buffer depending on 
the requirement for reducing or non-reducing conditions. For reducing conditions, samples were 
denatured by boiling for 5 min. The proteins were separated electrophoretically with constant 
180 V for 1 h. Protein bands were visualized by staining with Coomassie brilliant blue or 
transferred to nitrocellulose membrane for immunoblotting analysis (II.2.3.3). Staining and de-
staining of the gels were performed with Fairbank solutions following boiling by microwave and 
constant rocking (Wong et al., 2000). The purity of protein was quantified by densitometry of the 
Coomassie brilliant blue stained gels using AIDA image analysis software. 
 
Reducing SDS-PAGE sample buffer:                                     
Tris-HCl (pH 6.8) 
Glycerol 
62.5 mM 
 10% (v/v) 
β-mercaptoethanol 5% (v/v) 
SDS 
Bromophenol blue 
2% (w/v) 
0.05% (w/v) 
 
Non-reducing SDS-PAGE sample buffer (pH 8.3):                                     
Tris-HCl (pH 6.8) 
Glycerol 
62.5 mM 
 10% (v/v) 
SDS 
Bromophenol blue 
2% (w/v) 
0.05% (w/v) 
 
SDS-PAGE running buffer (pH 8.3):                                     
Tris base 25 mM 
Glycine 192 mM 
SDS 0.1% (w/v) 
 Immunoblot analysis  II.2.3.3
Separated proteins (II.2.3.2) were transferred from an SDS-PAA gel to a PVDF or Hybond™-C 
nitrocellulose membrane (0.45 μm) electrophoretically using the BioRad Mini Protean II tank blot 
device. After blotting the membrane was blocked with 1x PBST buffer containing 5% (w/v) skim 
milk powder. As primary antibody either rabbit anti-His6 tag polyclonal antibody or rabbit- or 
mouse anti-IBD-VP2 (0.2 and 0.1 µg/ml in 1x PBST) were used to detect his-tagged protein and 
Chapter II                                                                                                           Material and methods      
 
42 
 
IBD-VP2, respectively. Binding of the primary antibody was detected by addition of diluted 
(1:5000 in 1x PBST) alkaline phosphatase (AP)-conjugated secondary polyclonal antibodies, either 
goat anti-rabbit or goat anti-mouse (final concentration: 0.2 µg/ml). Bound secondary antibodies 
were finally revealed by addition of substrate BCIP/NBT in AP buffer. 
PBST buffer (pH 7.4):                                   
NaCl 137 mM 
KCl 2.7 mM 
Na2HPO4 8.1 mM 
KH2PO4 1.5 mM 
Tween 20 0.5-1.0% (v/v) 
 
Transfer buffer (pH 8.3):                                      
Tris-HCl 25 mM 
Glycine 192 mM 
Methanol 20% (v/v) 
 
AP buffer (pH 9.6): 
Tris-HCl, pH 9.6 100 mM 
NaCl 100 mM 
MgCl2 5 mM 
 Dot blot analysis  II.2.3.4
Around 5 µl of either tobacco or Pichia cell extracts producing IBD-VP2 (II.2.2.5, II.2.2.6) was 
immobilized on a nitrocellulose membrane. Immobilized IBD-VP2 was detected using rabbit anti-
IBD-VP2 polyclonal antibody (final concentration: 0.2 µg/ml) followed by AP-labeled goat anti-
rabbit polyclonal antibodies (final concentration: 0.12 µg/ml). Binding of AP-conjugated 
secondary antibodies was revealed by adding the BCIP/NBT substrate. This method was used for 
screening of transgenic plants and recombinant yeast colonies. 
 Size exclusion chromatography (SEC) II.2.3.5
Gel filtration was performed using superdex 200 and Hiprep 26/60 Sephacryl S-400 HR column 
(GE HealthCare). The columns were equilibrated with 1x PBS. Purified tobacco- (II.2.2.4) and 
Pichia-derived samples were loaded and run at 1 ml/min on the first and second column, 
respectively. The eluent was collected in 2-ml fractions. For calibration, Ovalbumin (43 kDa), 
Conalbumin (75 kDa), Aldolase (158 kDa), Ferritin (440 kDa) and thyroglobulin (669,000 Da) 
were run as molecular weight standards. The eluate fractions were monitored by UV 215 nm, 225 
nm and 280 nm. The IBD-VP2 containing fractions were evaluated by indirect ELISA. Briefly, 
100 µl of the fractions were coated into 96-well ELISA plate overnight at 4 ºC. The plates were 
blocked using 2.5% (w/v) skim milk in PBST for 1 h at RT. Immobilized IBD-VP2 was detected 
using rabbit anti-IBD-VP2 polyclonal antibody (final concentration: 0.2 µg/ml) followed by AP-
labeled goat anti-rabbit polyclonal antibodies (final concentration: 0.12 µg/ml). Washing was 
performed three times with PBST following each step. The bound antibodies were detected by 
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ABTS as substrate. The OD value was measured at 405 nm with a microplate reader and OD 
values >0.2 above background were considered as positive.  
 Immunogold labelling and transmission electron microscopy (TEM) II.2.3.6
The morphology of the IBD-SVPs was investigated by applying 30-µl aliquots of each sample for 
15 min onto discharged 400-mesh carbon-coated nickel grids (Plano, Wetzlar). Excess particles 
were removed by rinsing with 1x PBS. For conjugation analysis, the grids were blocked for 30 min 
with 1% (w/v) BSA containing 0.1% (w/v) sodium azide. Goat anti-biotin (final concentration: 
0.2 µg/ml in 1x PBS) antibodies labeled with 6-nm gold particles (Aurion, Wageningen, The 
Netherlands) were used for detection. The grids were incubated for 1 h with the antibody and 
washed three times each with 1x PBST and then with distilled water. Finally, the grids were 
negatively stained with a 2% (w/v) aqueous uranyl acetate and observed under a 400T electron 
microscope (Philips, Eindhoven, The Netherlands) operated at 60 kV accelerating voltage. Digital 
images were captured with an Olympus camera (MORADA) and processed using iTEM software 
(Olympus Soft Imaging System GmbH, Münster).  
 Glycan analysis II.2.4
 Immunoblot II.2.4.1
To analyze the glycosylation of the recombinant purified (II.2.2.5, II.2.2.6) IBD-VP2 protein, 
lection blots were performed following SDS-PAGE (II.2.3.2) and immunoblotting (II.2.3.3). For 
this purpose, rabbit anti-xylose (1 µg/ml in 1x PBS) antibody was used as primary antibody in 
immunoblot analysis for detection of tobacco-produced and purified glycoproteins followed by an 
alkaline phosphatase-conjugate goat anti-rabbit secondary antibody (0.2 µg/ml in 1x PBS). 
NBC/BCIP was used as substrate according as described above (II.2.3.3). For glycan analysis of 
purified Pichia-produced IBD-VP2, alkaline phosphatase conjugated Galanthus nivalis lectin    
(0.2 µg/ml) was used for detection of the glycoproteins followed by addition of NBC/BCIP as 
substrate.  
 Enzymatic deglycosylation  II.2.4.2
N-glycan chains of purified tobacco- and Pichia-produced IBD-VP2 proteins were removed by the 
peptide N-glycosidase F (Roche). Around 10 µg of purified IBD-VP2 was deglycosylated by 
incubating overnight at 37°C with 2 U of N-glycosidase F in PBS (containing 10 mM EDTA, pH 
7.4) to a final volume of 100 µl. The cleavage of the glycan branches resulting in a lower 
molecular weight and increased mobility was monitored by SDS-PAGE (II.2.3.2).  
 Glyco-proteomics analysis II.2.4.3
Purified tobacco- and Pichia-produced IBD-VP2 proteins were separated by SDS-PAGE and 
Coomassie-stained were cut out of the gel and put in distilled water and stored at 4°C. After the 
pieces were de-stained, carbamidomethylated, concomitantly digested with sequencing-grade 
trypsin and chymotrypsin, proteins were extracted from gel pieces as described (Kolarich et al., 
2006). The protein was taken to dryness in a Speed Vac concentrator and reconstituted with water 
before subsequent LC-MS analysis. Mass spectrometric analysis was performed on a Q-TOF 
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Ultima Global (Waters Micromass) equipped with a standard electrospray unit, connected to an 
Ultimate 3000 Cap-LC system (Dionex) as previously described (Stadlmann et al., 2008). Briefly, 
the tryptic (glyco)-peptides were separated using a Biobasic C18 column (100 x 0.18 mm, Thermo 
Electron), applying an acetonitrile gradient from 5 to 80% (v/v) acetonitrile at a flow-rate of 2 
µl/min, and analyzed in the ES+ MS mode. Data analysis was performed with MassLynx 4.0 SP4 
Software (Waters Micromass). 
 Immunization of mice II.2.5
Five female mice (BALB/c) each was immunized with 50 µg of purified tobacco-derived IBD-VP2 
protein (II.2.2.5) mixed with 40 µl GEBRU adjuvant MM (Gerbu, Wieblingen) via intraperitoneal 
injection. Six further boosts were given with 2 weeks intervals with the same amount of antigen 
and 20 µl GEBRU adjuvant MM per mouse. One mouse was used as a control in the same 
schedule but received just adjuvant without antigen. The final boost was performed 4 days prior to 
sacrifice. Blood samples were collected one week after each immunization and prior to sacrifice. 
Blood was taken from the tail vein making a wound with scissors on top of the tail and taking 5 µl 
of blood. The blood was diluted 100 fold with 1x PBS and stored at -20°C for estimation of 
antibody titers. 
 Determination of antibody titer II.2.5.1
Determination of polyclonal antibody titers in sera of mice was performed by direct ELISA using 
purified IBD-VP2 protein (II.2.2.5) as antigen. Briefly, 1 µg antigen/ml PBS was coated on 
polyvinyl chloride 96-well microtiter plates over night at 4°C. The following day, after washing, 
plates were incubated in 2.5% (w/v) skim milk in 1x PBST again for overnight at 4°C. After 
washing, serially diluted two-fold down of mouse sera, from 1:1,000 to 1:204,800 dilutions, were 
added to the plates. Test sera were also analyzed in wells lacking antigen in order to analyze 
background binding. After one hour incubation at 37°C and washing with 1x PBST, peroxidise-
conjugated goat anti-mouse antibodies were added at 0.2 µg/ml. After 1 h incubation at RT, plates 
were washed and stained with ABTS (2, 2- azino-bis-ethylbenzthiazolin-6-sulfonic acid) substrate 
solution. Extinction was measured at 405 nm after 20 min stain development.  
 Immunization of chickens II.2.6
 Vaccine component preparation II.2.6.1
Sixteen grams of the Pichia cells harvested from 1 litre culture was applied to freeze-drying.  
Freeze-drying was performed after inactivation of Pichia cells by applying to two thermo-cycles; 
heating to 70°C for 5 min directly after harvest followed by incubation for 5 min at 15°C. The 
freeze-drying machine was switched on for 30 min until the pump warmed-up and the 
condensation trap cooled down to -55°C.  Then the frozen samples were placed into the machine 
and the vacuum was adjusted to 0.31 mbar pressure. The process was continued until complete 
dryness of the samples (48 h for about 8 gram of fresh weight cells in a 50 mL falcon tube). 
Purified IBD-SVPs (II.2.2.6) was used in immunization, as well.  
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 Immunization plan II.2.6.2
Sixty-five chickens were hatched (day 0) from specific pathogen free (SPF) eggs (Lohmann 
Tierzucht, Cuxhaven) and divided randomly between 13 experimental groups, 5 for each group, 
according to the table II-7. Chickens were housed in separate isolators as below; Isolator 1: groups 
1, 2, 3 and 4; Isolator 2: groups 5, 6, 7 and 8; Isolator 3: groups 9, 10, 11; Isolator 4: group 12; 
Isolator 5: Group 13, under negative-pressure ventilation and filtrated air positive pressure. They 
were given free access to food and drinking water. Immunization started at day 14 and repeated 4 
times with one-week intervals. A mixture of 50 µg CpG ODN (II.1.7, table II.1.4) plus NaF (100 
mg per kg of chicken weight at the time of vaccination (based on the graph shown in figure II.1)) 
was used as oral adjuvant and Gerbu adjuvant 100 (Gerbu) was used as parenteral adjuvant in the 
immunization procedure. Oral immunization was administrated by oral gavage into the crop. 
Chickens in groups 1 and 2 received orally high dose (250 mg) of lyophilized Pichia cells 
producing IBD-SVP with and without adjuvant mixture, respectively. Chickens in groups 3 and 4 
received orally low dose (25 mg) of lyophilized Pichia cells producing IBD-SVP with and without 
adjuvant mixture, respectively. Chickens in groups 5 and 6, orally received low dose (50 µg) of 
purified IBD-SVP (II.2.2.6) with and without adjuvant mixture, respectively. Chickens in group 7 
and 8 orally received high dose (500 µg) of purified IBD-SVP (II.2.2.6) with and without adjuvant 
mixture, respectively. Chickens in group 9 orally received lyophilized non-transformed Pichia cells 
(250 mg) and were used as Pichia control. Individuals in group 10 received 20 µg of purified IBD-
SVP (II.2.2.6) plus 20 µl Adjuvant 100 intramuscularly (i.m). Birds in groups 11 and 13 were not 
vaccinated and used as challenge and normal control, respectively (table II-7). Birds in group 12 
orally received AviPro Gumboro vac (Lohmann Animal Health GmbH & Co. KG) and used as 
positive control of oral immunization. All the orally administrated vaccines were dissolved in 
distilled water. Then adjuvants were added. The final volume applied orally was 1 ml. The final 
volume of parenterally administrated vaccine was 0.1 ml. 
Blood samples (from the wing vein) and cloaca swab were collected from each chicken prior each 
immunization, challenge and day of euthanization. Cloaca swabs were rinsed in 500 µl PBS 
containing complete, EDTA-free Protease Inhibitor cocktail tablets from Roche (1 tablet for each 
25 ml of 1x PBS) for one hour. The samples were centrifuged (5000 ×g/5 min/RT) and after 
removing the insoluble part, stored at -20°C for further studies. One week after the last boost, 
chickens (except chickens from group 13) were challenged with a classical IBDV strain, MB3, 
from a recent outbreak in Germany. Because the strain did not grow in well in embryonated SPF 
eggs and was not cell culture adapted, the birds were infected ocularly with 0.1 ml homogenized 
and filtrated (0.2µm) bursa fabricious from naturally infected chickens kindly provided by Dr. 
Hermann Block (Poultry Practice Mayer-Block, Uelsen). A week after challenge, blood and cloaca 
samples were collected from all survived birds, chickens were sacrificed and bursa fabricious was 
isolated, divided into two segments and stored in -20ºC for virus clearance studies (II.2.6.4) and 
viral tissue damage analysis by histology tests (II.2.6.5).  
 Health status monitoring II.2.6.3
The health of chickens was monitored every week during immunization and every day following 
challenge. The weight of chickens was recorded at the beginning of immunization and every week 
Chapter II                                                                                                           Material and methods      
 
46 
 
before next round and right after death. All the observations of clinical sign were also recorded 
every day following challenge for 5 days before euthanization.  
 
Figure II.1 Weight development in Specific pathogen free (SPF) chickens. The data was provided by 
Dr. Rüdiger Hauck (Institute of Poultry Diseases, Freie Universität Berlin). 
 
Table II.7 Experimental design for chicken immunization. 
 
 
 Antibody titer determination  II.2.6.4
The titer of IBD-VP2-specific antibodies (IgY, IgM and IgA) in blood and (for IgA) in feces cloak 
swab) samples was measured by indirect ELISA. Microtiter plates (96-well) were coated with 
purified Pichia-produced IBD-SVPs (final concentration: 10 µg/ml) in PBS overnight at 4°C. The 
plates were blocked using 2.5% (w/v) skim milk in PBST for 1 h at RT. After 3 times washing 
with PBST, 100 µl of serially twofold dilutions of serum samples starting from 1:50 dilution in 1x 
PBS were applied. For IgA detection in the sera, 1:5 dilutions were used. Cloak swab was rinsed in 
500 µl of 1x PBS containing complete, EDTA-free Protease Inhibitor cocktail tablets from Roche 
(1 tablet for each 25 ml of 1x PBS) for 2 hours at 4ºC. Hundred microliters of the extract was 
applied to the ELISA plate following centrifugation at 3000 ×g for 5 min at RT. After 2 hours 
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incubation at RT and 3 times washing as described above, secondary antibodies were applied. 
They were horseradish peroxidase-conjugated rabbit anti-chicken IgY (2 µg/ml), goat anti-chicken 
IgM (5 µg/ml) and goat anti-chicken IgA (5 µg/ml) for detection of chicken IgY, IgM and IgA, 
respectively. Bound secondary antibodies were detected by ABTS as substrate. The OD value was 
determined at 405 nm using a microplate reader. The anti-IBD-VP2 titer was considered as the last 
dilution showing an OD405 nm higher than 0.2.    
  IBDV antibody test kit II.2.6.5
The anti-IBD-VP2 titer was also assessed by the commercial antibody ELISA test kit, IDEXX 
IBD-XR Ab test (IDEXX, Westbrook, ME, USA). This kit is commonly used in chicken farms to 
test the serum antibody titer against IBDV for evaluation of immunity in chickens. The method is 
based on indirect ELISA and individuals show titers above 396 are considered as resistant.   
 Detection of IBDV in bursa tissue II.2.6.6
The presence of the IBDV antigen in the bursa of Fabricius was analyzed using a sandwich ELISA 
as previously described (Rong et al., 2007) with some modifications. Briefly, wells of a flat bottom 
96-well microtiter plate were coated with mouse anti-IBD-VP2 antibody (15F5, final concentration 
100 µg/ml) for o/n at 4°C. Then, wells were washed with 1x PBS containing 0.05% (v/v) Tween 
20 (PBST). The plate was blocked by 150 µl/well of 2.5% (w/v) skim milk dissolved in PBST and 
incubated at RT for 1 h. Following the washing procedure as described above, the bursa of 
Fabricius was ground and diluted with 1x PBS at 1:1 (w/v). One hundred microliter of the 
homogenate was added to the wells. The plate was incubated o/n at 4°C. After washing as above, 
100 µl of rabbit anti-IBD-VP2 diluted at 1:5000 in PBST, was added to each well. Following 
incubation at RT for 1 h and wash, 100 µl of HRP-conjugated goat anti-rabbit (final concentration: 
0.12 µg/ml) was added as secondary antibody. The bound antibodies were detected by ABTS as 
the substrate. The OD value was determined at 405 nm with a microplate reader and the values 
higher than 0.2 were considered as positive.   
 Histological bursa lesion II.2.6.7
Bursa Fabricius was collected after euthanization and dissection of the birds from all 65 chickens 
and fixed in 10% (v/v) phosphate buffer formalin, were paraffin embedded, cut and stained with 
haematoxylin and eosin. Bursa lesion scores were determined using a light microscope and 
comparison between groups (Block et al., 2007). The bursal lesion scoring system was previously 
described by Li et al. (2004) and is as follows: score 0, no bursal damage and lesion in any follicle, 
clear demarcation of medulla and cortex; score 1, mild necrosis and mild lymphocyte depletion of 
a few follicles with overall bursal architecture maintained; score 2, moderate atrophy or 
lymphocyte depletion in 1/3 to 1/2 of the follicles, aggregation of heterophils, macrophages, and 
hyperplasia of epithelial reticular cells with some vacuole-like structures; score 3, more than 1/2 of 
follicles with severe necrosis, atrophy and lymphocyte depletion, and loss of the outline of 
follicular architecture such that it is replaced by proliferated connective tissue and fibroplasias. 
Chapter II                                                                                                           Material and methods      
 
48 
 
 Statistical analysis II.2.6.8
Statistical analyses were carried out using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). For 
all analyses, chicken was considered as an experimental unit. The significance level (α) was set to 
0.05. The normality of the data and the homogeneity of variances were assessed using Shapiro-
Wilk’s and the Levene’s tests, respectively. The collected data were subjected to one-way 
ANOVA analysis of variance followed by Duncan’s test at significance level of p< 0.05. 
 Bioconjugation analysis II.2.7
 Stability analysis of IBD-sub viral particles (IBD-SVPs)  II.2.7.1
The solvent stability of the IBD-SVPs was tested by dissolving purified particles (II.2.2.6) in 5, 10, 
20 or 50% (v/v) ethanol/water or DMSO/water to a final concentration of 1 mg/ml, with IBD-SVPs 
diluted to the same concentration in 1x PBS as a control. All samples were incubated at room 
temperature for 24 h then centrifuged at 13000 ×g for 20 min at RT prior to analysis. To test 
temperature stability, 50-µl aliquots of purified IBD-SVPs (1 mg/ml) were incubated at 25, 40, 50, 
60, 65, 68.5, 72, 75, 80 and 90°C for 1 h prior to centrifugation as above. To test pH stability, 
purified IBD-SVPs were dissolved in 50 mM acetate buffer pH 2.5, 50 mM acetate buffer pH 5.5, 
PBS pH 7.4, 50 mM Tris-HCl pH 8.0 or 50 mM Tris-HCl pH 9.0, to a final concentration of 0.5 
mg/ml. After overnight incubation at room temperature, the samples were centrifuged as above. In 
all three cases, the stability, conformation and integrity of the IBD-SVPs were determined by 
NAGE (II.2.7.2), spectroscopy (II.2.7.3), DLS (II.2.7.4) and TEM (II.2.3.6) as described. 
 Native agarose gel electrophoresis (NAGE) II.2.7.2
Treated samples were separated by 1% (w/v) native agarose gel electrophoresis at 50 V for 1 h. 
The agarose gel was prepared in buffer A (25 mM Tris-HCl pH 8.15, 19.2 mM glycine) as 
previously described (Kim et al., 2000). The protein bands were visualized by staining with 
Coomassie brilliant blue. 
 Spectroscopy  II.2.7.3
After solvent exposure, temperature and pH testing, each VP2 sample was centrifuged at 13000 ×g 
for 20 min at RT, and the absorbance spectrum (UV/Vis, 220–310 nm) was measured using a 
NanoDrop spectrophotometer (PeQlab Ltd., Erlangen). The total quantity of soluble protein was 
estimated from the A280 value (mean from three replicates). After dye molecule coupling, the 
absorbance was measured using the “protein and labels” option of the spectrophotometer.  
 Dynamic light scattering (DLS)  II.2.7.4
The radius of IBD-SVPs in solution (0.5-ml aliquots, 1 mg/ml) was determined by DLS in self-
beating mode on an ALV set-up comprising a 473-nm solid-state laser (Koheras, Kleinostheim) 
operating at a 60º angle. Experimentally measured autocorrelation functions (ACFs) of the 
intensity fluctuations g (2)(t) were determined using the CONTIN algorithm (Provencher, 1982a,b) 
yielding the distribution of the relaxation time t.  
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 Chemical bioconjugation II.2.7.5
Biotin was conjugated to the amine group of lysine residues or the carboxyl group of aspartic and 
glutamic acid residues of purified IBD-SVPs (II.2.2.6) exposed to the solvent. IBD-SVPs display 
five lysine residues (Lys 81, 192, 309, 316 and 381), four glutamic acid residues (Glu 300, 311, 
355 and 378) and nine aspartic acid residues (Asp 51, 83, 138, 190, 213, 267, 279, 287 and 323) 
per coat protein; IBD-SVPs are formed by 60 copies of identical coat protein units. Alexa Fluor 
488 N-hydroxysuccinimide (NHS) ester and the DyeLightTM antibody labeling kit (Pierce) were 
used to determine the number of accessible amines.  
Conjugation to amine groups was achieved using 1 mg/ml IBD-SVPs and biotinamidohexanoic 
acid NHS ester (Sigma) dissolved in DMSO to a concentration of 2.1 mM, and mixed with 1x PBS 
to a final DMSO concentration of 10% (v/v). The ratio of biotin to IBD-SVP was 6000:1. The 
reaction was allowed to proceed for 2 h at 4°C with gentle agitation.  
Conjugation to carboxyl groups was achieved by dialyzing IBD-SVPs in 1x PBS against 0.1 M 
MES buffer (pH 5.5) using a Nanosep centrifugal device with a 100 kDa MWCO (Pall, Dreieich). 
IBD-SVPs in MES buffer at a final concentration of 0.5–3.5 mg/ml were incubated with 6.5 mM 
EDC (1-[3-(Dimethylamino) propyl]-3ethylcarbodiimide methiodide) and 2 mM biotin hydrazide 
in DMSO (Sigma). The biotin hydrazide was used at a molar excess of 7800–15,600:1 biotin: IBD-
SVP and the final DMSO concentration was 10% (v/v). The reaction was allowed to proceed 
overnight at room temperature with gentle agitation to prevent precipitation.  
Modified particles were purified on a Hiprep 26/60 Sephacryl S-400 HR column (GE HealthCare) 
and the SVP peak was concentrated using a Vivaspin 20 with 300-kDa cut-off membrane 
(Sartorius). 
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III Results 
The result section contains two major parts: The first part describes the expression, purification 
and characterization of IBD-VP2 in tobacco plants to study protein accumulation in different cell 
compartments, stability, functionality, glycosylation, immunogenicity and self-assembly capability 
either in vivo or in vitro. Accordingly, the relevant cDNA of IBD-VP2 was cloned into the plant 
expression vector pTRAkc (III.1.1) and then expressed either transiently (III.1.2) or stably (III.1.3) 
in N. tabacum cv. Petite Havana SR1 leaves. The recombinant protein accumulation levels were 
evaluated using four sub-cellular targeting strategies (cytosol, apoplast, membrane-anchored and 
chloroplast) exploiting proper targeting peptide sequences. The target protein was purified (III.1.4) 
and characterized (III.1.5 and III.1.6). Furthermore, the immunogenicity of tobacco-derived 
proteins was analyzed in mice (III.1.7). Moreover, the yeast, Pichia pastoris, was used as an 
alternative expression system. The IBD-VP2 was cloned into the Pichia expression vector 
pPICZ_B (III.2.1) and expressed as either cytosolic or secreted protein (III.2.2). The produced 
proteins were purified (III.2.3) and characterized (III.2.3 and III.2.4) in the same manner as for the 
plant expression and moreover used as a vaccine for immunization of chickens in both oral and 
parenteral administrations (III.3).  
 
In the second part of the result section, the sub-viral particles (IBD-SVPs) derived from self-
assembly of recombinant IBD-VP2 monomers produced in Pichia, were investigated as a potential 
nanotechnology platform and characterized concerning organic solvent (III.4.1), heat (III.4.2) and 
pH (III.4.3) stability. Finally, the addressability of solvent-exposed amine and carboxylic groups 
on the surface of IBD-SVPs was tested via traditional bioconjugation methods (III.4.4). 
III.1 Expression and characterization of IBD-VP2 in N. tabacum 
 Cloning of IBD-VP2 gene sequence into pTRAkc vector for generation of III.1.1
tobacco expression vectors 
For recombinant expression of IBD-VP2 in tobacco, the corresponding cDNA was cloned into the 
plant expression vector pTRAkc containing the CaMV 35S promoter with the duplicated enhancer 
region (II.2.1.17). The cDNA of the mature IBD-VP2 sequence (strain IR01, DNA accession 
number: AY704912) was used as a template in PCR using high-fidelity Taq polymerase. The 
corresponding sequence of the first 441 amino acids (mature IBD-VP2) fused to the C-terminal 
His-tag was amplified using the primers VP2-forward and VP2-reverse-withHis6 (table II.1) 
containing BspHI and XbaI restriction recognition sites, respectively. Following direct cloning of 
the PCR product (~1.3 kb) into the pJET1.2/blunt vector, the sequence was verified by sequencing 
using the pJET1.2 forward and reverses primers and reconfirmed by the inner primer set 
VP2Primer1_forward and VP2Primer1_reverse (table II.3) (II.2.1.19). The IBD-VP2 encoding 
region was double digested by BspHI and XbaI and either cloned into the vector pTRAkc-GFPapo 
containing the sequence for the signal peptide LPH of the murine antibody 24 heavy chain 
(Vaquero et al., 1999) or into the vector pTRAkc-rbcs-cTP containing the Rbcs encoding for the 
chloroplast targeting signal peptide of Ribulose-1,5-bisphosphate carboxylase oxygenase 
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(RuBisCO) small subunit from Solanum via the restriction sites NcoI and XbaI, resulting in 
generation of the final expression vectors pTRAkc-VP2apo and pTRAkc-VP2chlo, respectively.  
For cytosolic accumulation, SOE (splicing by overlap extension) PCR was exploited as described 
(II.2.1.19) using the CHS-elongation5’ and VP2-reverse-withHis6 primers for elongation and 
Solulin-for5’UT and VP2-reverse-withHis6 for amplification of the chalcone synthase 5’ UT fused 
to the IBD-VP2 encoding sequence. The resultant 1.4 kb construct (CHS-VP2) was double 
digested with EcoRI and XbaI and cloned into the corresponding sites in the pTRAkc-GFPapo 
vector. The final vector was named pTRAkc-VP2cyto.                                 
For creation of the plant expression vector encoding for the membrane retained VP2, two separate 
fragments were constructed and fused together. To make the His-tag accessible for recombinant 
protein detection and purification, the tag was fused to the N-terminal end of IBD-VP2. For this, 
the fragment CHS-VP2 was generated using SOE-PCR. Briefly, IBD-VP2 cDNA was used as 
template in companion with CHS-elongation5’-withHis6 and VP2-reverse for elongation, Solulin-
for5’UT and VP2-reverse for amplification. The resulting fragment was 1.4 kb long. The second 
fragment was 128 bp long containing an ORF of 96 bp cytochrome b5 membrane anchor peptide 
encoding sequence (CytB5-MA), amplified by PCR using CytB5 cDNA as template and 
CytB5memAnch.-for and vIL-10_XbaI-bw primer sets. Eventually, the two generated fragments 
were fused together in a SOE-PCR using the generated overlapping region of the two fragments 
and the joint sequence was amplified using the primers Solulin-for5’UT and vIL-10_XbaI-bw. 
Finally, the generated construct was double digested with EcoRI and XbaI and subsequently cloned 
into the corresponding sites of the pTRAkc-GFPapo vector. The final construct was named 
pTRAkc-VP2mem. All PCR and cloning procedures as well as vector maps are illustrated in 
Appendix VII.2. All harboring plasmids were checked by restriction enzyme digestion following 
sequencing (data not shown). All four generated vectors carrying the correct sequence were 
transferred to Agrobacterium via electroporation (II.2.1.6). Recombinant agrobacteria were 
checked by colony PCR and positive clones used for transient and stable transformation of tobacco 
(II.2.2.2, II.2.2.3, II.2.2.4). The schemes of the constructs were demonstrated in figure III.1. 
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Figure III.1 Schematic drawing of the generated pTRAkc plant expression vectors for IBD-VP2 
expression in tobacco; P35S: CaMV 35S promoter with duplicated enhancer region; CHS: 5' untranslated 
region of the Petroselinum chalcone synthase; LPH: plant codon optimized leader sequence derived from 
the murine heavy chain of the TMV-specific mAb24; Rbcs: Rubisco small subunit chloroplast targeting 
signal; CytB5-MA: cytochrome b5 membrane anchor; H6: IBD-VP2: cDNA of infectious bursal disease 
viral protein 2 corresponding to the first 441 amino acids; H6: his-6 tag for detection and purification; 
pA35S: terminator from CaMV; SAR: scaffold attachment region; Pnos: nopaline synthase gene promoter; 
nptII: Neomycin phosphotransferase II (kanamycin resistance gene); pAnos: nopaline synthase gene 
terminator; LB: left border; RB: right border; (not drawn to scale). 
 
 Transient expression of IBD-VP2 in tobacco leaves III.1.2
For fast screening of the best targeting strategies resulting in the highest accumulation of IBD-VP2 
(or in brief VP2), transient expression experiments via agro-infiltration were performed (II.2.2.3). 
Three tobacco leaves for each construct were infiltrated with recombinant agrobacteria. After three 
days of incubation, soluble proteins were extracted (II.2.2.5) and analyzed by immunoblot 
(II.2.3.3) to determine the productivity and integrity for each of the four different VP2 constructs. 
The calculated molecular mass for VP2 fused to the His-tag is ~48 kDa. The fused membrane 
anchor (CytB5-MA) adds 3.7 kDa to the protein size. The protein was named based on the cellular 
accumulation site. Therefore, VP2apo, VP2chlo, VP2cyto and VP2mem stand for VP2 
accumulated in the apoplast, chloroplast, cytosol and cell membrane, respectively.   
Immunoblot analysis revealed a distinct band of ~40 kDa for the constructs pTRAkc-VP2cyto and 
pTRAkc-VP2chlo (figure III.2). While the corresponding band for pTRAkc-VP2apo was ~47 kDa, 
VP2mem was not detectable by immunoblot (figure III.2) under both non-reducing and reducing 
conditions. Interestingly, in contrast to most of the known proteins, the movement pattern of VP2 
under reducing condition is smeary whereas under non-reducing condition a distinct band was 
observed. Accordingly, detection and amount evaluation of VP2 was performed based on 
immunoblot under the non-reducing condition. Since equal amounts of total soluble proteins were 
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loaded onto the gel, the accumulation level of VP2 varied considerably between the tested 
expression constructs. Higher level of accumulation was observed for apoplastic localization of the 
VP2 protein followed by accumulation in the cytosol and chloroplasts. The size difference for 
VP2apo when compared to the cytosolic forms VP2cyto and VP2mem can be explained by 
glycosylation since only the VP2apo protein is transported to the secretory pathway.  
  
 
Figure III.2 Comparison of VP2 accumulation in various cell compartments using immunoblot. Total 
soluble leaf proteins were extracted by grinding a leaf disk from a transiently transformed tobacco leaf in 
two volumes extraction buffer (II.2.2.5), 10-12 µl of the extract containing equal amount of total soluble 
protein (TSP) was separated by 12% (w/v) SDS-PAGE either under non-reducing or reducing condition 
(II.2.3.2) and blotted onto nitrocellulose membrane (II.2.3.3). Immuno-detection was carried out using 
rabbit anti-IBD-VP2 (1:10000) as primary followed by phosphatase-conjugated goat anti-rabbit as a 
secondary antibody (0.12 µg/ml). Detection was performed with NBT/BCIP for 5 min at RT. M: prestained 
protein marker. 
 
Accumulation levels of the transiently produced four versions of VP2 recombinant protein were 
determined more precisely by ELISA (II.2.3.1). As standard, purified VP2 protein derived from 
transiently transformed tobacco leaves with pTRAkc-VP2cyto (III.1.4) was mixed with total 
soluble protein extract from wild type tobacco leaves and applied in serial dilution to the microtiter 
plate. Figure III.3 shows that the highest yield was obtained from the apoplastic located VP2 (~260 
µg/g FLW). VP2cyto (~160 µg/g FLW) and VP2chlo (~70 µg/g FLW) accumulated to lower 
levels. The ELISA confirmed the result from the immunoblot analysis because the level of 
VP2mem was close to the detection limit. 
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Figure III.3 Determination of VP2 content accumulated in different cell compartments of transiently 
transformed N. tabacum cv. Petite Havana SR1 leaves. Recombinant protein levels were determined by 
ELISA (II.2.3.1). 2.5 µl of tobacco extract was mixed with PBS and applied to 96-well ELISA plates in 
two-fold serial dilutions. 2.5 µl of wild type plant extract alone and with 2 µg of purified VP2cyto derived 
from transiently transformed tobacco leaves (III.1.4), were also applied into serial dilutions, used as 
negative and positive standards, respectively. Rabbit anti-VP2 antibody (1:10,000 µl in PBS) and GARHRP 
antibody (0.12 µg/ml) were used as primary and secondary antibodies, respectively. Detection was 
performed using ABTS as substrate after 10 min incubation at RT. The measurement was performed in 
three independent transient experiments (n=3) and error bars represents standard deviations. 
    Generation and screening of transgenic tobacco plants expressing IBD-VP2 III.1.3
Based on transient expression results, the apoplast-targeted (pTRAkc-VP2apo) and cytosolic 
expression (pTRAkc-VP2cyto) constructs were used for stable transformation of N. tabacum cv. 
Petite Havana SR1 plants via Agrobacterium-mediated transformation (II.2.2.3). Thirty transgenic 
lines (designated VP2apo_1→30) and thirty-five transgenic lines (VP2cyto_1→35) were 
regenerated from transformation experiments, respectively. The T0 generation showed a normal 
phenotype and was screened for recombinant protein accumulation by immunoblot (II.2.3.3) (data 
not shown). To achieve higher expression levels via genetic homogeneity, the top four producer 
plants for each construct were led to produce seeds upon self-fertilization. In total, 47 and 28 T1 
plants were analyzed by immunoblot for accumulation of VP2apo and VP2cyto, respectively. The 
best three elite VP2 producers was selected for each construct and the VP2 levels were determined 
by ELISA (II.2.3.1). These plants were led to self-pollination to generate seeds. Seed were stored 
as backup materials in the seed bank of the Fraunhofer IME. The productivity in VP2apo 
producing T1 plants was reaching to 20-30 µg/g FLW, whereas VP2cyto producing T1 plants 
showed levels of 10-20 µg/g FLW. Similar to the transient produced recombinant proteins, 
VP2apo and VP2cyto extracted from T0 and T1 plants were intact on 12% (w/v) SDS-PAA gels 
under non-reducing condition and had a molecular weight of ~47 and ~40 kDa, respectively (data 
not shown).  
    Purification of IBD-VP2 from tobacco leaves  III.1.4
Both plant-produced proteins, VP2apo and VP2cyto, contain a C-terminal His-tag facilitating 
purification by immobilized metal ion affinity chromatography (IMAC) using Ni-NTA columns. 
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Upon harvesting and vein removal, leaves from transiently producing VP2apo or VP2cyto were 
used for the purification of VP2 (II.2.2.5). The eluent was collected in 0.2 ml fractions using PBS 
containing 250 mM imidazole. To monitor the protein content during the each purification step, 
samples were collected and analyzed by 12% (w/v) SDS-PAGE followed by Coomassie staining 
and immunoblot using rabbit anti-His and phosphatase-conjugated goat anti-rabbit as primary and 
secondary antibodies. NBT/BCIP was used as a substrate for color development (figure III.4). 
Distinct ~40 and ~47 kDa bands were detected for VP2cyto and VP2apo, respectively. In case of 
VP2cyto, the protein is intact whereas in the case VP2apo the presence of fuzzy bands smaller and 
bigger than the intact protein size correlates with minor degradation and either aggregation or 
glycosylation, respectively. The purity of VP2 was determined 35% by densitometric analysis of 
Coomassie stained gel.  
 
 
Figure III.4 SDS-PAGE analysis of VP2 purified by IMAC form transiently transformed tobacco 
leaves using pTRAkc-VP2apo (A, B) and pTRAkc-VP2cyto (C, D). VP2apo and VP2cyto with His-tag 
fused at the C-terminal ends were purified using Ni-NTA (II.2.2.5). Twelve-microliter samples of each 
purification step (including extract, solution part of extract following pH shift (loading), flow through from 
Ni-NTA column, dead volume, elution fractions 1-4) were separated by 12% (w/v) SDS-PAA gel under 
non-reducing condition. The VP2 corresponding bands were detected in immunoblot (II.2.3.3) recruiting 
rabbit anti-His and phosphatase-conjugated goat anti-rabbit as primary and secondary antibodies, 
respectively. Color was developed using NBT/BCIP as substrate following 5 min incubation period. 
Distinct ~47 (A) and ~40 kDa (C) bands were detected for VP2apo and VP2cyto, respectively. Proteins 
content were visualized by Coomassie staining (II.2.3.2) for VP2apo (B) and VP2cyto (D). The purity was 
determined about 35% using densitometric method. M: prestained protein marker. 
 
To improve the purity, the VP2 bands were excised from the gel and the protein content was 
recovered using EzWayTM PAG protein elution kit (II.2.2.5). The recovered samples were 
concentrated using nanosep column with 10 kDa MWCO. The purity of the protein was 
determined >95% by densitometric method using Coomassie stained gel (figure III.5). Total 
protein content was measured using the BCA kit. The protein yield was estimated about 100 and 
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80 µg/g FLW for VP2apo and VP2cyto, respectively. The purified protein was stored at -80°C in 
50 µg fractions. 
 
 
 
Figure III.5 SDS-PAGE analysis to check the VP2 purity. The corresponding VP2 bands obtained from 
Ni-NTA purification (figure III.4) was recovered from the Coomassie stained gel using EzWayTM PAG 
protein elution kit and concentrated using 10 kDa MWCO. Twelve µl of the samples were separated using 
12% (w/v) SDS-PAA gel under non-denaturing condition. The purity of the proteins were evaluated >95% 
using densitometric method. Small degradation fractions, less than 10 kDa in size, are also observable.           
    Glycosylation analysis of IBD-VP2apo III.1.5
According to the SDS-PAGE analyses (figure III.5), the tobacco-produced full-size VP2cyto has 
mass of ~40 kDa whereas the size of VP2apo is ~47 kDa. This variation (~7 kDa) in addition to the 
smeary movement of VP2apo on SDS-PAA gels (figure III.5) can be explained by glycosylation. 
The IBD-VP2 contains three potential N-glycosylation sites (verified by the NetNGlyc 1.0 server 
used for N-glycosylation predictions) (figure III.6). Full glycosylation of all three sites with plant 
specific extracellular glycan adds additional ~7 kDa to the calculated mass of the protein 
increasing it to ~54 kDa which is in agreement with the size observed on the stained SDS-gel 
(figure III.5). To characterize the glycosylation pattern of the transiently produced VP2apo in 
tobacco leaves, the purified protein (III.1.4) was analyzed by different glycan analysis procedures.  
 
Figure III.6 Prediction of potential N-glycosylation sites of the IBD-VP2 protein predicted by the 
NetNGlyc 1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc/). Three recognized N-glycosylation 
positions (aa 46, aa 121, aa 396) are underlined. 
    Immunoblot analysis III.1.5.1
To determine if the tobacco-produced and IMAC purified VP2apo is glycosylated; an immunoblot 
analysis was performed using glycan-specific antibodies (figure III.7). Following SDS-PAGE and 
Chapter III                                                                                                                                 Results      
 
57 
 
blotting, the xylose residues were detected by using a rabbit anti-xylose antibody (1 µg/ml in 1x 
PBS) and detection was carried out using alkaline phosphatase-conjugate goat anti-rabbit as a 
secondary antibody. NBC/BCIP was used as substrate. VP2cyto and recombinant phl p 1 (timothy 
grass (Phleum pratense) pollen major glycoprotein allergen produced in transgenic tobacco) were 
used as negative and positive controls, respectively. The result indicates that VP2apo as well as the 
apoplastic targeted recombinant phl p1 in contrast to VP2cyto reacted with the anti-xylose 
antibody, confirming the glycosylation of VP2apo.     
 
 
Figure III.7 SDS-PAGE for glycosylation analysis of the tobacco-produced VP2 followed by (A) 
Coomassie brilliant blue staining and (B) glycan detection by immunoblot. Purified proteins (III.1.4) 
were separated by 12% (w/v) SDS-PAA gel under non-reducing condition (II.2.3.2). Rabbit anti-xylose (1 
µg/ml in 1x PBS) and phosphatase-conjugated goat anti-rabbit (0.2 µg/ml in 1x PBS) were used as primary 
and secondary antibodies. Detection was performed with NBT/BCIP. VP2cyto and phl p 1 (timothy grass 
(Phleum pratense) pollen major glycoprotein allergen produced in transgenic tobacco were used as negative 
and positive (Ctrl+) controls, respectively. M: prestained protein marker. 
    Enzymatic deglycosylation of VP2apo III.1.5.2
To demonstrate the addition of glycan chains to the secreted recombinant protein, the purified 
plant-produced VP2apo (III.1.4) was subjected to deglycosylation (II.2.4.2) with PNGase F and the 
resulting product was separated by SDS-PAA gel followed by Coomassie staining using VP2cyto 
as non-glycosylated control (figure III.8). After glycan removal through enzymatic digestion and 
electrophoretic separation VP2apo showed a molecular weight of 40 kDa, the same size as 
VP2cyto which accumulates in the cytosol, demonstrating that glycosylation was responsible for 
the mass differences of ~7kDa. 
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Figure III.8 SDS-PAGE analysis of the deglycosylated tobacco-produced and affinity-purified 
VP2apo using peptide N-Glycosidase F (PNGase F). VP2apo after enzymatic deglycosylation (II.2.4.2) 
has the same size as tobacco-produced and affinity purified VP2cyto (III.1.4) on 12% (w/v) SDS-PAA gel 
stained with Coomassie brilliant blue (II.2.3.2). 
    Glyco-proteomics analysis III.1.5.1
The VP2 contains three potential glycosylation sites (aa 46, aa 121, aa 396). To determine if all 
three sites contain glycan chains and to analyse the corresponding glycan composition of each site, 
the purified tobacco-produced VP2apo (III.I.4) was separated by SDS-PAGE. The Coomassie 
brilliant blue stained band was excised from the gel digested with trypsin and chemotrypsin and 
finally analyzed by LC-MS (Dr. F. Altmann, J. Stadlmann and BoKu Vienna, Austria). The result 
of the LC-MS is shown in figure III.9 and summarized in table III.1. Complex type N-glycans such 
as GnGnXF and GnGnF were the most prominent glycan types and accounted for 55.7% of the 
total VP2 glycosylation profile. GnMXF and GnMX were present at lower levels (~20%), while 
the other types of glycan were found in only few amounts (about 2% or less each). The obtained 
glycan data showed that the leader peptide (LPH) was fully functional in leading VP2 to the 
secretory pathway and finally to the apoplast. All three N-glycan sites were glycosylated with 
variation in glycan compositions and their frequencies are described in more detail in table III.1 
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Table III.1 Glycan compositions and their ratio at the three N-glycan sites (1, 2 and 3) of the plant-
produced and affinity-purified VP2 was determined by liquid chromatography-mass spectrometry (LC-MS). 
 
 Glycan type Relative frequency (%) Site 1 Site 2 Site 3 
GnGnXF (M3Gn4X1F1) 33.8 30.1 19.6 
GnGnF (M3Gn4F1) 30 29.3 24.4 
GnMXF (M3Gn3X1F1) 6.5 9.1 13.1 
GnMF (M3Gn3F1) 7.4 7.5 17.5 
GnUF(Man2Gn3F1) 2 2.9 7.6 
GnM (M3Gn3) 2 2.4 3.2 
AGnX (A1M3Gn4X1) 0 2.2 0 
AGnF (A1M3Gn4F1) 0 2.2 0 
AGn (A1M3Gn4) 0 3 0 
MU (M2Gn2) 2.2 0 0 
GnMX (M3Gn3X1) 1.9 1.8 2.1 
Other types  13.3 12 6.6 
 
 
 
Figure III.9 Liquid chromatography-mass spectrometry (LC-MS) of the three N-glycosylation sites of 
plant-produced and affinity-purified VP2apo. Purified VP2apo (III.1.4) separated by 12% (w/v) SDS-
PAGE (II.2.3.2) was excised from the gel. Following protein recovery, it was digested with trypsin and 
chemotrypsin and the resultant peptides were applied to LC-MS analysis (II.2.4.3). The spectrum of 
glycosylated peptides are shown in A (site 1), B (site 2) and C (site 3) (see also Figure III.6).  
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     Analysis of plant-produced VP2 assembly III.1.6
To study if the purified tobacco-produced VP2cyto and VP2apo assembled into SVPs, the 
recombinant proteins were analyzed by size exclusion chromatography using Superdex 200 having 
a separation range of 10-600 kDa for analysis of globular proteins (II.2.3.5). The chromatographic 
profiles were obtained by measuring the absorption at 215 nm (figure III.10). The first two peaks 
showed the highest content of intact VP2apo and VP2cyto, respectively, as determined by 
immunoblot. The corresponding size of each peak was calculated based on the elution volumes 
using a calibration curve equation obtained by running the molecular weight standards: ovalbumin 
(43 kDa), conalbumin (75 kDa), aldolase (158 kDa), ferritin (440 kDa) and thyroglobulin (670 
kDa). As indicated in the figure, the first two peaks are matching with trimers and monomers, 
respectively. The shift in peak profile between VP2apo and VP2cyto are due to the glycan 
moieties, which are covalently attached to VP2apo and are absent in VP2cyto. The two latter peaks 
which are in size of 5 and less than 1 kDa belong to degradation fractions and salt impurities, 
respectively. This result shows that the trimer form is the maximum assembly level observed in 
IMAC-purified VP2 samples. 
 
 
 
Figure III.10 Chromatographic profile obtained by separation of purified (III.1.4) VP2cyto (red) and 
VP2apo (blue) in two separate runs using a Superdex 200 column (II.2.3.5). To estimate the VP2 
content of each peak, the elution fractions corresponding to the tip of the peaks were separated by 12% 
(w/v) SDS-PAA gel followed by immunoblot using rabbit anti-IBD-VP2 (1:10000) and phosphatase-
conjugated goat anti-rabbit (0.12 µg/ml) as primary and secondary antibodies, respectively. Color was 
developed using NBT/BCIP as substrate following 5 min incubation period. The intact VP2 was eluted in 
trimeric and monomeric forms in about 12 and 14 ml of the elution volume. The degradation fractions (~5 
kDa) and salt impurities (>1 kDa) were also eluted at about 19 and 24 of the elution volume. Standard 
calibration curve equation obtained by running the molecular weight standards (black triangles): ovalbumin 
(43 kDa), conalbumin (75 kDa), aldolase (158 kDa), ferritin (440 kDa) and thyroglobulin (670 kDa).   
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As shown previously, it is possible to purify IBD-subviral particles produced by recombinant 
expression of VP2 with His-tagged using IMAC (Wang et al., 2000). Based on structural analysis 
it was indicated that His-tags fused either to the N- or C-terminal end of VP2 monomers are 
located on the interior face of fully assembled particles and are not accessible on the surface (Lee 
et al., 2006; Garriga et al., 2006). Even though, it was still possible to purify IBD-SVPs using 
IMAC even after his tag removal (Lee et al., 2006). The affinity of IBD-SVPs to Ni+2 is due to two 
His residues (His 249 and His 253) located on the outer surface of the IBDV particles (Doong et 
al., 2007). Sequence alignment between the IBD-VP2 sequence described by Doong et al. (2007) 
with the peer one used in this study showed that the two mentioned His residues are replaced by 
Glu residues (Appendix VII.3), which do not bind to the Ni+2 column. As described above (III.1.4) 
the majority of plant-produced VP2apo and VP2cyto was able to adsorb to the Ni+2 column (figure 
III.4). This fact reveals that either the assembled particles disrupted during extraction/ purification 
steps due to the pH shifts or high salt concentration or VP2 monomers to not assemble efficiently 
in tobacco cells.  
VP2cyto was selected to study the in vitro assembly post extraction and purification because 
VP2apo carries superimposed glycan chains that may interfere in assembly. Several conditions 
have been tested during extraction such as lower salt concentration, detergent removal in extraction 
buffer and keeping the pH constantly neutral in all extraction and purification steps to support 
assembly of SVPs. In all the efforts, VP2cyto could be purified by IMAC indicating the 
accessibility of the His-tag but this means also that assembly of VP2 monomers did not occurred 
(data not shown). Finally, ultracentrifugation as an alternative purification method was exploited 
(II.2.2.4). The total soluble protein was extracted from transiently transformed leaves and applied 
to the 10-60% gradient sucrose column (II.2.2.5). Following ultracentrifugation, one milliliter 
fractions of the sucrose column were collected from the top to the bottom of the sucrose gradient 
and were analyzed by indirect ELISA (II.2.3.1) to estimate the VP2 content. As depicted in the 
figure III.11, only one major peak representing the sucrose factions 8 to 17 was observed. The 
presence of the VP2cyto protein in these fractions was confirmed by immunoblot (data not shown). 
Fractions 8 to 17 containing the major part of the purified VP2cyto were concentrated using 
nanosep 10 kDa MWCO devices and analyzed by immunogold labeling and electron microscopy 
(II.2.3.6). However, no SVPs could be detected (data not shown). Furthermore, efforts to detect 
SVPs in stably transformed leaf tissues using immunogold labeling and electron microscopy did 
not succeed (data not shown). All these observations indicated that VP2cyto does not form 
complexes larger than trimers when produced in tobacco. 
  
Chapter III                                                                                                                                 Results      
 
62 
 
 
Figure III.11 ELISA analysis (II.2.3.1) for the VP2 content of the tobacco-produced VP2cyto 
separated by 10-60% sucrose gradient ultracentrifuge (II.2.2.5). One milliliter fractions were collected 
from top to the bottom of the sucrose column and the corresponding VP2cyto content was determined by 
indirect ELISA (II.2.3.1) using polyclonal anti-VP2 as primary (1:10,000) followed by goat anti-rabbit 
HRP-labeled as a secondary antibody (0.2 µg/ml). Wild type tobacco cell extract separated by the same 
procedure was used as a negative control. Detection was performed with ABTS as a substrate for 5 min at 
RT. The fractions 8 to 17 containing high amounts of VP2cyto were isolated, concentrated using nanosep 
column with 10 kDa MWCO devices and used for electron microscopy. 
 
To facilitate in vitro assembly, fractions 11-15 ml of the superdex 200 column (figure III.10) 
containing VP2cyto monomers and trimers were collected and mixed. The trimer-monomer 
mixture was dialyzed overnight against PES buffer containing Ca+2. Although Ca+2 is known as an 
essential factor for IBD-VP2 assembly (Garriga et al., 2006), it may induce incorrect protein 
aggregation and precipitation. To inhibit non-proper subunit interactions, detergents such as 
dithiothreitol (DTT) and/or Tween-20 were added to the mixture and removed gradually stepwise 
while the Ca+2 concentration was gradually increased using dialysis as described (Lipin et al., 
2006). Even though, protein precipitation could not be avoided. As an alternative approach, the 
trimer-monomer VP2 mixture was completely disassembled using 8 M urea and 5 mM DTT 
followed by stepwise removal of urea through dialysis to facilitate re-assembly (Klikova et al., 
1995; Acosta-Rivero et al., 2004). The urea content was reduced to 2 M, 1 M and 0 M in three 
steps through dialysis using PES buffer containing Ca+2. As shown in figure III.12, addition of urea 
not only destroyed the trimer structure, but also increased the degradation of the protein as shown 
by SEC. Even after stepwise dialysis, the trimer assembly did not reproduce (data not shown) and 
consequently higher assembly could not take place, meanwhile, the monomer content remained 
intact after urea treatment and dialysis.  
In summary, SVP assembly did not occur in tobacco and the alternative approach to initiate SVP 
assembly after VP2 purification was also not successful. Consequently, it was decided to 
investigate production of VP2 in an alternative system such as Pichia (III.2). Nevertheless, 
immunogenicity of the VP2 monomer-trimer mixture was tested in mice.  
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Figure III.12 Chromatographic profile obtained by separation of VP2cyto before (blue) and after 
incubation with urea (brown) in two separate runs using a Superdex 200 column (II.2.3.5). The degradation 
fractions (~5 kDa) and salt impurities (>1 kDa) were also eluted at about 19, 21 and 24 of the elution 
volume. Standard calibration curve equation obtained by running the molecular weight standards (black 
triangles): ovalbumin (43 kDa), conalbumin (75 kDa), aldolase (158 kDa), ferritin (440 kDa) and 
thyroglobulin (670 kDa).  
 
 Immunogenicity of tobacco-produced VP2 in mice III.1.7
To check the immunogenicity of the tobacco-produced VP2, two groups of mice each containing 
five individuals were immunized either with purified (III.1.4) VP2apo (group 1) or VP2cyto 
(group 2), respectively. As indicated in figure III.15, immunization was repeated seven times, 
intraperitoneally at two-week intervals (II.2.5). After each boost, polyclonal antisera were 
collected from each mouse from the tail vein and the titer was determined by direct ELISA 
(II.2.5.1). The antibody titer refers to the highest dilution at which VP2-specific binding was 
detectable above background binding to mock- vaccinated mouse antisera as negative control 
(OD405 nm >0.2 was considered as positive signal). To estimate the cross-reactivity of antibodies 
with the blocking agent, a PBS sample (serum-free) was also applied to the test. All obtained 
quantified signals were subtracted from the latter sample to remove cross-reactivity effects and 
increase the accuracy. After the seventh boost, the final polyclonal antibody titer was higher than 
1:500,000 at least in one mouse for each group; mouse 1 for VP2cyto and mouse 5 for VP2apo 
(figure III.14). This experiment indicated that the tobacco-produced monomeric and trimeric VP2 
accumulating either in the cytosol or apoplast is immunogenic in mice. 
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Figure III.13 Schematic diagram shows mice immunization and blood sampling plan. 
 
 
 
Figure III.14 Determination of polyclonal IgG antibody titers in the sera of five mice immunized with 
(A) VP2apo or (B) VP2cyto, respectively, by indirect ELISA (II.2.5.1). Purified tobacco-derived VP2 (1 
µg/ml) was coated to ELISA plate (II.2.5.1). Mouse 2 from the VP2apo group died after the second boost 
and was removed from the experiment. Serial dilutions of the collected sera were added to the coated plates 
and bound antibodies were detected by addition of GAMHRP polyclonal antibody (0.2 µg/ml). ELISA 
reading was performed at OD405 nm after 20 minutes incubation with ABTS substrate at 37°C. X represents 
the antiserum dilutions. The arrows are indicating the titers above 1:500,000 in the immunized mice.    
 
III.2 Expression and characterization of IBD-VP2 in P. pastoris 
Since the level of transiently and stably plant-produced VP2apo and VP2cyto was relatively low to 
perform oral vaccination experiments and, more important, did not assemble to SVPs, which is 
required to induce a robust immune response, the VP2 was produced in the alternative eukaryotic 
expression system P. pastoris. 
 Cloning of IBD-VP2 gene sequence into pPICZ_B vector for generation of III.2.1
Pichia expression vectors 
P. pastoris transformation was performed using pPICZ_B (Invitrogen) as yeast expression vector. 
The IBD-VP2 encoding fragments were excised from the plant expression vectors pTRAkc-
VP2apo and pTRAkc-VP2cyto using EcoRI and XbaI and cloned into the same restriction sites of 
pPICZ_B, resulting in the final expression vectors pPICZ_B-VP2sec and pPICZ_B-VP2cyto, 
respectively (figure III.15). As a result, VP2, which was fused to the C-terminal His-tag was 
expressed under the control of the methanol-inducible alcohol oxidase 1 (AOX1) promoter and 
terminator, downstream of the CHS 5’ UT sequence with and without the targeting signal sequence 
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LPH of the murine antibody 24 heavy chain (Vaquero et al., 1999) in pPICZ_B-VP2sec and 
pPICZ_B-VP2cyto, respectively (vector maps in appendix VII.2B). 
 
 
Figure III.15 Schematic presentation of the final yeast pPICZ_B based expression vectors. 5’ AOX1 
and AOX1 TT: alcohol oxidase 1 gene promoter (methanol-inducible) and terminator, respectively; CHS: 5' 
untranslated region of the Petroselinum chalcone synthase; LPH: plant codon optimized targeting signal 
sequence derived from the murine heavy chain of the TMV-specific mAb24; IBD-VP2: cDNA of infectious 
bursal disease viral protein 2 corresponding to the first 441 amino acid; H6: his-6 tag for detection and 
purification; pTEF1: transcription elongation factor 1 gene promoter from S. cerevisiae that drives 
expression of the Sh ble gene in Pichia conferring zeocin resistance; pEM7: constitutive synthetic 
prokaryotic promoter that drives expression of the Sh ble gene in E. coli conferring zeocin resistance; Sh 
ble: Streptoalloteichus hindustanus bleomycin resistance gene; cyc1 TT: CYC1 transcription termination 
region (GenBank accession number M34014), 3’ end of the S. cerevisiae CYC1 gene that allows efficient 3’ 
mRNA processing of the Sh ble gene for increased stability; (not drawn to scale). 
  Pichia transformation, screening and expression III.2.2
Following positive selection and amplification of both vectors pPICZ_B-VP2sec and pPICZ_B-
VP2cyto in E. coli XL1-blue, the IBD-VP2 sequences and reading frames were confirmed by 
sequencing. Around 3 µg of the purified plasmid DNA was linearized with SacI by overnight 
incubation and introduced into P. pastoris X-33 cells by electroporation. The transformed X-33 
cells were initially screened on YPG plates containing 100 µg/ml zeocin. All of the resulted 
colonies showed the Mut+ (methanol utilization plus) phenotype on minimal methanol medium 
based on the screening method described in the EasySelect Pichia Expression kit instruction 
(Invitrogen, II.2.1.8). Ten positive colonies per construct were selected for analysis of recombinant 
protein expression (II.2.2.6). After cultivation and induction of VP2 expression by addition of 0.5- 
1% (v/v) methanol, yVP2sec and yVP2cyto levels were evaluated in cell extracts and culture 
media by dot blotting (figure III.16). Glycerol stocks were prepared from clones with the highest 
yVP2sec level in the media (colony 8) and yVP2cyto level in the cell extract (colony 9).  
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Figure III.16 Dotblot analyses for screening of yVP2sec or yVP2cyto in recombinant P. pastoris 
cultures (II.2.3.4). Colonies were inoculated in 3 ml YPD medium and grown o/n at 28 ˚C. At the 
following day, the expression of recombinant protein was induced by switching the medium to BMMY 
containing 0.5% (v/v) methanol while the OD600 nm was adjusted to 1.0. Twenty-four hours after expression 
induction, the cells were harvested by centrifugation at 5,000 ×g for 5 min. Total soluble proteins of the 
cells was obtained using Y-PER yeast protein extraction reagent (Pierce) according to the manufacture’s 
instruction. A) Five µl of total soluble proteins of the cell extracts and B) five µl of culture medium were 
coated on nitrocellulose membrane, following by blocking and immuno-detection using polyclonal anti-
VP2 as primary (1:10,000) followed by phosphatase-conjugate goat anti-rabbit (0.2 µg/ml) as a secondary 
antibody. Detection was performed with NBT/BCIP for 5 min at RT. Wild type Pichia (X-33) extract was 
used as a negative control (Ctrl-). 
 
To provide larger quantities of the recombinant protein for subsequent assays, the best induction 
time for yVP2 production was evaluated in 0.5 l culture. The production level of yVP2cyto#9 and 
yVP2sec#8 (figure III.16) was monitored each 24 h during the 96 h expression induction period as 
recommended by the manufacture’s instruction (EasySelect Pichia Expression kit, Invitrogen). For 
this purpose, 1 ml of the culture was collected at each day and the presence of yVP2 was 
determined in the medium culture of yVP2sec and in the cell extract of yVP2cyto using ELISA 
(II.2.3.1). The accumulation level of yVP2sec in the culture medium increased from about 22 mg/l 
at 24 h to about 65 mg/l at 96 h of expression induction whereas cytosolic accumulation of 
yVP2cyto increased from about 20 mg/l after 24 h to 76 mg/l at 96 h expression induction (figure 
III.17). The highest expression levels were detected at an induction of 96 h, therefore in all 
subsequent experiments an induction time of 96 h was used. 
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Figure III.17 Time-course study for evaluation of production levels of Pichia-produced (A) yVP2sec 
and (B) yVP2cyto accumulating in the medium and inside the cell, respectively. Evaluation was 
performed using ELISA (II.2.3.1). The expression of the recombinant proteins was induced in 500 ml of the 
Pichia culture at OD600 nm=1.0 by adding 0.5% (v/v) methanol for the first two days and 1% (v/v) for the 
following two days until 96 h (II.2.2.6). One milliliter of the cultures was collected at each day. Cells were 
separated from the medium. Total soluble protein was extracted from the harvested cells. Two microliter of 
the obtained medium and cell extract were used in ELISA to measure the VP2 content. Two µl of wild type 
yeast extract alone and in companion with affinity purified VP2cyto (III.1.4) with final concentration of 2-
10 ng/µl were used as negative and positive standards, respectively. Rabbit anti-VP2 antibody (1:10000) 
and GARHRP antibody (0.2 µg/ml) were used as primary and secondary antibodies, respectively. Detection 
was performed using ABTS as substrate after 10 min incubation at RT. The experiment was performed in 
biological triplicates. 
 
To verify the productivity and integrity of yVP2sec and yVP2cyto, culture medium samples 
without processing and cell extract samples after extraction using Y-PER protein extraction 
reagent, obtained from 96 h of expression induction were analyzed by SDS-PAA gel followed by 
Coomassie staining and immunoblot. As shown in figure III.18, cytosolic expression of yVP2cyto 
in Pichia resulted in intact VP2, which showed the same size as the purified tobacco-produced 
VP2cyto (~40 kDa). Small amounts of the protein were also detectable in the medium of 
yVP2cyto, which probably is originated from disrupted cells during cultivation. The upper band on 
top of the blot, which was also observable in plant-derived VP2cyto, was due to non-systematic 
hydrophobic interactions between the monomers. The smeary movement pattern of yVP2sec 
obtained either from cells or medium in addition to its higher molecular mass compared to 
VP2cyto indicates the presence of glycan chains attached to yVP2sec. Hyper-mannosylation is 
common for secreted proteins in Pichia. Interestingly, yVP2sec fractions from cell extract and 
medium have the same separation pattern and size in the immunoblot. This observation indicates 
that yVP2sec located inside the cells is glycosylated like yVP2sec secreted to the medium. Since 
the medium contains less host protein when compared to cell extracts, purification of yVP2sec 
from medium is easier and faster.  
In summary, the result demonstrates that yVP2 can be produced in Pichia and accumulates to high 
levels, both inside the cells or when secreted to the medium. As a next step, the assembly of the 
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VP2 inside and outside the cell as well as the role of glycosylation on protein assembly was 
investigated. Further studies on glycan analysis are described below (III.2.4.1). 
    
 
Figure III.18 SDS-PAGE analysis of yVP2sec and yVP2cyto obtained from selected Pichia colonies 
(III.2.2) after 96 h expression induction followed by Coomassie brilliant blue staining (A and C) and 
immunoblot (B and D). Twelve-microliter samples were separated by 12% (w/v) SDS-PAA gel (II.2.3.2): 
(1) yVP2cyto cell extract, (2) yVP2cyto medium culture, (3) yVP2sec cell extract, (4) yVP2sec medium 
culture, (5) wild type Pichia (X-33) cell extract and (6) wild type medium culture as negative controls, (7) 
tobacco-derived and affinity purified VP2cyto and (8) VP2apo as controls (III.1.4). The experiment was 
performed under reducing (A and B) and non-reducing (C and D) condition. The VP2 corresponding bands 
were visualized in immunoblot (II.2.3.3) recruiting rabbit anti-VP2 antibody (1:10000) and phosphatase-
conjugated goat anti-rabbit (0.2 µg/ml) were used as primary and secondary antibodies, respectively. 
Detection was performed with NBT/BCIP for 5 min at RT. 
  
 Expression and purification of IBD-VP2 and analysis of SVP assembly III.2.3
Production of yVP2sec and yVP2cyto was performed on a 500-ml culture with 96 h induction of 
recombinant protein expression (II.2.2.6). For small-scale protein extraction from the cells (up to 5 
ml culture), Y-PER protein extraction reagent was used whereas for larger cell amounts (> 100 ml 
culture) the extraction was performed in 0.1 M acetate buffer pH 6.0 containing 1 mM PMSF, 1 
mM EDTA and 5% (v/v) glycerol. Following extraction of the soluble proteins, the pH was 
decreased to 4.0. Then the extract was incubated at 4 ºC for 1 h while stirring to precipitate the host 
proteins. Precipitated proteins were pelleted at 13,000 ×g for 20 min at 4 ºC. The soluble fraction 
and the pellet were collected. The pellet was resuspended in PBS to the equal initial volume before 
the pH shift. A sample of the soluble fraction and the pellet was analyzed for VP2 content (figure 
III.19). Although dropping the pH to 4.0 led to a loss of about 40% of VP2 content the purity was 
improved about 75%. Therefore the acetate buffer pH of 4.0 containing the same components 
(breaking buffer; II.2.26) was used for direct extraction of yVP2cyto and yVP2sec from the cells.  
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Figure III.19 First step purification of yVP2cyto using pH-shift from 6.0 to 4.0. Following total soluble 
protein extraction from the cells using acetate buffer pH 6.0, the pH was shifted to 4.0 by adding 1 M HCl. 
The solution was centrifuged at 13,000 ×g/ 20 min/ 4 ºC. The pellet was resuspended in PBS to the equal 
initial volume before pH shift. Twelve-microliter of the supernatant and the resuspended pellet were 
separated on 12% (w/v) SDS-PAA gel under non-denaturing condition followed by Coomassie brilliant 
blue staining (II.2.3.2) (A) and immunoblot (II.2.3.3) (B). Rabbit anti-VP2 antibody (0.12 µg/ml) and goat 
anti-rabbit AP-labeled (0.2 µg/ml) were used as primary and secondary antibodies, respectively. Purified 
tobacco-derived VP2cyto was used as a positive control. Densitometric quantification revealed that 
although this procedure led to the loss of 40% of VP2 content, it increases the purity up to 75%.  
 
The data were shown for yVP2cyto but a compatible result with respect to purity and integrity was 
obtained for yVP2sec extracted from the cells. Due to the low total protein content in the Pichia 
medium culture, the pH shift strategy was not administered for the purification of yVP2sec from 
the medium. Hereafter yVP2sec-c and yVP2sec-m were chosen to show yVP2sec from the cell and 
medium, respectively.  
As the second purification step, precipitation of yVP2sec-c and yVP2cyto as well as yVP2sec-m  
was performed by gradual increasing the concentration of ammonium sulfate salt to 50% followed 
by resuspension of the pellet into 10 ml PBS resulting in the recovery of almost all yVP2 content 
(60% of the total content) with 90% purity (data not shown).  
To polish the purified protein and coincidently analyze the protein assembly through studying the 
molecular mass, the protein samples were applied to a Hiprep 26/60 Sephacryl S-400 HR (GE 
HealthCare) size exclusion chromatography column with 20- 8000 kDa separation range (II.2.3.5). 
The eluent was collected in 2 ml fractions and samples (10 µl) from each fraction were used in 
indirect ELISA (II.2.3.1) to determine the yVP2 content (figure III.20). As depicted (A1) applying 
yVP2cyto purified from cell extracts onto SEC led to the formation of two major peaks at 152 and 
250-ml elution volume. The ELISA response (figure III.20, A2) showed that both peaks contain 
the major yVP2cyto contents. The same peaks were also obtained by analyzing yVP2sec-c (figure 
III.20, B1) whereas in case of yVP2sec-m, only a 250-ml peak was observed (figure III.20, B2). 
Both peaks were absent in the wild type Pichia X-33 cell extract treated by the same purification 
process (figure III.20, B3). ELISA confirmed that in case of yVP2sec-c and yVP2cyto, both 152-
and 250-ml peaks contained the yVP2 protein (data not shown) indicating that cell extracted yVP2 
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is present in the form of high (152-ml peak) and low molecular mass (250-ml peak) while the 
yVP2sec-m sample purified from the medium contained only the low molecular mass fraction.  
For yVP2cyto and yVP2sec-c, 152-ml peak fractions were collected, mixed and concentrated using 
nanosep centrifugal device with 300 kDa MWCO. Fractions of 250-ml peak were collected 
separately from yVP2cyto, yVP2sec-c and yVP2sec-m samples, mixed and concentrated using 10 
kDa MWCO devices. 
 
 
Figure III.20 Separation of Pichia-produced yVP2 using size exclusion chromatography (A, B) and 
further electron microscopy studies (C). The yVP2sec-c and yVP2cyto proteins were produced and 
purified from Pichia cells (II.2.2.5) using breaking buffer pH 4.0 and 50% (w/v) ammonium sulfate 
precipitation. Similarly purified Pichia X-33 wild type cell extract was used as a negative control in the 
purification procedure. yVP2sec-m was extracted from the culture medium directly, using 50% (w/v) 
ammonium sulfate precipitation. The purified protein was separated by size exclusion chromatography 
(SEC) using a S-400 HR column with a size separation range 20-8000 kDa: (A1) purified yVP2cyto, (B1) 
purified yVP2sec-c, (B2) purified yVP2sec-m and (B3) Pichia wild type similarly purified cell extract. The 
eluted fractions were tested for VP2 content by indirect ELISA (II.2.3.1). ELISA confirmed that both 152-
ml and 250-ml peaks containing yVP2(A2) (data shown for yVP2cyto). Analysis of VP2sec-m (B2) as well 
as X-33 wild type cell extract (B3) as negative control showed that 152 ml-peak is absent in the medium 
extracted yVP2sec. 
Electron microscopy for the concentrated 152-ml and 250-ml peaks revealed that only 152-ml peak 
contained fully assembled IBD-SVPs. Electron micrograph for the 152-ml peak for the purified yVP2cyto 
named as IBD-SVPcyto (C1) and yVP2sec-c named as IBD-SVPsec (C2) was shown. The conformational 
changes in IBD-SVPsec are due to the glycosylation. Scale bar represents 50 nm. 
 
The concentrated samples were studied by TEM (II.2.3.6). Electron microscopy revealed that the 
152-ml peak contained fully assembled IBD-SVPs (figure III.20C) whereas no symmetrical 
Chapter III                                                                                                                                 Results      
 
71 
 
structure was detected in the 250-ml peak (data not shown), although it contained yVP2 according 
to ELISA (figure III.20 A2). This shows that the partially purified and concentrated cell extracted 
yVP2cyto and yVP2sec-c both contained a mixture of two types: fully assembled symmetrical 
IBD-SVPs with 23 nm in diameter, T= 1 lattice, based on previous studies (Caston et al., 2001; 
Coulibaly et al., 2005) and not-fully assembled yVP2. Determination of the assembly level in the 
250 ml-peak was not possible due to the low resolution of the column at low molecular weight 
range. The 152 ml-peak representing IBD-SVPs was present both in yVP2cyto and yVP2sec-c 
samples derived from cell extracts but was absent in the wild type purified cell extract and 
yVP2sec-m purified from medium (figure III.20B3 and 4), while the second peak eluted at 250 ml 
was present in the purified yVP2cyto, yVP2sec-c as well as yVP2sec-m samples, obviously 
containing only VP2 monomers and/or less assembled VP2 proteins. This fact revealed that 
yVP2cyto and yVP2sec was present as SVPs inside the Pichia cells but not in the medium. This 
observation may be explained by the pore size of the Pichia cell wall, which prevents the passage 
of big structures such as SVPs into the medium; consequently, SVP structures were entrapped in 
the cell space between the cell wall and cell membrane.  
As it is shown in figure III.20C, SVPs derived from yVP2cyto (IBD-SVPcyto) have regular 
doughnut-like shape with a central hole whereas SVPs derived from yVP2sec-c (IBD-SVPsec) are 
less homogeneous and showed a stretched conformation. Also the putative central holes appear 
filled in IBD-SVPsec. These conformational differences when compared to IBD-SVPcyto are due 
to glycosylation of IBD-SVPsec, which influences the appearance of yVP2sec SVPs (Figure 
III.20C1 and C2), which is analyzed in more detail in section III.2.4.  
Purified yVP2cyto separated into two distinct bands on SDS-PAA gel, one at about 40 kDa, 
matching with the mass of the VP2 monomer, and the other one with a high molecular mass appear 
on top of the blot (figure III.21A). Purified yVP2sec-c could be also separated into two bands on a 
SDS-PAA gel, one at about 60 kDa and one with high molecular mass and a smear between the 
two bands (figure III.21B). The size difference for yVP2cyto when compared to the yVP2-sec-c 
and also the smeary band pattern of yVP2sec-c on the SDS-PAGE can be explained by 
glycosylation of yVP2sec-c. 
The purity of purified of SVPs derived from yVP2cyto and yVP2sec-c were determined by SDS-
PAGE and Coomassie staining followed by densitometric calculation of the protein bands 
(II.2.2.6). They were calculated about 96.2% and 90%of intact proteins, respectively (figure 
III.21A, B).  
In contrast to the SVPs structure that hides the His-tag inside making it inaccessible, yVP2sec-m, 
which was present in the non-fully assembled form (figure III.20 B2) has an accessible C-terminal 
His-tag that facilitates purification using IMAC. Therefore, the culture medium of yVP2sec was 
applied to Ni-NTA column after pH shifted to 8.0. The purification steps were studied by SDS-
PAGE. As shown in the figure III.21C, yVP2sec-m binds to the column as expected and elutes by 
applying immidazole. The eluent showed a smeary movement pattern on the SDS-PAA gel, which 
extends form the top to about 60 kDa with a purity of about 90% (figure III.21 C). The 
glycosylation may explain the smeary band pattern since yVP2sec is transported to the secretory 
pathway in Pichia.  
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IBD-SVPcyto isolated from the 152-ml fractions of yVP2cyto after SEC were used for subsequent 
vaccination (III.3) and nanobiotechnology (III.4) studies. The total amount isolated from one-liter 
culture volume, was 38 mg as determined by the BCA kit (II.2.3.1) with a purity of 96.2%. Since 
the total expression level of yVP2cyto was 76 mg/l (figure III.17), by using the explained 
purification procedure, half of the yVP2cyto content was yielded as purified fully assembled IBD-
SVPcyto. Purified IBD-SVP derived from yVP2cyto were distributed in separate vials each 
containing 1 mg and stored at -80°C for the subsequent studies.  
 
 
Figure  III.21 SDS-PAGE analyses of yVP2. Purified IBD-SVPcyto (A) and IBD-SVPsec (B) obtained by 
pH shift and salt precipitation and polished by SEC: one microgram of the proteins were separated on 12% 
(w/v) SDS-PAA gel followed by Coomassie brilliant blue staining (cbbs) (II.2.3.2) and immunoblot (ib) 
(II.2.3.3). Two bands were detected for yVP2cyto, a ~40 kDa-band and a band on top of the gel. Also two 
bands observed for yVP2sec-c, a ~60 kDa-band and a band on top of the gel. In addition a smear between 
the bands was visible. The purity was determined about 96.2% for yVP2cyto and 90% for yVP2sec-c using 
densitometry method (B) Analysis of yVP2sec-m purified by IMAC: A Twelve-microliter sample of each 
purification step (including culture medium, supernatant after pH shift to 8.0, loading, flow through from 
Ni-NTA column, dead volume and elution fraction) of culture medium of yVP2sec-m was studied by 12% 
(w/v) SDS-PAA gel. Further analysis was performed using Coomassie brilliant blue staining (II.2.3.2) and 
immunoblot under non-reducing condition. For immunoblots (II.2.3.3), rabbit anti-His antibody (0.12 
µg/ml) and goat anti-rabbit AP-labeled (0.12 µg/ml) were used as primary and secondary antibodies, 
respectively. Detection was performed with NBT/BCIP for 5 min at RT. Like yVP2sec-c, yVP2sec-m was 
smeary which extends form top of the gel to about ~60 kDa. The purity was determined about 90% using 
densitometric method.  
    Glycosylation analysis of yVP2sec III.2.4
As described above (figure III.6), VP2 has three N-glycosylation sites. The smeary and slower 
movement of yVP2sec–m and IBD-SVPsec compared to IBD-SVPcyto on SDS-PAGE (figure 
III.21) indicated glycosylation of the secreted yVP2. Hyper-glycosylation, more specifically, 
hyper-mannosylation is often observed for secreted recombinant proteins produced in P. pastoris 
(Hellwig et al., 1999; Promdonkoy et al., 2009). To verify glycosylation of purified IBD-SVPsec, 
isolated form the cells by pH shift and salt precipitation and polished by SEC (III.2.3; figure 
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III.21B) as well as purified yVP2sec-m isolated form the culture medium by IMAC (III.2.3, figure 
III.21C) was applied to further glycan analysis. 
   Lectin blot III.2.4.1
The potential glycosylation of IBD-SVPsec and yVP2sec-m was first analyzed by a lection blot 
(II.2.4.1) using mannose-specific Galanthus nivalis lectin. Following SDS-PAGE and blotting onto 
a nitrocellulose membrane, IBD-SVPsec and yVP2sec-m, both having a purity of about 90% 
(figure III.21B, C), were detected by alkaline phosphatase-conjugated Galanthus nivalis lectin. 
IBD-SVPcyto (figure III.21A) and tobacco-derived VP2apo (III.1.4) were used as negative and 
positive control, respectively. Figure III.22 shows that IBD-SVPsec as well as yVP2sec reacted 
with mannose-specific lectin and consequently were glycosylated. Although VP2apo should 
contain plant type glycan containing mannose residues in the structure, obviously the low 
frequency and reduced availability of mannose residues limits the proper reaction with Galanthus 
nivalis lectin resulting in no visible band. In other words, mannose residues in complex plant 
glycans are buried by other residues such as GlcNaC whereas in the complex Pichia glycans a 
large number of mannose residues (9-17 residues) are present. In contrast IBD-SVPcyto, which 
accumulated in the Pichia cytosol, did not show any binding to the lectin demonstrating that this 
protein is not glycosylated, as expected.  
 
Figure III.22 Lectin blot analysis of yVP2 produced in Pichia. One microgram of purified yVP2sec-m 
isolated from the culture medium, IBD-SVPcyto isolated from the cells, IBD-SVPsec isolated from the cells 
(figure III.21) and tobacco-derived VP2apo (III.1.4) were separated by 12% (w/v) SDS-PAGE followed by 
blotting onto nitrocellulose membrane. The membrane was blocked using 2.5% (w/v) skimmed milk in 
PBST. The detection was carried out using mannose specific AP-labelled Galanthus nivalis lectin (0.2 
µg/ml) and NBT/BCIP as a substrate. 
 
   Enzymatic deglycosylation of yVP2sec-m III.2.4.2
As was demonstrated by the lectin blot analysis, both yVP2sec-m and IBD-SVPsec are 
glycosylated. Since they are both composed of the same protein and passed through the secretory 
pathway, they only differ in their level of assembly. Therefore, hereafter only yVP2sec-m was 
studied due to its more simple structure and ease of reaction with the deglycosylation and digestive 
enzymes. yVP2-sec-m was subjected to deglycosylation using PNGase F (II.2.4.2). IBD-SVPcyto 
as well as non-deglycosylated yVP2-sec-m was used as controls. The resulting products were 
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separated by SDS-PAA gel electrophoresis followed by Coomassie staining and lectin blot analysis 
(figure III.23). After glycan removal through enzymatic digestion from yVP2sec-m and 
electrophoretic separation, yVP2sec-m had the same size of ~40 kDa as the non-glycosylated IBD-
SVPcyto on the Coomassie stained gel (figure III.23A), demonstrating that glycosylation was 
responsible for the observed mass differences. Lectin blot was also performed with the same 
samples using Galanthus nivalis lectin (II.2.4.1). Only intact yVP2sec-m reacted with the lectin 
whereas the deglycosylated yVP2sec-m as well as IBD-SVPcyto showed no reactivity with the 
lectin indicating that they do not contain any attached glycans. These results showed that the 
difference in size between yVP2 accumulated in cytosol and yVP2 passed through secretory 
pathway as well as smeary movement of yVP2sec on SDS-PAA gel is due to the glycosylation.  
 
 
Figure III.23 SDS-PAGE analysis of the deglycosylated yVP2sec-m using peptide N-glycosidase F 
(PNGase F) and lection blot. One microgram of (1) deglycosylated purified yVP2sec-m, (2) purified IBD-
SVPcyto (3), purified yVP2sec-m without deglycosylation were separated by 12% (w/v) SDS-PAA gel 
electrophoresis followed by Coomassie brilliant blue staining (A) and lectin blot (B) using AP-labelled 
Galanthus nivalis lectin (0.2 µg/ml) and NBT/BCIP as a substrate (II.2.4.1).  
    Glyco-proteomic analysis of yVP2sec  III.2.4.3
The glycan composition of purified yVP2sec-m isolated from the Pichia culture medium (figure 
III.21B) was analyzed by LC-MS. Following IMAC purification and dialysis of the elution fraction 
against PBS, yVP2sec-m was digested with trypsin and chemotrypsin and finally analyzed by LC-
MS (II.2.4.3). As described above VP2 contains three potential glycosylation sites (figure III.6; aa 
46, aa 121, aa 396). The result of LC-MS is shown in figure III.24 and summarized in table III.2. 
Mass spectrometry revealed that high mannose type glycan are abundant at all three sites of 
yVP2sec-m. A monosaccharide (such as mannose) with six carbon atoms was shown as Hex thus 
HexNac2Hex11 with the 33.71% average abundance between the three sites of followed by 
HexNac2Hex10 (31.67 %) are the most prominent glycan compositions. HexNac2Hex9 (with 8.4% 
average abundance) is the simplest recognized glycan-type and more complex-types such as 
HexNac2Hex12-17 are also present. Glycosylation analysis of yVP2sec-m confirmed that the signal 
peptide of the murine heavy chain antibody (LPH) is also functional in Pichia in leading yVP2 to 
the secretory pathway and finally to the medium. All three N-glycan sites were glycosylated with 
variation in glycan compositions and their frequencies are described in Table III.2 in more detail.  
  
a 
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Table III.2 Glycan composition and their ratio at the three N-glycan sites (1, 2 and 3) of IMAC-
purified yVP2sec-m (III.2.3) studied by liquid chromatography-mass spectrometry (LC-MS).   
 
Glycan type Relative frequency (%) Site 1 Site 2 Site 3 
HexNAc2HeX9 3.39 9.33 12.68 
HexNAc2HeX10 34.13 38.59 22.30 
HexNAc2HeX11 39.86 35.51 25.78 
HexNAc2HeX12 9.83 10.14 16.31 
HexNAc2HeX13 6.28 6.43 10.03 
HexNAc2HeX14 3.28 0.00 5.57 
HexNAc2HeX15 2.59 0.00 3.97 
HexNAc2HeX16 0.66 0.00 2.09 
HexNAc2HeX17 0.00 0.00 1.25 
 
 
 
Figure III.24 Liquid chromatography-mass spectrometry (LC-MS) of the three N-glycosylation sites 
of Pichia-produced and affinity-purified yVP2sec-m. yVP2sec-m was purified by IMAC (III.2.3) from 
the medium of the Pichia culture, dialyzed against PBS and digested with trypsin and chemotrypsin 
(II.2.4.3). The resultant peptides were applied to LC-MS analysis (II.2.4.3). The spectrum of glycosylated 
peptides are shown in figure A (site 1), B (site 2) and C (site 3) based on their position in the yVP2sec-m 
sequence (figure III.6).   
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III.3 Chicken immunization with yVP2cyto 
Aglycosylated yeast-produced VP2 either in purified (IBD-SVPcyto) (III.2.3) or cell-capsulated 
(Pichia yVP2cyto) form (III.2.2) was used in chicken immunization experiments against IBDV. 
The experiments were performed at Institute of Poultry Diseases, faculty of Veterinary Medicine, 
Freie Universität Berlin. To diminish regulatory issues regarding the release of genetically 
modified organisms (GMOs) during transport and immunization, Pichia cells (cell-capsulated 
yVP2cyto) containing the antigen were subjected to inactivation procedure. For this purpose, the 
freshly harvested cells were applied into two thermal cycles of 70 °C and 15 °C each for 5 min. 
About 16 g of the cells was harvested by centrifugation from 1 l culture and resuspended in 
distilled water to a final volume of 40 ml in a 50-ml tube and subsequently applied to the thermal 
cycles.  To confirm proper inactivation, a vitality test was performed on yeast selection solid 
medium, Sabouraud agar (Heipha Dr Müller GmbH), in three cell concentration and three 
repetitions (data not shown). The result showed that about 99.3 % of the cells were inactivated 
after the first cycle and applying the second cycle inactivated the rest. The inactivated cells were 
stored at -80 °C for one day and then freeze-dried.  
To test the stability and integrity of the antigen after cell inactivation and freeze-drying, a sample 
of the cells was subjected to purification of yVP2 as described before (III.2.3). The resulting 
sample was studied by SDS-PAGE and SEC using purified IBD-SVPcyto as a control. As 
illustrated in the figure III.25, the movement pattern of yVP2cyto on SDS-PAA gel and SEC 
remains intact after inactivating and freeze-drying and are identical to the purified IBD-SVPcyto 
(III.2.3). The elution pattern of yVP2cyto in SEC derived from inactivated Pichia is also 
comparable with the purified IBD-SVPcyto (III.2.3). The major fractions eluted at 152-ml peak, 
which corresponds to IBD-SVPcyto (figure III.20). This observation indicates that the heat 
inactivation does not impair the structure of the antigen; yVP2 remains intact and can be purified 
in the form of SVPs. The lyophilized inactivated Pichia yVP2cyto cells as well as purified IBD-
SVPcyto were used in oral immunization of the chickens.  
To evaluate the dosage of the cell-capsulated vaccine, the yVP2 content inside the cells was 
measured using SDS-PAGE followed by immunoblot and densitometric method using AIDA 
software. The known concentrations of purified IBD-SVPcyto (II.2.3) measured using BCA kit 
were applied to the same blot and used as standards. Calculations indicated that in one milligram 
of freeze-dried inactivated Pichia yVP2cyto powder about 16 µg of yVP2 exists.  
Two-week old SPF white Leghorn chickens were immunized using either the freeze-dried 
inactivated Pichia yVP2cyto or purified IBD-SVPcyto. The immunization and challenge scheme as 
well as immunization groups are shown in figure III.26. Both antigen vaccine types were applied 
four times, weekly: each in two different doses, high and low: 250 mg or 25 mg of freeze-dried 
inactivated Pichia yVP2cyto and 500 µg and 50 µg of purified IBD-SVPcyto. Each vaccine dose 
also was tested in companion with oral adjuvant. 50 µg CpG ODN (table II.1.4) plus an adequate 
amount of NaF (100 mg per kg of chicken weight) was used as an oral adjuvant mixture. As a 
negative control, 250 mg of freeze-dried inactivated wild type Pichia was applied to the group 9 
(mock-immunized) in order to study the side effects of the expression platform on the chickens.  
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Figure III.25 Analysis of stability and integrity for IBD-SVPcyto after Pichia cell inactivation using 
SDS-PAGE and SEC. Twelve microliter of: (1) Purified yVP2cyto derived from freeze-dried inactivated 
Pichia cells, (2) Purified yVP2cyto derived from active freeze-dried Pichia cells, (3) Purified IBD-SVPcyto 
(III.2.3) as a positive control, were separated on 12% (w/v) SDS-PAA gel followed by Coomassie brilliant 
blue staining (A) and immunoblot (B) using rabbit anti-VP2 (1:10,000) and GARAP (0.2 µg/ml) as primary 
and secondary antibodies, respectively, and NBT/BCIP as a substrate (C) Chromatographic profile obtained 
by separation of the corresponding samples 1, 2 and 3 using SEC S-400 HR column and Äkta Explorer 
(II.2.3.5).  
 
The Pichia cells and the purified antigen were administered in one-ml and 0.5-ml volumes, 
respectively. Oral immunization was carried out by oral gavage into the chickens’ crop. AviPro 
Gumboro vac (Lohmann Animal Health) vaccine composed of attenuated virus was also applied 
orally according to the manufacturer’s instruction as a positive control.  
To test the ability of IBD-SVPcyto to induce anti-IBDV antibody production, the most direct 
method with confirmed efficacy is to use the purified antigen and deliver by injection. Therefore, 
20 µg of purified IBD-SVPcyto were delivered intramuscularly in combination with adjuvant 100 
(Gerbu) in 100 µl total volume for the chickens in group 10. Two groups of the chickens not 
receiving any immunization treatment were used as negative controls of virus challenge and 
vaccine treatment, respectively. All chickens except those of group 13 (vaccine control) were 
challenged with a classical IBDV strain, MB3, inoculated ocularly to the chickens at 28 day post 
immunization (dpi).  
Blood and cloakal samples were collected according to table II.7; prior to each immunization, at 
viral challenge as well as death/euthanization days. In addition weight of the birds was recorded 
and monitored as a health index each week during the whole period of the experiment. 
During a week following challenge, the observed clinical signs were recorded and at the last day 
(35 dpi) the surviving chickens were euthanized, bursa Fabricious was extracted, the bursa weight 
to body weight (BF/BW) ratios were determined. Also, the bursal damage score, viral clearance 
and mucosal antibody response were investigated.   
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Figure III.26 Immunization of the chickens randomly allocated between 13 immunization groups. (A) 
Immunization scheme: Two-week old chickens were immunized at the indicated times (schematized as 
black bars) by either orally (groups 1-9) or intramuscularly (group 10). Oral immunization was carried out 
using 250 mg and 25 mg of freeze-dried Pichia (groups 1-4) or 500 µg and 50 µg of purified (III.2.3) 
Pichia-derived IBD-SVPcyto (groups 5-8) with and without oral adjuvant mixture. The yeast P. pastoris X-
33 and Avipro Gumboro vac (Lohmann Animal Health, Cuxhaven, Germany), which composed of 
attenuated virus, were applied as mock-immunized (group 9) and positive (group 12) controls, respectively. 
Intramascular immunization was carried out using 20 µg of purified Pichia-derived IBD-SVPcyto mixed 
with adjuvant 100 (Gerbu). Two groups were remaining unimmunized, one was applied to challenge 
experiment and named as a challenge control (group 11) and the other was kept unchallenged as a vaccine 
control (group 13). The gray bar indicates the time interval following viral challenge; arrow indicates the 
time point of euthanization of the survivorss. 
    Health monitoring, clinical signs  III.3.1
The weight gaining of the chickens as a health index was monitored during the experiment. No 
significant difference (p> 0.05) in weight increase was observed between all groups during the 
immunization, which indicates that the vaccine was not interfering in growth rate (figure III.27).  
The typical IBD clinical signs including ruffled feathers, depression, feces form and color as well 
as death were investigated daily after the viral challenge. Clinical signs of IBDV usually appear at 
day 2 post infection and start to disappear at day 4 due to rapid recovery of the survivors 
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(Mahgoub, 2012).  All the detailed clinical sign observations are summarized in table VII.2 in 
appendix VII.6.  
 
 
 
Figure III.27 Weight of the chickens was monitored as a health index during immunization. The 
variations among the groups (II.2.6.8) of vaccinated and non-vaccinated are not significant (p> 0.05). 
 
Briefly, at the 2nd day post challenge (dpc), the moderate to severe clinical signs appeared among 
the birds in the groups of mock-immunized (group 9) and challenge control (group 11). Most of 
the birds in the other groups developed slight clinical signs. At the 3rd dpc, the mortality started 
among mock-immunized (group 9) and challenge control (group 11) as well as birds in groups 5 
and 6 that received 25 mg of Pichia yVP2cyto without and with oral adjuvant, respectively. The 
other chickens in these groups also showed severe clinical signs. Other groups that orally 
immunized with cell-capsulated antigens showed slight to moderate clinical signs. The mortality 
started among the latter groups at day 4th dpc with lower frequency (two in group 1 and one in 
group 4) compared to mock-immunized and challenge control. At this day slight clinical signs 
appeared in birds of group 7 and 8, which received 500 µg of the purified IBD-SVPcyto without 
and with oral adjuvant, but they recovered until the next day. In contrast, among birds of groups 5 
and 6, which received 25 mg of Pichia yVP2cyto, similar to mock-immunized (group 9) and 
challenge control (group 11) mortality as well as moderate to severe clinical signs was observed. 
At the 5th dpc, the survivors showed the first signs of recovery. Chickens in group 10 that received 
the vaccine parenterally, group 12 that received the live-vaccine showed no clinical signs 
following viral challenge. 
These observations indicate that oral immunization either with cell capsulated or purified antigen 
is immunogenic but the potency of conferring immunity is dose and formulation-dependent. 500 
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µg of purified IBD-SVPcyto more efficaciously inhibits clinical signs compared to 50 µg of 
purified IBD-SVPcyto and even 250 mg of Pichia yVP2cyto that containing 4 mg of yVP2cyto. 
 Immune response and protection analysis III.3.2
Mucosal immunization, in contrast to parenteral immunization, has the advantage of inducing both 
systemic and local mucosal immune response. In response to antigen application, secretory 
immunoglobulin A (SIgA) is generated at stimulated mucosal surfaces. This antibody isotype is 
produced by B cells localized underneath of the mucosal surface. Since secretory IgA has high 
affinity to the mucus, excreted mucus is an enriched source of IgA. Following oral immunization, 
secretion of IgA launches in gut lamina proporia. Thus feces samples have been used as a source 
for mucosal immune response analysis. In addition to SIgA, some IgA molecules without secretory 
component pass through paracellular passive transfer and also reach to the secretions (Johansen et 
al., 1999 a, b). Since oral immunization has the ability to induce systemic immune responses in 
peripheral lymphoid organs, the antigen-specific serum IgY, IgM and IgA antibody responses, 
other than mucosal immune response in feces, should be studied to evaluate the efficacy of the 
vaccine. For this purpose, peripheral blood and feces samples were collected weekly before each 
immunization at 0, 7, 14, 21 dpi, before viral challenge at 28 dpi and at the death/euthanization day 
and were studied using indirect VP2-based ELISA (II.2.6.2). Pichia-derived purified IBD-SVPcyto 
was used as an antigen coated in microtiter plate to study the specific immune response against 
IBDV in the chickens.  
 
To study systemic and local IgA immune response the 1:5 diluted sera and feces extract (II.2.6.4) 
were applied to the coated antigen in microtiter plate (II.2.6.4). For preparation of feces extract or 
cloakal swab sample were used (II.2.6.2). The detection was carried out using horseradish 
peroxidase-conjugated goat anti-chicken IgA (5 µg/ml). Finally, ABTS was used as substrate. The 
mean OD405 nm values over that the mean absorbance plus two times standard deviation of the pre-
immune sera (> 0.2) was considered as positive antibody responses. 
IgA response was undetectable (<0.2) in all samples collected before challenge among all chickens 
(data not shown). But about a week after challenge IgA response appeared in the sera and most 
feces samples of vaccinated chickens (figure III.28). This response was absent in challenge (group 
11) and vaccine (group 13) controls. However, the mock-immunized group (group 9) that received 
250 mg of Pichia wild type cells also was seropositive. This unexpected observation might be 
explained by the reaction of generated chicken antibodies against Pichia proteins since the coated 
IBD-SVPcyto derived from Pichia. The strength of the signals is not significantly differing from 
the mock-immunized group and other orally immunized groups. Only in group 12 that orally 
immunized with attenuated virus, the response is higher than in the mock-immunized and other 
groups. As a conclusion, secretory IgA response was not strongly stimulated regardless of route of 
immunization except in the group 12 which received live attenuated virus. 
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Figure III.28 Serum IgA and intestinal IgA response in chickens immunized with freeze-dried 
inactivated cell-capsulated and purified IBD-SVPcyto after viral challenge. Oral immunization 
was carried out using 250 mg and 25 mg of freeze-dried Pichia (groups 1-4) or 500 µg and 50 µg of purified 
(III.2.3) Pichia-derived IBD-SVPcyto (groups 5-8) with and without oral adjuvant mixture in all cases. The 
yeast P. pastoris X-33 and Avipro Gumboro vac (Lohmann Animal Health, Cuxhaven, Germany), which 
composed of attenuated virus, were applied as mock-immunized (group 9) and positive (group 12) controls, 
respectively. Intramascular immunization was carried out using 20 µg of purified Pichia-derived IBD-
SVPcyto mixed with adjuvant 100 (Gerbu). Two groups were remaining unimmunized, one was applied to 
challenge experiment and used as a challenge control (group 11) and the other was kept unchallenged as a 
vaccine control (group 13). All chicken sera were diluted 1:5 in PBS and feces samples were prepared by 
rinsing the cloak swab in 500 µl PBS containing protease inhibitor cocktail for one hour and used undiluted 
in VP2-based ELISA (II.2.6.4). The detection was carried out using horseradish peroxidase-conjugated goat 
anti-chicken IgA (5 µg/ml). Finally, ABTS was used as substrate. The mean OD405 nm values over that the 
mean absorbance plus two times standard deviation of the pre-immune sera (> 0.2) was considered as 
positive antibody responses. Each bar is the average of OD405 nm reading from five individual serum samples 
or five individual fecal samples with standard error indicated by error bars.  
 
The IgM and IgY immune response were also investigated by ELISA as described (II.2.6.2). The 
OD405 nm values above the mean absorbance plus two times standard deviation of the pre-immune 
sera (> 0.2) were considered as positive antibody responses (seropositive).  
 
As it is illustrated in the figure III.29A and B, the IgM and IgY antibody levels at day 0 dpi of all 
chickens and the vaccine control (group 13) showed that all chickens were seronegative for IBDV 
antibodies prior to vaccine administration. Following immunization but before viral challenge, 
IgM response (figure III.29B) was only detectable in the chickens of group 10 that received the 
purified antigen intramuscularly. Subsequent to viral challenge, all groups were stimulated and 
started to produce IgM upon the virus entrance. The levels of IgM in the chickens only in group 10 
drops down after viral challenge. This observation might be explained by quick class switch from 
IgM to IgY in this group indicating that intramascular immunization triggers the immune system 
more efficacious in the context of affinity maturation and isotype switching. 
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Figure III.29 Immunization of chickens with freeze-dried inactivated cell-capsulated and purified 
IBD-SVPcyto. Reactivity of serum IgM (A) and IgY (B) of the chicken sera with IBD-SVPcyto were 
determined by ELISA (II.2.6.4). The serum samples were collected before each immunization, before viral 
challenge and before dead/euthanization. The 1:50 diluted sera were applied to the coated antigen in 
microtiter plates. The detection was carried out using either horseradish peroxidase-conjugated goat anti-
chicken IgM (5 µg/ml) or horseradish peroxidase-conjugated goat anti-chicken IgY (2 µg/ml). Finally, 
ABTS was used as substrate. The mean OD405 nm values over that the mean absorbance plus two times 
standard deviation of the pre-immune sera (> 0.2) was considered as positive antibody responses. The mean 
of absorbance at 405 nm was shown for five chickens in each group with standard error indicated by error 
bars. The 0.2 value as a cut off value was shown by blue line; chickens with higher antibody titer were 
considered as seropositive. 
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In contrast to IgM, IgY responses was observed in groups 8, 10 and 12 prior to viral challenge 
(figure III.29B). However, it is predominantly observed in chickens of group 10 that received the 
purified antigen intramuscularly followed by group 12 that received attenuated virus. After viral 
challenge, chickens of groups 10 and 12 increased their IgY titer. Also chickens of groups 2 that 
received 250 mg Pichia yVP2cyto with adjuvant and 8 that received 500 µg of purified IBD-
SVPcyto with adjuvant showed a potent IgY response leading to full protection (table III.4). 
Although only 80% of the chickens are IgY seropositive in group 3, which received 25 mg Pichia 
yVP2cyto and group 7, which received 500 µg IBD-SVPcyto, all were fully protected against the 
virus. It was speculated that in these cases IgM provides protection. This was also observed among 
the chickens of groups 4 and 5.  
 
In field studies, the anti-IBDV antibody titer in the serum is determined by using the commercial 
IDEXX IBD-XR Ab test to assess the status as well as the potency of the serum antibodies in 
identification of IBDV. In other words, it evaluates the protective antibody titer against IBDV. In 
this experiment, all the blood samples collected from the chickens were studied using the IDEXX 
IBD-XR Ab kit according to the manufacture’s instruction. Chickens with titer above 396 were 
considered as seropositive (Rong et al., 2007).  
Among all the chickens, only chickens in group 12 immunized with live attenuated virus and three 
birds in the group 10, which received the purified antigen intramuscularly and two birds in group 
8, which orally received 500 µg purified IBD-SVPcyto showed titers over 396 before viral 
challenge. After the challenge all the survivors were IDEXX IBD-XR seropositive. The results are 
summarized in the table III.4. The result confirmed the previous speculation that IgM could be 
protective antibody as IDEXX IBD-XR shows the protective antibody titer irrespective whether it 
originates from either IgY or IgM.  
 
The best method for evaluation of vaccine efficacy is to characterize the survivors after challenge 
with the infectious virus. In this study, the mortality rate was recorded during one week post 
challenge (table III.4 and III.5). All chickens that died before the 7th dpc were considered as 
mortality affected by the virus. After this period, all survivors were euthanized at the 7th dpc.  
Accounting the survivors in each group one week after viral challenge indicated that orally 
immunized chickens in group 2 (immunized with 250 mg Pichia yVP2cyto with adjuvant), group 3 
(immunized with 25 mg Pichia yVP2cyto), group 7 (immunized with 500 µg of purified IBD-
SVPcyto), group 8 (immunized with 500 µg of purified IBD-SVPcyto with adjuvant), group 12 
(immunized with attenuated virus) as well as group 10 (immunized intramuscularly) were fully 
protected. This result indicates that oral administration of yVP2cyto both in the purified or cell-
capsulated form is protective. However as previously mentioned (III.3.1) the potency of conferring 
immunity is dose and formulation-dependent. 500 µg of purified IBD-SVPcyto regardless of 
adjuvant effect gives full protection whereas 250 mg of Pichia yVP2cyto regardless of adjuvant 
effect gives 80% protection. Applying 50 µg of purified IBD-SVPcyto regardless of the presence 
of adjuvant gives only 50% protection. 
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A successful vaccination other than conferring full protection should prevent virus replication 
inside the body and clear the contaminated host cells. Therefore the vaccination should induce 
CTLs in order to clear the virus from the vaccine recipient following viral challenge. There is a 
chance that survivors induce protective immune response but are unable to completely remove the 
virus particles from the body. In such cases, although the host survives, it can act as a virus carrier 
to the other chickens in the flock. Therefore, the presence of virus in the bursa of dead/euthanized 
chickens was analyzed by ELISA (II.2.6.6) and the corresponding results are shown in table III.5. 
Oral vaccination with either purified or cell-capsulated antigen partially prevented virus replication 
inside the body with various successes. The viral prevention rates among all orally immunized 
groups are only between 0-10% except group 8 that immunized with 500 µg of purified IBD-
SVPcyto with adjuvant which showed predominant viral clearance potency with 60% prevention 
(table III.5).  
 
The bursa of Fabricius (BF)/body weight (BW) ratio is an index to evaluate the viral morbidity and 
shows the immunity level. It is calculated using the formula: BF weight (g)/BW (Kg). In this 
study, the significant difference between the mean of this ratio was revealed using one-way 
ANOVA test followed by Duncan’s test with alpha level of 0.05 (table III.5). The ratios for the 
survived chickens in groups 1-7 and those of mock-immunized (group 9) and unvaccinated (group 
11) were significantly different (p< 0.05) from groups 8, 10, 12 and unchallenged group 13. This 
observation indicated that among orally vaccinated groups only 500 µg of the antigen in the 
purified form in companion with adjuvant (group 8) worked as efficacious as either attenuated 
virus or parenteral vaccine to confer protection. However, the 250 mg of Pichia yVP2cyto with 
adjuvant (group 2), 25 mg of Pichia yVP2cyto(group 3) as well as  500 µg of the purified IBD-
SVPcyto even without adjuvant gives full protection but less success in virus removal (maximum 
10%) and prevention of bursal atrophy.   
The bursal lesion was also studied according to the previously described scoring system based on 
histopathological and morphological studies (II.2.6.7). The result of the observations and the 
resulting scoring in case of bursa extracted from chickens of each group is summarized in table 
III.5 and in more detail described in the appendix VII.6. All chickens in vaccine control group 
(group 13) as well as chickens that received attenuated virus (group 12) and those that received the 
purified antigen intramuscularly (group 10) showed score 0 in the histopathological study with no 
bursal damage.  The unvaccinated and challenged chickens (group 11) and mock-immunized 
chickens (group 9) as well as those that received 50 µg of the purified IBD-SVPcyto, showed the 
highest lesion score (= 2.2). Other groups showed moderate bursal lesion score (1-1.6) but 
chickens of group 8 that received 500 µg of the purified IBD-SVPcyto with adjuvant and group 2 
that received 250 mg Pichia yVP2cyto with adjuvant showed score 1 which is the minimum among 
orally immunized chickens.  
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III.4 IBD-SVPcyto as a nanoplatform 
SVPs are a type of virus nanoparticles (VNPs) that are genome-free with a huge potential 
application as nano-platforms. In this section the tolerance of the produced IBD-SVPcyto will be 
studied against heat, pH and organic solvent, which are commonly applied to the production 
procedure of functionalized VNPs. Moreover, the addressability of solvent-exposed amine and 
carboxylic groups on the surface of IBD-SVPcyto will be tested via traditional bioconjugation 
methods (Taghavian et al., 2012). 
 Solvent stability of IBD-SVPcyto III.4.1
The stability of nanoparticles in solvents is an important requirement because bioconjugation is 
usually carried out in an environment containing up to 20% (v/v) DMSO, whereas mineralization 
(e.g. with silica) requires up to 20% (v/v) ethanol as a solvent. Therefore, the IBD-SVPcyto 
(III.2.3) was dissolved in ethanol/water and DMSO/water solutions, with PBS as a control. The 
electrophoretic mobility of IBD-SVPcyto was tested under native conditions following O/N 
incubation at RT. As it is shown in figure III.30A, particles prepared in up to 20% (v/v) solutions 
of either ethanol or DMSO exhibited the same mobility as those prepared in PBS. SVP solubility 
decreased gradually as the ethanol concentration increased from 5 to 20% (v/v) (figure III.30A, B) 
and complete precipitation occurred in a 50% (v/v) solution. In contrast, there was little change in 
SVP solubility as the DMSO concentration increased to 20% (v/v), and only partial precipitation 
occurred at 50% (v/v) along with an increase in electrophoretic mobility (figure III.30A, B). 
Although the particles were stable in up to 20% (v/v) of DMSO, amine and carboxylate coupling 
worked also using a 10% (v/v) solution (data not shown).  
Conformational changes in the particles were monitored by Dynamic light scattering (DLS), 
reflecting changes in the mean particle hydrodynamic radius. Two peaks were observed, the first 
(~ 12 nm) corresponding to the hydrodynamic radius of single intact particles and the second (~ 
100 nm) corresponding to particle aggregates (figure III.30C). Increasing the ethanol concentration 
to 20% (v/v) appeared to have no impact on conformation, most of the particles still gathering in 
the first peak. In contrast, some aggregation was apparent at 20% (v/v) DMSO because the 
particles were distributed evenly between the two peaks (figure III.30C). At 50% (v/v) DMSO, 
there was a significant shift towards the second peak as most of the particles aggregated. TEM 
analysis confirmed the changing conformation of particles at high solvent concentrations (figure 
III.30D). These results show that IBD-SVPcyto can tolerate up to 20% (v/v) ethanol or 20% (v/v) 
DMSO, confirming their suitability for bioconjugation and mineralization reactions under standard 
conditions. 
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Figure III.30 Stability of IBD-SVPcyto in ethanol–water and DMSO–water mixtures determined by NAGE 
(A) (II.2.7.2), A280 spectroscopy (B) (II.2.7.3), DLS (II.2.7.4) (C) and TEM (D) (II.2.3.6). Particles were 
dissolved in 5, 10, 20 and 50% (v/v) ethanol–water and DMSO–water, respectively. After 24 h the samples 
were centrifuged at 13000 ×g for 20 min and the supernatant was analyzed. All the protein precipitated in 
50% ethanol so in this case the pellet was used for TEM. Scale bar = 100 nm. As a control (ctrl), SVPs were 
dissolved to the same concentration in PBS. Data shown in panel B are derived from three independent 
experiments; error bars show standard deviations. 
 
   Temperature stability of IBD-SVPcyto III.4.2
The electrophoretic mobility of the IBD-SVPcyto under native conditions remained constant after 
incubation for 1 h at temperatures between 25 and 60°C (figure 31A). No precipitation or 
conformational changes were observed within this temperature range (figure 31B, C, D). This 
indicates that IBD-SVPcyto are relatively heat resistant, with temperature stability comparable to 
that of CPMV particles (Strable and Finn, 2009). At temperatures above 60°C, extensive 
precipitation was observed along with significant changes in electrophoretic mobility and 
conformation (figure 31A–D). 
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Figure III.31 Stability of IBD-SVPcyto at different temperatures determined by NAGE (A) (II.2.7.2), A280 
spectroscopy (B) (II.2.7.3), DLS (II.2.7.4) (C) and TEM (D) (II.2.3.6). SVPs were dissolved in PBS to a 
final concentration of 1 mg/ml and incubated for 1 h at 40, 50, 60, 65, 68, 72, 75 and 80°C in a gradient 
thermocycler. The samples were then cooled on ice, centrifuged at 13000 ×g for 20 min at 4°C, and the 
supernatant was used for analysis. Scale bar = 100 nm. SVPs incubated at room temperature were used as 
the control. Data shown in panel B are derived from three independent experiments; error bars show 
standard deviations. 
 
 Stability of IBD-SVPcyto in different pH environment  III.4.3
SVP preparations were dispersed in buffer solutions with pH values of 2.5, 5.5, 8.0 and 9.0. PBS 
(pH 7.4) was used as the reference buffer. The IBD-SVPcyto remained stable after incubation in 
these buffers at RT for 24 h. The electrophoretic mobility of the SVPs was similar over the pH 
range 5.5–9.0, but increased slightly at pH 2.5 probably reflecting changes to the net charge on the 
particle surface (figure III.32A). There was no significant difference in particle solubility over the 
pH range 2.5–9.0, suggesting there was no aggregation or precipitation (figure III.32B) and in 
agreement there was no significant shift in the particle hydrodynamic radius (figure III.32C). TEM 
revealed slight conformational change at pH 5.5 and pH 9.0 but this did not affect the particle 
radius (figure III.32D). 
 
 
 
Figure III.32 Stability of IBD-SVPcyto in different pH environments determined by NAGE (A) (II.2.7.2), 
A280 spectroscopy (B) (II.2.7.3), DLS (II.2.7.4) (C) and TEM (D) (II.2.3.6). Particles were dissolved in 
buffers at pH 2.5, 5.5, 7.4, 8.0 and 9.0, to final concentration of 0.5 mg/ml. The samples were incubated 
overnight at room temperature and centrifuged at 13000 ×g for 20 min at 4 °C, and the supernatant was 
used for analysis. Scale bar = 100 nm. SVPs incubated at pH 7.4 were used as the control. Data shown in 
panel B are derived from three independent experiments; error bars show standard deviations. 
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 Addressability of IBD-SVPcyto III.4.4
IBD-VP2 contains two cysteine residues that do not participate in disulfide bond formation, but the 
side chains are not exposed to the solvent and are therefore poor targets for bioconjugation (figure 
III.33). However five lysine residues present accessible amine groups (Lys 81, 192, 309, 316 and 
381) and there are 13 acidic residues that present accessible carboxyl groups (Asp 300, 311, 355, 
378 and Glu 51, 83, 138, 190, 213, 267, 279, 287 and 323). Each IBD-SVP comprises 60 VP2 
monomers, resulting in a total of 300 potentially addressable amines and 780 carboxyl groups per 
particle. 
 
 
Figure III.33 Structural analysis of IBD-SVPcyto. (A) Surface Lys residues shown in yellow and reactive 
amine side chains highlighted in red. (B) Surface Glu and Asp residues shown in orange and pink, 
respectively. The reactive carboxyl side chains of both residues are highlighted in blue. (C) Surface Cys 
residues are shown in purple, but the potentially reactive thiol groups are hidden inside and not exposed to 
the solvent. (D) The IBD-SVP asymmetric unit (VP2) is shown in green with five solvent-exposed amine 
residues in yellow. (E) Nine and four solvent-exposed Glu and Asp residues rendered in orange and pink 
respectively. All the figures of protein coordinates were rendered using the program PyMOL using the file 
with PDB code 2DF7 (Lee et al., 2006a). 
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 Addressability of amine groups III.4.4.1
The number of addressable amines on each IBD-SVPcyto was determined by coupling DyLight 
488 NHS ester to the particles using the DyLightTM Antibody Labeling Kit (Pierce). The amount 
of 1 mg of IBD-SVPcyto (2 mg/ ml) per dye batch and the dye concentration (c) was determined 
by measuring its absorbance (A) at 493 nm and using the dye-specific molar extinction coefficient 
(e) of 70 000 (A = cde, with d = pathlength). This showed that on average 63 dye molecules were 
attached to each particle. Biotinamidohexanoic acid NHS ester has been used to determine whether 
biotin could be installed on the accessible amine groups. The reaction was carried out at pH 7.4 
because under these conditions only the amine groups of lysine residues exposed to the solvent are 
expected to react with the ester (figure III.34).   
 
Figure III.34 Labeling of amine groups on the surface of IBD-SVPcyto using biotinamidohexanoic acid N-
hydroxysuccinimide ester. Schematic IBD-SVP refers to Protein Data Bank reference 2DF7 (Lee et al., 
2006a). 
 
The coupling of biotin to IBD-SVPcyto was confirmed by Western blot using alkaline 
phosphatase-conjugated streptavidin (figure III.35A). SEC showed that the particle mass had 
increased after biotinylation (figure III.35B). Staining with gold-labeled anti-biotin antibodies 
followed by TEM also confirmed that the particles were labeled with biotin (figure III.35 C). 
 
 
 
Figure III.35 Biochemical analysis of biotinylated IBD-SVPcyto by Western blot (A) (II.2.3.3), SEC (B) 
(II.2.3.5), TEM (II.2.3.6) after amine conjugation (C) (II.2.7.5) and TEM after carboxyl conjugation (D) 
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(II.2.7.5). Western blot was performed either by subsequent incubation with rabbit anti-IBD-VP2 (1: 
10,000) and phosphatase-conjugated goat anti-rabbit antibody (2 µg/ml) each for 1 h at room temperature 
(A1) or by incubating with alkaline phosphatase-conjugated streptavidin (final concentration 0.2 mg/ ml in 
PBS) for 1 h at room temperature (A2). The signal was detected with NBT/BCIP (Sigma); IBD-SVPcyto 
(lane 1), biotinylated IBD-SVPcyto via amine and carboxyl chemistry (lane 2 and 3 respectively) were 
analyzed. SEC was carried out using a Hiprep 26/60 Sephacryl S400 column and Äkta Explorer (II.2.3.5). 
Samples were analyzed at a flow rate of 0.5 ml min, and elution profiles were detected by 
spectrophotometry (A215). TEM micrographs show biotinylated SVPs detected with a gold-labeled goat 
anti-biotin antibody (1: 20 in PBS). Scale bar = 50 nm. 
 
 Addressability of carboxyl groups III.4.4.2
Next, it was attempted to label exposed carboxyl groups with biotin, first by priming with EDC to 
produce the active intermediate O-acylisourea ester. The amine group of biotin hydrazide can then 
attack this intermediate to form an amide bond (figure III.36). Biotin conjugation was confirmed 
by Western blot, SEC and TEM as described above (figure III.35). 
 
Figure III.36 Labeling carboxyl groups on the surface of IBD-SVP. Reaction with EDC (1-[3-
(dimethylamino)propyl]-3ethylcarbodiimide methiodide) produces the intermediate O-acylisourea which 
reacts with the amine group of biotin hydrazide. Schematic IBD-SVP refers to Protein Data Bank reference 
2DF7 (Lee et al., 2006a). 
 
This result demonstrated that IBD-SVPcyto can be functionalized on exposed carboxyl as well as 
amine groups by decorating the particles with biotin. 
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IV Discussion 
Infectious bursal disease virus (IBDV) is a highly contagious agent that causes acute 
immunosuppressive disease in young chicken flocks. It specifically attacks and replicates in 
developing B-lymphocytes, cause apoptosis (Rodriguez-Lecompte et al., 2005) and due to lack of 
potent antibody response leads to vaccination failure and immunosuppression to other infectious 
diseases. The primary method for controlling the virus is vaccination. Currently flocks are 
vaccinated with conventional inactivated or attenuated live virus. The most common method 
strategy for vaccination in breeder flocks is priming vaccination using attenuated live vaccine at 
2-4 weeks of age followed by a boost with oil-emulsified inactivated virus at 10-18 weeks of age. 
This boost induces high titers of antibody, which not only lead to a long-lasting immunity for the 
recipients but also transfers to the offspring as maternal antibody and gives protection to the 
newborn chickens in the early stage of their life when their immune system is still immature 
(Wyeth et al., 1992; Eteradossi and Saif, 2008). In contrast, broilers may be vaccinated once to 
induce active immune response against IBDV. However the correct time of vaccination is critical 
to avoid the inactivation of the vaccine by maternal antibodies (Tsukamoto et al., 1995).  
In spite of vigorous vaccination strategies, the available vaccines are not fully protective against 
emerging very virulent IBDV (vvIBDV) strains, which is of constant concern for the poultry 
industry worldwide. Although inactivated vaccines have been produced against vvIBDV, the 
production requires infection and sacrificing a large number of birds to obtain the desired amount 
of antigen. Adaptation of vvIBDV to cell culture-based systems requires extensive passages in 
embryonated chicken eggs before the resulting attenuated virus that can be propagated in cell 
culture (van Loon et al., 2002). Site-direct mutagenesis that has been introduced to adapt the 
virus had led to significant drop in virus replication (Lim et al., 1999; Eteradossi and Saif, 2008). 
But the use of inactivated or attenuated vaccine is accompanied with the risk of remaining the 
pathogenicity and reversion to virulence. Consequently, the development of new vaccination 
strategies with improved safety and effectiveness as well as low price is a market demand (Chen 
et al., 2012). Recombinant vaccines have been receiving great interest since the last decades. 
Recombinant vaccines are composed of the immunogenic part of the virus, which upon 
administration to the host induce neutralizing antibodies against the target virus and provide 
protection. In case of IBDV, the VP2 coat protein is the major host-protective immunogen and 
contains the conformational epitope which is responsible for induction of neutralizing antibodies. 
In addition, IBD-VP2 proteins can aggregate to more immunogenic subviral particles (SVPs). 
Many efforts have been made in producing IBD-VP2 as a subunit vaccine in different expression 
systems. It has been expressed in E. coli (Chen et al., 2005), Saccharomyces cerevisiae (Garriga 
et al., 2006; Dey et al., 2009), and Sf9 and H5 insect cell lines (Dybing and jackwood, 1997; 
Wang et al., 2000; Caston et al., 2001; Lin et al., 2007; Luque et al., 2007) resulting in SVP 
assembly. Chimeric SVPs have been also used to display VP2 epitope and mimotopes to induce 
protective immunity against IBDV (Chen et al., 2012; Wang et al., 2012). Also several viral 
expression systems such as fowlpox virus (Heine and Boyle, 1993; Tsukamoto et al., 2000), 
Marek’s disease virus (Tsukamoto et al., 1999), Semliki forest virus (Phenix et al., 2001) and 
Newcastle disease virus (Huang et al., 2004) have been recruited for expression of IBD-VP2 
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leading to induction of protective immune response. However many of those expression systems 
have not yet found practical usage mainly due to low productivity, high production costs, low 
immunity and the potential risk such as integration to the host genome, viral reversion, 
recombination and reassortment to virulent phenotype in case of viral expression systems (Phenix 
et al., 2001).  
Plants have been introduced as a reliable alternative for expression of subunit vaccines (Tiwari et 
al., 2009). They are the main part of human and animal diet, which makes them more 
advantageous for mucosal vaccine approaches. The plant-produced IBD-VP2 conferred 
protection to the immunized chickens although protein expression levels of up to 4.8% of TSP 
were achieved in Arabidopsis thaliana as reported by Wu et al. (2004). In their study, dried, 
powdered leaves were resuspended in water for oral immunization. One-week old chickens 
received five oral doses (~5 µg IBD-VP2) at 3 days intervals. The protection rate was 80% after 
challenge with an IBDV virulent strain. The IBD-VP2 protein was also expressed in transgenic 
rice seeds up to 4.5% of TSP, which corresponds to 40 µg per seed (Wu et al., 2007). Anti-VP2 
of the sera was increased in orally immunized 2 week old chickens that received four times 5 g 
(~10 mg IBD-VP2) seed weekly and led to 83% protection after challenge with an IBDV virulent 
strain. Whereas admiration 3 g (~3.3 mg IBD-VP2) and 1 g (~2 mg IBD-VP2) seed led to only 
33% and 16% protection, respectively. The experiment showed that the IgG and protection levels 
correlate positively with the dosage. The protection efficiency also revealed that the higher 
dosage administrated, the more protection obtained. IBV-SVPs are known as highly 
immunogenic structure compared to monomeric and other aggregation forms of IBD-VP2 like 
tubular form. It was demonstrated that 3 µg of IBD-SVPs is adequate to induce fully protective 
immunity when administered subcutaneously (Martinez-Torrecuadrada et al., 2003). The 
necessity of applying ~10 mg rice-produced IBD-VP2 to confer protection raising the question 
that whether or not plant-produced IBD-VP2 assemble into SVPs. IBD-SVP assembly has not 
been reported in plant expression systems. In this study, the accumulation levels of tobacco-
produced IBD-VP2 were studied upon various protein compartmentalization. The produced VP2 
was characterized concerning self-assembly and also glycosylation. 
IV.1 Characterization of tobacco-produced IBD-VP2  
IBD-VP2 (495 aa) produced in Arabidopsis thaliana (Wu et al., 2004) under the control of 
octopine synthetase promoter and translational leader sequence had apparent 45 kDa mass on 
SDS-PAGE. Rice-producd IBD-VP2 (510 aa) under the control of rice endosperm-specific 
glutelin promoter (Gt 1) promoter and nopaline synthase terminator showed apparent 50 kDa 
mass. In this study, the corresponding sequence of mature IBD-VP2 protein (441 aa) was cloned 
into pTRA vector downstream of Cauliflower mosaic virus (CaMV) 35S constitutive promoter 
and chalcone synthase 5’ untranslated region with and without proper targeting signal to facilitate 
apoplastic, cytosolic, plastid and membrane anchored accumulation (figure III.1). The protein 
was transiently expressed in tobacco (Nicotiana tabacum L. cv. Petite Havana SR1) using agro-
infiltration. In immunoblot, using non-reducing condition, a distinct band in size of ~40 kDa was 
detected in case of cytosolic and chloroplast accumulation. No band was detected by membrane 
integration strategy whereas a fuzzy/diffused band pattern which is sharper in size of ~47 kDa 
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was observed in case of apoplast accumulation (figure III.2). Apparently the fussy pattern is due 
to different degree of glycosylation, which resulted in the variation of molecular mass of the 
protein and poor electrophoretic mobility of the sugar containing molecule. This result is in 
accordance to the fact that there are three potential N-glycosylation sites predicted by using 
NetNGlyc 1.0 server (figure III.6). Glycosylation of the accumulated protein in apoplast was also 
confirmed by immunoblot using rabbit anti-xylose antibody (III.7) as well as deglycosylation 
analysis performed on purified protein (figure III.8). The type and proportion of the glycan 
branches were studied in more detail using LC-MS (figure III.9).  
For N-glycosylation, the asparagine (Asn) residue should be in tandem tripeptide order Asn-X-
Ser/Thr which X could be any amino acid except proline. However, it was reported that only 66% 
of the potential glycosylation sites on secreted proteins are actually glycosylated (Apweiler et al., 
1999; Petrescu et al., 2004). Following trypsin and chemotrypsin digestion of tobacco-produced 
VP2apo, analysis of the respective peptides bearing potential N-glycosylation site confirmed all 
three sites were fully N-glycosylated. The N-glycans attached to these peptides exhibited plant-
typical N-glycosylation profiles (table III.1, figure III.9), comprising of plant-specific complex-
type N-glycans (containing α (1, 3)-linked fucose and β (1, 2)-linked xylose) mainly with 
GnGnXF and GnGnF with frequency of 55.7% of the total VP2 glycosylation profile. 
The prediction of final glycosylation profile for a particular protein is not yet possible. The 
glycosylation pathway and the final destination/accumulation of the heterologous protein as well 
as its intrinsic characters determine the glycan profiles (Bosch et al., 2013). The amino acids in 
and around of the glycan attachment site, the folding pattern of he protein that determines the 
accessibility of the site and the availability of polysaccharide precursors, all may influence the 
efficiency and the profile of the glycosylation. This fact may explain the variation of glycan 
profile in three N-glycosylation sites of VP2.  
 
The hydrophobic nature of IBD-VP2 (figure I.4) is its common characteristic with membrane 
proteins and the explanation of its aggregation under denaturing condition (figure III.2). Under 
denaturing condition, the protein must be heated at high temperatures, which might introduce 
artifacts to dissolution of existing aggregates or formation of new aggregates, as in the case of 
membrane proteins (Thomas and McNamee, 1990). In addition, this characteristic affects its 
movement pattern on SDS-PAA gel any may explain the variation between calculated mass (~ 47 
kDa) and the mass that protein marker shows (~40 kDa). Wu et al. (2004) also reported smeary 
movement of VP2 on SDS-PAGE. Similar observation was previously reported by Jagadish et 
al., 1998. It was suggested that hydrophobic feature of VP2 is responsible for conformation 
dependent distortion on SDS-PAGE (Wu et al., 2004). In this study, immunoblotting was 
performed under non-reducing condition which facilitates the detection of a distinct band of IBD-
VP2.  
The protein expression levels were compared by an ELISA-based assay. The highest protein 
levels were observed by apoplast (~260 µg/g of FLW) and cytosolic (~160 µg/g of FLW) 
accumulation, respectively (figure III.3). Therefore, these to accumulation strategies were chosen 
for further studies. Stable transformation of tobacco (Nicotiana tabacum L. cv. Petite Havana 
SR1) resulted in lower accumulation levels compared to transient expression as expected. The 
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accumulation levels were 20-30 µg/g of FLW for apoplast and 10-20 µg/g of FLW for cytosolic 
accumulation. The VP2 accumulation levels in rice seeds reached to 2 mg/g of seed (Wu et al., 
2007). Seed specific promoter (Gt1) that enables high VP2 expression, low protease activity and 
low water content in rice seeds explains such a high accumulation level.    
In previous studies, it was shown that 3 µg of fully-assembled VP2 produced in baculovirus 
expression system and Sf9 cells elicits protective immunity and confers comparable protection to 
that induced by inactivated vaccine when administered subcutaneously (Martinez-Torrecuadrada 
et al., 2003). The expression levels in tobacco plant are comparable to what was observed in 
Arabidopsis thaliana (Wu et al., 2004). But the format of the antigen and the assembly level 
needed to be studied in plant systems.  
 
The purification of IBD-VP2 was achieved by IMAC. It was previously shown that assembled 
IBD-SVPs produced by recombinant expression of rVP2H (fused to C-terminal his-tag) in 
baculovirus expression system were able to be purified by IMAC (Wang et al., 2000). By solving 
the 3D structure of IBD-SVP, it was revealed that His-tags fused to the C or N terminus of VP2 
are located on the interior face of fully assembled particles and is not accessible to the solvent 
(Lee et al. 2006b, Garriga et al. 2006). Nonetheless, it was possible to purify intact IBD-SVPs by 
IMAC. Lee et al. (2006b) had speculated that the affinity of IBD-SVPs to Ni-NTA as due to the 
negative charge present on their outer surface. Ultimately Doong et al. (2007) proved that this 
affinity is due to two histidine residues (His249, His253) on the surface of SVPs. Sequence 
alignment between the IBD-VP2 sequence used by Doong et al. (2007) and the counterpart 
sequence used in this dissertation showed that the two mentioned His residues were replaced by 
Glu residues (Appendix VII.4); therefore these residues are not able to participate in the affinity 
to Ni-NTA. Therefore the observed affinity of tobacco-produced VP2 to the IMAC column is a 
hint for a deficiency in assembly. The assembly level analysis using SEC confirmed this 
speculation (figure III.10). The purified tobacco-produced IBD-VP2 showed high amounts of 
trimers and a significant portion of unassembled monomers. The separation of VP2-producing 
tobacco extract using ultracentrifugation (figure III.11) followed by TEM studies as well as TEM 
studies using VP2-producing tobacco leaf sections (data not shown) indicated that the tobacco 
system is not a method of choice for in vivo production of IBD-SVPs. That may contribute to the 
intracellular conditions of tobacco such as pH, ion strength and availability of chaperonin.  
Although, according to thermodynamic modeling, self-assembly of IBD-VP2 and formation of 
SVP is highly favorable, the SVP formation depends on VP2 concentration and is proportional to 
the protein synthesis (Hu and Bentley, 2000). Therefore, low accumulation of IBD-VP2 in 
tobacco cells obviously hampers trimer assembly and SVP formation. A similar result was 
reported when the human papillomavirus L1 protein was produced in Nicotiana benthamiana 
even though a TMV-based viral vector was used for expression (Varsani et al., 2006). In this case 
the assembly level did not achieve higher than pentamers, the structural unit of HPV (Biemelt et 
al., 2003; Varsani et al., 2003).  
Formation of self-assembled proteins to VLPs and SVPs is not always favored. The ionic 
strength, pH and the relationship of the structural units, are the cooperative factors in interactions 
and free energies of association between the proteins (Hu and Bentley, 2000). 
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Salunke et al. (1986) showed that disassembled polyomavirus pentamers could only reassemble 
at high ionic strength. Similarly, Budgerigar fledgling disease virus capsid protein (VP1) forms 
pentamers in vitro but for further assembly to VLPs, addition of Ca2+ and the removal of 
chelating and reducing agent are essential (Rodgers et al., 1994).  
Addition of Ca2+and increasing the ionic strength was not helpful to induce proper self-assembly 
of the purified tobacco-produced VP2 into SVPs and led to protein aggregation and precipitation 
(III.1.6). Addition of detergent to disperse unfavorable aggregation followed by stepwise removal 
of detergent in companion with Ca2+ increasing to facilitate the VP2 assembly also led to non-
proper subunit interactions and protein precipitation. Addition of urea to denature the protein and 
facilitate the proper refolding and assembly in vitro was also not successful.  
Trimeric capsomers are the main structural unit for IBDV, IBD-VLP and IBD-SVP assembly 
(Böttcher et al., 1997; Pous et al., 2005; Garriga et al., 2006; Luque et al., 2007). On the other 
hand, urea alters water structure and dynamics. The protein in the solution unfolds rapidly under 
8 M urea conditions (Bennion and Daggett, 2003). As shown in figure III.12, urea destroys the 
trimers, which are structural units and due to rapid protein unfolding breaks them into small 
fractions (~ 5 kDa and ~ 1 kDa) without any influence on the monomers (figure III.12).  
It was demonstrated that some virus-like protein subunits such as Human papillomavirus-like 
particles could be renatured from denatured forms in vitro into virus-like particles without the 
presence of chaperons (Zhang et al., 1997). In case of IBD-VP2, it seems that for proper folding 
and subsequent assembly to SVPs, the activity of chaperons is essential. It was also reported that 
denatured and renatured IBD-VP2 is also unable to induce neutralizing antibodies in chickens 
(Öpplin et al., 1991) which manifests that in vitro folding occurs in non-proper form. 
 
Immunogenicity of tobacco-produced VP2 was investigated in mice and led to high serum titer 
IgG induction observable after the first boost (III.1.7; figure III.14). The generated mAbs (III.1.7; 
data not shown) against the tobacco-derived mixture of VP2 monomer and trimer mixture 
showed high reactivity against tobacco-produced recombinant VP2, but no detectable reactivity 
against Pichia produced IBD-SVPs (data not shown). This fact showed that the selected clones 
screened against epitopes that are hidden (cryptotope) when the protein is assembled into the 
subviral particle.    
IV.2 Characterization of Pichia-produced IBD-VP2  
Generally, low accumulation levels are the major drawback for plant-produced vaccines 
especially when the vaccine should be applied orally since oral immune system stimulation 
usually needs higher dosages of the antigen compared to parenteral immunization methods. 
Moreover, tobacco leaves contain toxic alkaloids such as nicotine, which restricts the application 
of the produced protein without extensive purification. On the other hand, the multi-
immunogenic form of VP2, IBD-SVP could not be generated in tobacco. Expression of VP2 in E. 
coli expression system has led to contradictory results. Jagadish et al. (1998) reported that VP2 
produced in E. coli is not protective. However, Rong et al., (2005) showed that administration of 
E. coli producing VP2 is immunogenic and protective.  
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Alternatively, methylotrophic yeast Pichia pastoris is an important organism for recombinant 
protein production at large scales owing to its high expression levels, low production costs and 
high cell density growth in bioreactors (Jiang et al., 2011). It was demonstrated that the protein 
production yield in Pichia could achieve up to 14.8 g/l (Werten et al., 1999). 
Pichia has also been widely used for production of therapeutic proteins. The main concern about 
the Pichia expression system is the N-linked glycosylation of the high-mannose type. However, 
the length of the oligosaccharide chains added post-translationally to proteins in Pichia (average 
8-14 mannose residues per side chain) is much shorter than those in Saccharomyces cerevisiae 
(50-150 mannose residues) (Grinna and Tschopp, 1989; Tschopp et al., 1987b) and the protein 
expression level is 10-100 fold higher. Interestingly, P. pastoris in contrast to S. cerevisiae is not 
capable of adding the immunogenic α (1, 3)-terminal mannose to oligosaccharides. Very little O-
linked glycosylation has been observed in Pichia. However fungal-like glycans such as β-
mannose linkages, which exist in produced glycoprotein may stimulate an immune response or 
binding to mannose receptors and consequently reduce the efficiency of the produced proteins 
such as enzymes or antigen vaccines (Hopkins et al., 2011). To avoid such an effect, either the 
glycan sites should be genetically eliminated by introducing point mutations or the enzymes 
involved in transfer of immunogenic glycans residues during glycosylation pathway, should be 
eliminated or suppressed. Another alternative is the production of the non-glycosylated form of 
the target protein by cytosolic expression, if the protein folding is not being damaged. In this 
study the aglycosylated yVP2 produced by cytosolic expression used as a vaccine in 
immunization of chickens (III.3). 
  
The expression level of IBD-VP2 in P. pasroris reached up to 76 mg/l culture after 4 days of 
induction (figure III.17). The standardized purification procedure enabled the recovery of about 
50% of the produced VP2 at ~96.2% purity (figure III.21). SEC and TEM, respectively, showed 
that in contrast to the tobacco expression system, VP2 monomers assembled into higher 
assembled symmetrical SVPs in yeast (figure III.20). However, a smaller part of the VP2 fraction 
was not fully-assembled. While the VP2 content from the secreted version (VP2sec) accumulated 
in the medium was not present in the assembled form, the cell extract from the same culture 
apparently contained the SVPs, which was confirmed by SEC and TEM (figure III.20). Such 
SVPs had different configuration compared to SVPs present in VP2cyto producing yeast due to 
the glycosylation. This observation showed that only less assembled forms of VP2 and monomers 
pass through the cell wall pores and reach to the medium while fully assembled particles, due to 
their size, entrapped in extracellular space between the cell membrane and cell wall.   
IV.3 Vaccine preparation 
Vaccination is an efficient and most cost-effective method for preventing infectious disease. 
Homogeneity to ensure the consistent dosing of subjects; efficacy to achieve protective 
immunity; stability to reduce the costs of storage and shipping and potency (or concentrated 
material) to provide easy delivery of desired dose are main concerns in any vaccination platform 
development. Recombinant vaccines have attracted the attention especially in last two decades 
due to their benefits and less concerns. However, so far, most developed vaccines of these types 
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are delivered by injection (parenteral), which makes mass immunization costly, laborious and 
less safe especially in poor-developed regions of the world. In contrast, oral delivery of vaccine is 
safe, easy to apply and reduces the immunization costs. Other advantage of an oral vaccine is the 
possibility of mucosal immune response induction, in particular, secretory IgA (SIgA). SIgA 
inhibits pathogen from colonization in the gut and consequently disease. Although oral 
administration of vaccines is beneficial, in practice, it has been faced several obstacles such as 
harsh conditions exist in the digestive tract and targeting M cells in the gut, which have limited 
its success. A successful oral vaccine delivery comprises of different elements and stages; (1) the 
proper immunogen (vaccine) (2) it must enter via the oral cavity and passes through the 
gastrointestinal tract and reaches to mucosal inductive sites in the intestine, (3) it must be taken 
up by M cells to reach to gut-associated lymphoid tissue (GALT) and (4) it must induce 
protective immune response against the target pathogen. 
 
The neutralizing antibody response is required for protection against IBDV. VP2 has been 
identified as the major host protective immunogen against IBDV that carries neutralizing 
epitopes (Jianrong et al., 2004). The ability of VP2 to confer protection is dependent on its 
conformation and structure. VP2 produced in E. coli was unable to induce neutralizing antibodies 
(Jagadish et al., 1998). Although later Rong et al. (2005) showed that live E. coli producing VP2 
could confer 90-100% protection.  
VP2-based DNA vaccines can prevent the clinical outbreaks and mortality but can not prevent 
bursal damage. That may be due to the inherent low immunogenicity of DNA vaccines or 
improper folding (Jianrong et al., 2004). In contrast, it was also shown that VP2 as a subunit 
vaccine is resistant to the proteolytic and acidic conditions of the gastrointestinal tract, is taken by 
M cells, and has the ability to induce a protective immune response in chickens (Li et al., 2004). 
VLPs and SVPs are multi-immunogenic forms of the antigen that have less available target sites 
for proteolytic enzymes compared to VP2 monomers and low levels of assembly or tubular 
aggregation (Martinez-Torrecuadrada et al., 2003). Therefore full-assembly of VP2 into either 
VLP or SVP improves the vaccine efficacy and decreases the required dosage.  
 
Protection of vaccines against the acidic and proteolytic conditions of the gastrointestinal tract 
has been achieved by co-administration of sodium bicarbonate as acid neutralizing agents in 
chicken (McCluskie et al., 2000; Hoshi et al., 1995). It was also shown that oral administration of 
Virginiamycin (antibiotic) and Cysteamine (Yang et al., 2007) had a positive effect on the 
stimulation of the mucosal immune system in chicken. Using a system consisting of non-ionic 
surfactant vesicles in companion with bile salts (bilosomes) to protect the vaccine against 
gastrointestinal digestion was also accomplished (Mann et al., 2009).  
 
In this study, the generation of IBD-SVPs via recombinant expression of IBD-VP2 was aimed. 
Expression of VP2 in tobacco did not lead to generation of SVP whereas expression in Pichia 
resulted in the production of SVP structures at high protein levels (76 mg/l). Cytosolic expression 
of VP2 not only prevented the glycosylation, which could induce a non-favorable immune 
response but also capsulated the produced SVPs inside the Pichia cells. These cells, after 
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successful heat inactivation without any damage to the vaccine (figure III.25), were used as oral 
vaccine. The idea was that cell capsulation should protect the vaccine against the acidic and 
proteolytic conditions of the gut and consequently targets the vaccine more efficiently to the 
inductive sites. To standardize and concentrate the cell-capsulated vaccine, a simple food-
processing technique was used in this study. Freeze-drying is a simple and inexpensive method 
that facilitates antigen stability at ambient temperatures for a long time without any loss of 
antigenic protein. In addition, freeze-dried materials can be formulated in combination with food 
and adjuvants. Besides, purification of the vaccine is carried out with a simple, fast and cost-
effective method and yielded to highly pure protein suitable for immunization approach.   
It was shown that induction of immune tolerance in chickens in contrast to mammals is difficult 
to generate even with high doses of the antigen due to two main reasons: first, innocuous food 
antigens are ignored by the immune system. Second, the soluble antigens are immunogen rather 
than tolerogen (Klipper et al., 2000). Oral tolerance was induced by using encapsulated powdered 
antigens in chickens but not with the same antigen dissolved in water (Friedman et al., 1998). To 
address this issue, cell-capsulated or purified IBD-SVPcyto has been used in this thesis. 
However, the highest considered dosage (4 mg of antigen) was relatively high but there was no 
concern for induction of immune tolerance since previously 10 mg of IBD-VP2 produced in rice 
seeds was successfully tested as an oral vaccine (Wu et al., 2007). 
In separate previous studies, the positive affect of CpG ODN (Mallick et al., 2011; Zhang et al., 
2008; McCluskie et al., 2001) and NaF (Hoshi et al., 1999) or their mixture (Zhang et al., 2007) 
as oral adjuvants for chicken immunization has been shown. For the experiments in this thesis the 
mixture of CpG ODN and NaF has been added to the antigen as described before (Zhang et al., 
2007).  
IV.4 Induction of immune response against IBDV by applying Pichia-
produced IBD-SVPcyto administered either orally or parenterally  
Attenuated vaccines are usually efficient in inducing long-lasting protective immune response 
including B and T cell responses upon just one-shot vaccination. But they carry the potential risk 
of reversion to virulence and transmission of the attenuated virus to susceptible individuals with 
immature immune system such as newborns. To provide more safety, inactivated and subunit 
vaccines have been utilized. But safety comes at the cost. Inactivated virus and subunit vaccines 
are less immunogenic than attenuated virus-based vaccines. To induce protective immunity, 
usually multiple boosts and adjuvants are required. Viruses are highly immunogenic due to their 
ability of proliferation inside the cells that leads to induction of cellular immune response and 
their ordered-repetitive antigen presentation. In case of IBDV, only mild and intermediate strains 
are used as attenuated virus vaccines (Carballeda et al., 2011). More pathogenic strains may 
cause bursal atrophy and thus immunosuppression as possible consequences (Müller et al., 2012). 
Due to the emergence of very viral IBDV strains, conventional vaccine does not confer full 
protection. Therefore the development of new protective vaccines is required.  
Another problem with applying full virus as a vaccine both in inactivated and attenuated forms is 
interfering of these sort of vaccine in differentiating infected from vaccinated animal (DIVA). 
Infection with the virus like vaccination induces humoral immune response that prevents the 
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serological discrimination between infected and healthy vaccinated animals, hampering 
controlled eradication of the disease. Whereas recombinant VP2 vaccine makes DIVA feasible 
through the detection of antibody responses against other viral proteins such as VP3 that only 
exist in the full virus but not in the vaccine.  On the other hand, subunit vaccines are safe because 
they are free of pathogen genetic materials compared to the risk of incomplete viral inactivation 
and reversion of virulence when using full virus vaccines.  
Also, recombinant vaccines eliminate the need to infect and sacrifice animals to propagate and 
extract adequate amount of virus for full virus vaccine production. As an alternative to cell 
culture that need sequential passage of the virus through the culture in order to attenuate the 
virus, subunit vaccine production is less laborious and more economical. Moreover subunit 
vaccines are the only option for the viral strains that can not be adapted to the cell culture.   
It was shown previously that Pichia cells are safe for chickens (Pitkovski et al., 2003). Hundred 
microgram of partially purified rVP2 produced in Pichia was administered intramuscularly to the 
chickens without showing any harm. The large-scalability of Pichia production has made it the 
most economical eukaryotic system for recombinant protein production. 
 
Induction of neutralizing antibodies is required to confer protection against IBDV. Therefore, 
VP2 carrying the neutralizing epitopes was used as antigen in this study. The neutralizing 
epitopes are conformational (Rong et al., 2005). Therefore, to maintain the antigen structure the 
full-length of mature IBD-VP2 was used for recombinant production of vaccine. Furthermore, 
IBD-VP2 subunits are capable of self-assembling to subviral particles (SVPs). 
 
VLPs and SVPs are genome-free viral particles that mimic the virus in stimulation of host 
immune response. Due to genome depletion, they are unable to induce innate immunity via 
pattern-recognition receptors (PRRs) such as Toll-like receptors (TLRs) and RIG-I-like receptors 
(RLRs). TLR-3, TLR-7, TLR-8 and TLR-9 are endosomal membrane proteins that recognize 
dsRNA, ssRNA, G-rich oligonucleotide and unmethylated CpG DNA, respectively (Kawai and 
Akira, 2008). In this study CpG ODN was added to the antigen to compensate the lack of 
unmethylated CpG DNA but its effect could not be statistically analyzed due to high variation in 
immune responses and low number of the chickens in each immunization group. But chickens of 
group 8 that received high doses of the purified IBD-SVPcyto in combination with adjuvant 
containing NaF and CpG ODN showed better immunity against IBDV; BF/BW ratios 
comparable with the oral application of attenuated virus and parenteral vaccines, full protection 
and moderate bursal damage (table III.5). Achieving 60% viral clearance indicates that the 
antigen with adjuvant mixture was able to induce CTL response. 
 
VLPs and SVPs are able to induce an innate immune response due to not clearly known 
procedure but perhaps by contaminating proteins from their expression system (Demi et al., 
2005). Also their symmetrical structure and repetitive epitope presentation may serve to induce 
cellular as well as humoral immune response even in the lack of adjuvants (Bachmann et al., 
1993). They are also ideal as a mucosal vaccine because their particulate nature and size 
facilitates better uptake by M cells and dendritic cells. 
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Ten to fourteen day old birds are the most suitable source for starting the specific pathogen free 
(SPF) chicken immunization (Rong et al., 2007). The immune system of newborn chickens and 
their lymphoid organs develop slowly (Beirao et al., 2012). It has been shown that the proportion 
of immune cell subsets differ dramatically by age. This proportion correlates with susceptibility 
and resistance of chickens to pathogens (Beirao et al., 2012, Cheng et al., 2001a). For instance, 
the T helper cell population is significantly increasing in two phases; since the day of birth until 
the 5th week and since then to the 12th week of age (Beirao et al., 2012). It was previously shown 
that the pathogenesis of IBDV may differ depending on the age of the infected chickens due to 
unknown reasons. Chickens between 3-6 weeks after hatching are most susceptible for clinical 
signs, while younger chickens are devoid of clinical signs but severe immunosuppression 
(Rautenschlein et al., 2007). Pathogenesis variation of a specific pathogen such as IBDV in 
different ages can be explained by the maturity stage of immune system. These facts may explain 
why the antibody response in the chickens remains irresponsive during the early immunizations 
even until virus encounter (figure III.29). 
Previous studies and field observations has indicated that genetic variation between individuals, 
affect the induction of innate and acquired immune response when encountered to IBDV 
(Aricibasi et al., 2010). Therefore, it was suggested to analyze individuals rather than pooled 
samples from the immunized group (Douce et al., 1999). Accordingly, all the detailed 
observations for each chicken were listed into the table in appendix VII.6 and the result was also 
studied individually as well as statistically. To make the data more valuable, a large number of 
chickens in each experimental group have to be investigated to provide enough data for statistical 
evaluations. 
 
As mentioned before, neutralizing antibodies are essential to promote protection against IBDV. 
Therefore VP2 carrying the neutralizing epitopes was used as antigen in this study and the 
antibody response was investigated in the immunized and challenged chickens. In addition, the 
efficacy of the vaccine was evaluated by studying the potency of cytotoxic T cells to remove the 
virus.  
The contribution of humoral immunity in conferring the protection has been proved as 
demonstrated by transferring the maternal antibody. Evidence in finding the role of cell-mediated 
immunity is in progress (Eteradossi and Saif, 2008).   
There is a positive correlation between being IgY seropositive and survival (table III.4). This 
means that the chickens that had developed IgY immune response, survived after the viral 
challenge. However this correlation is not always present. For instance, in groups 4, 5 and 7 there 
are survivors that were not IgY seropositive but IgM seropositive (table III.4). Perfect 
compatibility between being seropositive in the IDEXX kit assay and survivance reveals that in 
those individuals IgM instead of IgY is responsible to develop protective immune response.  
 
Study the IgM response for some individuals in groups 1 that immunized with 250 mg Pichia 
yVP2cyto, group 4 that immunized with 25 mg Pichia yVP2cyto with adjuvant mixture, group 5 
that immunized with 50 µg of purified IBD-SVPcyto, group 6 that immunized with 50 µg of 
purified IBD-SVPcyto with oral adjuvant mixture as well as mock-vaccinated group (group 9) 
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showed that in spite of induction of IgM immune response, without IgY response, the chickens 
were unable to tolerate the viral challenge. This observation can be explained by the fact that IgM 
is the primary induced serum antibody in response to the pathogen. The immune system of these 
individuals is unprepared and those IgM molecules are immature to combat the virus following 
viral challenge. Consequently they start to produce IgM lately in response to the attacking virus 
when the disease has developed into a uncontrollable stage.  
Among the individuals in groups 7 and 8 that were immunized with 500 µg of purified IBD-
SVPcyto with and without adjuvant, respectively, as well as mock-immunized chickens in group 
9 no IgM response was detected while a protective IgY response was detectable (data not shown). 
As described above, IgM is the primary humoral immune response to the pathogen. But 
afterwards, the IgM response shifts to more stable antibody isotype, IgY, during a process named 
isotype switching. Therefore, in such individuals, obviously due to their genetic background, the 
immune system is well prepared to face with the virus and to prevent the disease. 
 
One of the major sites for detection of IgA response are bile samples but the disadvantage of 
measuring biliary IgA is that IgA measured in the bile may not be effective on other remote sites 
such as intestine (Mockett and Rose, 1986). This is due to selective localization of mucosal 
lymphocytes to specific tissue that called “homing”. Homing phenomena explains the intrinsic 
local mucosal immune response and determines the most efficient route of mucosal 
administration of vaccines. To provide more precise data, the intestinal fluid (data not shown) 
and feces samples were collected to study the IgA response in the intestine (figure III.28). 
Besides, the serum IgA was also analyzed (figure III.28). Although no significant amount of IgA 
was detected in the intestinal fluid and feces, IgA response is detectable in the serum of all 
chickens, which received the vaccine orally and even in the parenterally immunized chickens. 
But as explained in the result section, probably this response is against Pichia proteins orally 
administered and could not be evaluated as mucosal immune response against VP2.    
Overall, the IgY and IgM response was detectable in all the orally administrated groups upon 
vaccination and challenge. This observation indicates that the induction of the systemic immune 
response through oral feeding of Pichia-produced SVPs either in the purified form or cell-
capsulated is possible. However, it seems that purified SVPs (III.2.3) showed an improved 
immunogenicity compared to cell-capsulated SVPs. The reason is that purified IBD-SVPcyto 
(III.2.3) are stable enough to pass harsh condition in the gastrointestinal tract and reach the M 
cells and become absorbed by them while perhaps due to incomplete digestion of the Pichia-cell 
wall, the chance to release from the cells and absorption is less for cell-capsulated vaccines. 
The lack of correlation between antibody titer and clinical signs indicates the critical role of cell-
mediated immune response in controlling the disease. Previously, it was shown that cell-mediated 
immunity alone in the absence of antibody can be protective against IBDV (Yeh et al., 2002). 
Moreover, inherent resistance has been observed in some breeds of chickens (Hassan et al., 
2002). 
The weight increase of the chickens during the experiment is a hint that the vaccines were not 
interfering in chickens’ growth rate. Monitoring the IBDV clinical signs following viral challenge 
(table VII.1) indicated that the clinical signs initially appeared in the groups that mock-
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immunized (group 9) and challenge control (group 11) as well as those received 50 µg of purified 
IBD-SVPcyto (group 5 and 6). Then the slight clinical signs appeared in all the orally vaccinated 
groups including those that received Pichia-capsulated and purified antigen (groups 1-8). In the 
following days moderate to severe clinical signs observed in challenge control (group 11) and 
mock-immunized (group 9) groups, the intensity of clinical signs and mortality increased in those 
groups as well as the groups that received 50 µg of purified IBD-SVPcyto (group 5 and 6). 
While, parenterally-vaccinated as well as the group that received the live-attenuated virus as a 
vaccine showed no clinical signs. Within orally vaccinated groups, chickens in the groups 7 and 8 
which received 500 µg purified IBD-SVPcyto without and with adjuvant showed less clinical 
signs and just in slight form whereas chickens that received 4 mg of vaccine in cell-capsulated 
form were not protected to that level. This result is in agreement to antibody titers (figure III.29 
and table III.4) and revealed that the cells need to be disrupted before administration as vaccine in 
order to improve the efficiency of vaccine presentation and absorption by the M cells.   
    
The challenge virus (MB3) is a classic strain and differs from the IBD-SVP vaccine strain (IR01) 
that belongs to very virulent strains (I.4.1). It was shown that protection against IBDV was highly 
dependent on the antigenic correlation between the vaccine and the circulating virus strains 
(Shaw and Davison, 2000). On the other hand, IBD-VP2 amino acid sequences of all known 
strains described all over the world are more than 93% identical. This homogeneity between 
Asian and European strains is more than 98%. IR01 is an Asian strain that used to generate the 
subunit vaccine and MB3 belongs to European strain obtained from recent IBDV outbreak in 
Germany. The variations between the strains locate in major hydrophilic region where the virus 
neutralizing epitopes exist (I.4.6; figure I.4). Nevertheless, it was demonstrated that vaccination 
with classical strains confers partial protection against variant strains whereas vaccination with 
variant strains confers protection against homologous and heterologous variant and classical 
IBDV strains (Ismail et al., 1991). Therefore, vaccination with higher pathogenic strains confers 
protection against less pathogenic challenge strains. However, the dose and strain of both vaccine 
and challenge virus affects the degree of protection (Jackwood et al., 2001; Ismail et al., 1991).  
Cross protection has been observed in IBDV vaccines. Since the protective immune mechanism 
to IBDV is mostly humoral, the serological cross reactivity existing among IBDV isolates is the 
reason of conferred protection. Therefore, it is expectable to see that chickens vaccinated with 
IBD-SVPcyto derived from IR01 strain show reduction in viral damage when challenged with the 
heterologous classical strain, MB3. Therefore, challenging with a heterologous strain may help to 
evaluate either the cross-protection or in contrast, the specificity of the vaccine. Cross protection 
is of interest for vaccine development but is not the case all the time. Conventional inactivated 
influenza vaccine does not provide cross-protection against unmatched strains (Schneider-Ohrum 
and Ross, 2012). As a result, vaccines should be generated based on seasonal or pandemic strains 
at each time and region.  
 
From the aspect of virus clearance, the injected and live-virus vaccinations were thoroughly 
successful in virus removal and confer full protection. Groups that received 500 µg of purified 
IBD-SVPcyto regardless of their partial virus removal confer full protection to their receivers. 
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Although the rest have been protected from the disease but they may act as virus carrier to other 
healthy individuals. Generally, in this experiment, orally vaccinated groups (groups 1-8) were 
unable to remove the virus as efficient as both injected and attenuated virus vaccination.  
In addition, bursal damage scores as putative damage index of IBDV was used to analyze the 
efficiency of the vaccines. The data demonstrated that chickens, which received 50 µg of purified 
IBD-SVPcyto (groups 5 and 6) as well as chickens in mock-immunized and negative control 
group showed the maximum score. Other orally vaccinated groups (groups 1-4 and 7-8) showed 
moderate bursal damage. Injected and live-virus vaccinated groups were quite efficacious without 
any damage to bursa. 
 
Another index for evaluation the vaccine efficiency is the ratio of bursa weight in gram to the 
body weigh in kilogram (Bursa/BW ratio). The obtained data showed that chickens in challenge 
control, mock-immunized, and those that received 50 µg of purified IBD-SVPcyto in groups 5 
and 6 have the minimum values or maximum bursal atrophy, respectively. Statistical 
categorization puts the group 8 that received 500 µg of IBD-SVPcyto in combination with 
adjuvant in the same group as attenuated virus vaccinated and intramuscularly vaccinated group.  
This observation indicated that among orally vaccinated groups only 500 µg purified IBD-SVPs 
dose in companion with adjuvant worked as efficacious as either attenuated virus or parenteral 
vaccine to confer protection. Although the chickens received live attenuated vaccine (group 12) 
showed more bursal atrophy (3.16) comparing to those that received the vaccine parenterally in 
group 10 (3.72), the difference is not statistically significant.  
 
While the resulting data do not show the advantage of oral over parenteral immunization in 
prevention of IBDV and conferring the protective immunity, there are indications that oral 
vaccination with 500 µg purified IBD-SVPcyto could potentially provide an alternative to 
vaccination through injection. The challenge trial manifested definitive evidence that this 
approach could protect the chickens against IBDV. In addition, oral vaccination provide a 
number of advantages over injection such as ease of administration, reducing the stress for 
chickens and cutting the risk of contamination due to needleless vaccination and decreasing the 
cost of vaccine due to omitting the need to medical facilities and treated personnels. The 
drawback of oral immunization that is low immunogenicity can be improved by optimization of 
the format, dose and co-administration with proper adjuvants.   
IV.5 IBD-SVPcyto as a potential platform for nanobiotechnology 
Viral nanoparticles (VNPs) are suitable for a vast range of applications ranging from medical 
imaging and drug delivery to the design of novel materials and electronic devices. It is important 
as part of the development process to determine the versatility of new VNPs and their tolerance 
of different chemical environments, particularly the harsh environments necessary for 
modification and functionalization. Many bioconjugation reactions must be carried out in the 
presence of the organic solvent DMSO, whereas ethanol is required for mineralization and 
electronic devices must be heat resistant. The tolerances are often highly constrained and specific, 
e.g. mineralization generally requires a narrow pH and temperature range specific for each 
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mineral (Douglas et al., 1999). Novel SVPs such as the particles based on IBDV described herein 
must therefore undergo tolerance tests to study their integrity across a range of temperatures, pH 
values and solvent concentrations, and the accessibility of addressable conjugation targets on the 
particle surface must also be determined. In this study IBD-SVPcyto with a T= 1 produced in P. 
pastoris was purified by pH shift and salt precipitation and polished by SEC (III.2.3). The 
spectrophotometry was found to be the most accurate method to determine particle concentration 
in solution. Because colorimetric methods cannot distinguish SVPs from stray peptides, whereas 
spectrophotometry generates separate peaks for peptides without aromatic side chains (190–220 
nm) and proteins plus peptides with aromatic side chains (280 nm). The integrity of the particles 
has been investigated by Native agarose gel electrophoresis (NAGE), Dynamic light scattering 
(DLS) and Transmission electron microscopy (TEM).  
DMSO is a versatile solvent for bioconjugation but high concentrations can induce 
conformational changes in proteins by binding to hydrophobic and aromatic side chains that are 
normally shielded inside the structure, resulting in precipitation (Arakawa et al., 2007). Similarly, 
ethanol is required for mineralization reactions but high concentrations disrupt intermolecular 
hydrogen bonds and cause proteins to denature and precipitate (Falk et al., 2002). It was found 
that IBD-SVPcyto remained stable in solutions containing up to 20% (v/v) DMSO or ethanol, but 
that higher concentrations altered the electrophoretic mobility of the particles and caused them to 
precipitate. DLS showed that particles in 20% (v/v) ethanol and DMSO increased in size (the 
radius increased by 1.3 and 0.6 nm, respectively; figure III.30). In contrast, 50% (v/v) DMSO 
either stretched the particle into an elliptical conformation or shrank them to a smaller radius 
(peak at 10 nm) and faster running in electrophoretic mobility, which induced rapid precipitation.  
Previous studies have shown that IBDV is moderately stable in an acidic environment (pH 3), 
and also in the presence of certain disinfectants and when heated to 60°C for 30 min (MacLachlat 
and Stott, 2005). It was expected the corresponding SVP to have similar properties despite the 
additional rigidity of the parent virus conferred by RNA-protein and heteromeric protein-protein 
interactions, because the VP2 protein plays an important role in virion stability. It was found that 
the IBD-SVPcyto were thermostable at 60ºC for 1 h, retaining 90% of the solubility observed at 
room temperature. After incubation at 68ºC for 1 h, 70% of the particles remained stable and 
soluble. VLPs can display extraordinary thermostability, e.g. bacteriophage PP7 VLPs are stable 
at 90ºC for more than 2 min because of the disulfide bonds linking coat protein dimers (Caldeira 
and Peabody, 2007). IBD-SVPcyto do not form disulfide bonds but strong interactions between 
VP2 monomers help to preserve the integrity of the particles at temperatures between 60 and 
70ºC, making their heat tolerance comparable to CPMV (Strable and Finn, 2009).   
The IBD-SVPcyto was also stable across a wide pH range. As previously reported (Reiss et al., 
2004), TEM analysis revealed minor conformational (more condensed in pH 9.0) changes in 
alkaline solutions but this did not affect the hydrodynamic radius of the particles, and the slight 
change in electrophoretic mobility is likely to reflect the differing net charge of the particles in 
different pH environments. The IBD-SVPcyto therefore appears comparable to acidophilic 
viruses such as Sulfolobus islandicus rod shaped virus 2 (isolated from pH 2.5 acidic springs in 
Iceland) (Steinmetz et al., 2008). 
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The ability to modify specific sites on the surface of VNPs allows them to be used as scaffolds 
that can be functionalized with diverse reagents including peptides, nucleic acids, metal ions, 
organic molecules and florescent dyes. Amine groups on lysine side chains are often used as 
attachment sites, e.g. for polymers (Comellas-Aragones et al., 2009), fluorescent dyes (Steinmetz 
et al., 2010; Barnhill et al., 2007b) and redox-active complexes (Steinmetz et al., 2006a). There 
are five accessible lysine side chains per VP2 monomer, and with each SVP comprising 60 VP2 
subunits this equates to 300 accessible amine groups per particle. Carboxyl groups on the side 
chains of acidic residues can also be used as attachment sides following activation, if the 
conjugation target contains a primary amine group (Barnhill et al., 2007b; Steinmetz et al., 
2006b; Schlick et al., 2005). Each VP2 monomer has four Glu residues and nine Asp residues 
with an accessible carboxyl group, making 13 accessible sites per monomer and potentially 780 
per SVP. TEM analysis confirmed successful biotinylation; several antibodies were bound per 
IBD-SVP (figure III.35), indicating multivalent display of biotin moieties. The immuno-staining 
and TEM method, however, can not be regarded as a quantitative method; steric hindrance effects 
prevent large numbers of gold-labeled anti-biotin antibodies binding to the SVP surface 
(Steinmetz et al., 2008). To gain quantitative data on biotin labeling efficiency, the number of 
addressable amine sites per SVP was determined by the direct coupling of fluorescent (Alexa 
fluor 488) N-hydroxysuccinimide (NHS) esters. This showed that each SVP carried an average of 
60 dye molecules, indicating that only one amine side chain can be occupied on each monomer, 
perhaps due to steric hindrance of the four remaining lysine residues once the first dye molecule 
is installed.  
A small amount of inter-particle aggregation observed during carboxylate conjugation, probably 
reflecting the formation of peptide bonds between the activated carboxyl groups on one particle 
and exposed amine groups on the lysine side chains of other particles (data not shown), but 
overall the integrity of the particles was maintained with both conjugation methods. It has 
previously been suggested that the sensitivity of IBD-SVP detection by spectrophotometry 
(A280) is too low for SEC (Cheng et al., 2001b). It is shown that A215 measurements are more 
useful for this purpose and show adequate sensitivity. 
IV.6 Conclusion and future prospects 
Although the IBD-VP2 expression level in tobacco is high enough for application as oral vaccine, 
assembly into SVPs did not occur in the plant system. As an alternative, Pichia pastoris has 
many of the advantages of higher eukaryotic expression systems such as protein processing, 
protein folding, and posttranslational modification, while being as easy to manipulate as E. coli or 
Saccharomyces cerevisiae. It is faster, easier, and less expensive to use than other eukaryotic 
expression systems and generally gives higher expression levels (10- to 100-fold higher 
heterologous protein expression levels compared to S. cerevisiae). In addition, lower degree of 
immunogenic N-glycosylation compared to other yeast expression systems and very little O-
linked glycosylation make Pichia very useful as a protein expression system especially for 
vaccine production. The high production levels of IBD-VP2 in Pichia cells as well as non-
toxicity of the expression system and economical optimized protein purification make Pichia as 
profitable IBDV subunit vaccine production. The generated vaccine either in the form of cell-
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capsulated or purified IBD-SVPcyto enhanced the IBDV-specific antibody response and provides 
protection against a heterologous classical IBDV strain. Further research is needed to optimize 
the vaccine dose in combination with a proper adjuvant for use against very virulent strains such 
as the homologous strain IR01.    
 
The Pichia-produced IBD-SVP were also shown to be stable in 20% (v/v) solutions of DMSO or 
ethanol and also resistant to heat and pH extremes. This means IBD-SVPcyto can be used under 
the harsh environmental conditions required for bioconjugation, mineralization and other 
modifications. It was confirmed that IBD-SVPcyto could be functionalized on exposed amine and 
carboxyl groups by decorating the particles with biotin. The combination of stability, 
accessibility and amenability for large-scale production in yeast makes IBD-SVPcyto an ideal 
platform for diverse applications in nanobiotechnology. The multivalent display of fluorescent 
molecules at discrete sites on the VNP surface provides a high density of such traceable 
molecules without fluorescent quenching, increasing the sensitivity of detection. Combined with 
the possibility of dual labeling, IBD-SVPcyto could also be developed as a multifunctional 
platform, e.g. carrying both targeting ligands and fluorescent tracers for bioimaging applications 
(Brunel et al., 2010; Lockney et al., 2011). IBD-SVPcyto could therefore be developed as a novel 
platform for medical imaging and/or targeted drug delivery. Although no in vivo studies have yet 
been performed, on the basis of the presented in vitro results it is speculated that IBD-SVPcyto 
could be recruited as a nanobiotechnology platform. 
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V Summary  
Infectious bursal disease virus is a causative agent of infectious bursal disease in young chickens 
causing significant losses to the poultry industry worldwide. In this study the gene encoding the 
viral capsid protein (VP2, IR01 strain) with self-assembly capability was cloned into a plant 
expression pTRAkc vector and expressed in tobacco. Recombinant protein levels in tobacco 
leaves reached to 260 µg/g and 160 µg/g fresh leaf weights (FLW) in apoplastic and cytosolic 
protein accumulation, respectively. These numbers were 20-30 µg/g and 10-20 µg/g FLW in 
stable transformation while the assembly level did not reach higher than trimers. Nonetheless the 
recombinant VP2 protein was highly immunogenic in mice. Alternatively, VP2 was cloned into 
the yeast expression vector, pPICZ_B, and produced in Pichia pastoris resulting in the formation 
of ~23 nm homomeric subviral particles (SVPs) composed of the VP2 protein. The recombinant 
protein levels reached 76 mg/l culture and the final yield after purification was 38 mg/l. Anti-
IBDV antibodies were detected in chickens vaccinated by injection of purified IBD-SVPcyto or 
by feeding either purified IBD-SVPcyto or recombinant Pichia expressing IBD-VP2cyto. 
Challenge of vaccinated chickens with the heterologous IBDV strain (MB3) and subsequent 
analysis of antibody response, mortality, virus clearance, bursal damage score and bursa weight 
to body weight (BF/BW) ratio demonstrated that 20 µg of purified IBD-SVPcyto intramuscularly 
administered confers full protection, complete viral clearance and thoroughly prevents bursal 
damage and atrophy whereas the mortality rate in non-vaccinated and mock-immunized groups 
was 60% with a high bursal damage score and atrophy. Commercial vaccine also conferred full 
protection and viral clearance while partial bursal atrophy was inevitable. Orally administered 
purified 500 µg IBD-SVPcyto with and without adjuvant conferred 100% protection, however, 
only in companion with adjuvant showed 60% viral clearance and in the absence of the adjuvant 
showed no viral clearance. In both cases, moderate bursal damage was observed whereas in 
combination with adjuvant provided BF/BW ratio similar to live-attenuated vaccine and 
intramuscularly administered 20 µg of purified IBD-SVPcyto.    
Administration of 250 mg of Pichia-capsulated IBD-SVPcyto with and without adjuvant resulted 
in 100% and 60% protection, respectively. Moderate bursal damage and moderate atrophy was 
present in both groups. In the groups that received 25 mg of Pichia-capsulated IBD-SVPcyto and 
purified 50 µg IBD-SVPcyto, the protection rate was 90-100% and 40-60%, respectively. In the 
first group moderate bursal lesions and severe atrophy and in the latter groups severe bursal 
lesions and severe atrophy was observed. Monitoring the weight of chickens as a health index 
showed no interruption of vaccination in growth rate.  
This study demonstrates the ability of Pichia-produced IBD-SVPcyto to induce specific immune 
response against IBDV either in oral or parenteral administration. The ability of orally 
administered vaccine in induction of protective local as well as systemic immune response is 
demonstrated.  
 
In the second part of this study, the potential application of Pichia-produced IBD-SVPcyto as a 
novel nano-platform was investigated. The purified particles were able to tolerate organic 
solvents up to 20% concentration (ethanol or dimethylsulfoxide); they resisted temperatures up to 
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65 ˚C and remained stable over a wide pH range (2.5–9.0). Bioconjugation to the amine groups of 
lysine residues and to the carboxyl groups of aspartic and glutamic acid residues were achieved, 
allowing the functionalization of IBD-SVPcyto with biotin. The accessibility of surface amine 
groups was measured using Alexa Fluor 488 N-hydroxysuccinimide (NHS) ester, an amine-
selective fluorescent dye, revealing that approximately 60 dye molecules were attached to the 
surface of each particle. IBD-SVPcyto can therefore be exploited as a robust and versatile 
nanoscaffold to display diverse functional ligands. 
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VI Zusammenfassung  
 
Das Infectious bursal disease virus (IBDV) ist der Auslöser der infektiösen Bursitis bei jungen 
Hühnern. IBDV führt weltweit zu beträchtlichen ökonomischen Schäden in der 
Geflügelindustrie. Im Rahmen dieser Arbeit wurde die cDNA für das selbst-assemblierende 
Capsid-Protein (VP2, IBDV Stamm IR01) in den Pflanzenexpressionsvektor pTRAkc kloniert 
und in Tabak exprimiert. Bei transienter Expression wurden für das rekombinante Protein eine 
Akkumulation von 260 µg/g Frischgewicht im Apoplasten und 160 µg/g Frischgewicht im 
Cytosol von Tabakblattgewebezellen beobachtet. Analog wurden in stabil transformierten 
Pflanzenlinien 20-30 µg/g bzw. 10-20 µg/g festgestellt. Das VP2 lag dabei in trimerisierter und 
nicht wie erhofft in größeren Aggregationsformen vor. Trotzdem war das rekombinante VP2 
Protein hoch-immunogen in Mäusen. Alternativ wurde VP2 in den Hefeexpressionvektor 
pPICZ_B kloniert und in Pichia pastoris produziert. Bei Expression in Hefezellen konnte die 
Assemblierung von VP2 Monomeren in ~23 nm subvirale Partikel (SVPs) beobachtet werden. 
Dabei wurden für das rekombinante Protein eine Produktivität von 76 mg pro Liter 
Kultuvolumen erreicht und die finale Ausbeute nach Reinigung lag bei 38 mg/l.  
Nach parenteraler und oraler Vakzinierung von Hühnern mit gereinigtem oder Pichia-
verkapseltem IBD-SVPcyto konnten IBDV-spezifische Antikörperantworten nachgewiesen 
werden. Die vakzinierten Tiere wurden mit dem heterologen IBDV-Stamm MB3 infiziert und 
beobachtet. Anschließend wurden Antikörperantworten, Mortalität, Virus Clearance, Bursale 
Läsionen und Atrophien sowie das Verhältniss Bursagewicht zu Körpergewicht gemessen und 
analysiert. Während für intramuskulär verabreichtes, gereinigtes IBD-SVPcyto (20 µg) 
vollständige Protektion und Virus Clearance sowie die komplette Abwesenheit von 
Bursaschäden beobachtet wurde, waren bei nicht- oder Mock-immunisierten Tieren eine hohe 
Mortalitäts-Rate von 60% sowie starke bursale Läsionen und Atrophien zu verzeichnen. Ein als 
Kontrolle verwendetes kommerzielles Vakzin erreichte ebenfalls vollständige Protektion und 
Virus Clearance. Auch hier wurden bursale Atrophien beobachtet. Orale Administration von 
gereinigtem IBD-SVPcyto (500 µg) mit und ohne Adjuvant induzierte eine 100%ige Protektion, 
wobei nur in Kombination mit dem Adjuvant eine Virus Clearance von 60% beobachtet werden 
konnte. Bursale Läsionen konnten in beiden Fällen beobachtet werden. Die Administration von 
250 mg Pichia-verkapseltem IBD-SVPcyto mit und ohne Adjuvant resultierte in 100%- bzw. 
60%iger Protektion, wobei in beiden Gruppen nur moderate bursale Läsionen oder Atrophien 
festgestellt wurden. In den Gruppen, denen entweder 25 mg Pichia-verkapseltes IBD-SVPcyto 
oder 50 µg gereinigtes IBD-SVPcyto verabreicht wurde, konnte ein Schutz von 90-100% sowie 
40-60% beobachtet werden. Dabei waren in der ersten Gruppe moderate bursale Läsionen und 
starke Atrophie und in der zweiten Gruppe starke bursale Läsionen und Atrophien zu verzeichen. 
Über Monitoring und Vergleich der Versuchstier-Lebendgewichte über den Verlauf der Studie 
wurde außerdem demonstriert, dass es keinen Einfluss der Immunisierungen auf das Wachstum 
der Tiere gab. 
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In dieser Arbeit konnte erfolgreich gezeigt werden, dass in Pichia produzierte subvirale IBDV 
Partikel sowohl bei parenteraler als auch bei oraler Verabreichung protektive, lokale und 
systemische Immunantworten gegen IBDV auslösen können. 
 
Im zweiten Teil dieser Arbeit wurde die Eignung von Pichia-produzierten subviralen IBDV 
Partikeln (IBDV-SVPs) als neuartige Nano-Platform untersucht. Gereinigte IBDV-SVPs waren 
in bis zu 20%tigen Lösungen der organischen Lösungsmittel Ethanol und Dimethylsulfoxid stabil 
und wiesen eine hohen Temperatur- und pH-Stabilität (65˚C, pH 2.5-9.0) auf. Eine 
Funktionalisierung konnte am Beispiel der Biokonjugation von Biotin an auf der Oberfläche der 
IBDV-SVPs liegende Aminogruppen (Lysin) oder Carboxylgruppen (Aspartat und Glutamat) 
demonstriert werden. Über die Kopplung von Alexa Fluor 488 N-hydroxysuccinimid (NHS) 
Ester konnte die hohe Zahl von adressierbaren Aminogruppen (>60) pro IBDV-SVPs quantitativ 
bestätigt werden. Mit diesen Studien konnte gezeigt werden, dass IBDV-SVPs robuste und 
vielseitig funktionalisierbare Nanopartikel mit großem Entwicklungspotenzial darstellen. 
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VIII Appendices 
VIII.1 Abbreviations 
 
2, 4-D 2, 4-Dichlorophenoxyacetic acid 
Ab Antibody 
ABTS 2,2’-Azino-di-(3-ethylbenzthiazoline sulphonate) 
Amp Ampicillin 
AP Alkaline phosphatase 
BCIP 5-bromo-4-chloro-3-indolyl phosphate 
bp Baise pair 
BSA Bovine serum albumin 
CaCl2 Calcium chloride 
CaMV Cauliflower mosaic virus 
Carb Carbenicillin 
cDNA Complementary DNA 
cfu Colony-forming units 
CTAB Cetyltrimethylammonium bromide 
Cys Cysteine 
cv. Cultivar 
DCs 
DEPC 
Dendritic cells 
Diethylpyrocarbonate 
DLS 
DMSO 
Dynamic light scattering 
Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleoside triphosphate 
DTT 1,4-dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylenediamine tetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
EtOH Ethanol 
Fab Fragment antigen binding 
FAE 
Fc 
follicle-associated epithelium 
Fragment crystalline 
GALT gut-associated lymphoid tissue 
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GMO 
g 
Genetically modified organism 
Relative centrifugal force (RCF) 
GSM (Agrobacteria) glycerol stock media 
h Hour(s) 
HCl 
His (H) 
H6 
Ig 
IMAC 
kbp 
kDa 
KH2PO4 
Km 
LiAc 
M 
MES 
min 
MgSO4 
MnCl2 
mRNA 
ms 
NaAc 
NaCl 
NAGE 
NaH2PO4 
Na2HPO4 
NHS 
OD 
o/n 
ORF 
Ori 
PBS 
PBST 
PCR 
pH 
pIgR 
PVDF 
Rif 
RIG-I 
RNA 
rpm 
Hydrochloride 
Histidine 
His-tag 
Immunoglobulin 
Immunized metal ion affinity chromatography 
Kilobase pair 
Kilodalton 
Potassium dihydrogen phosphate 
Kanamycin 
Lithium acetate 
Molarity 
2-(N-morpholino)-ethanesulphonic acid 
Minute(s) 
Magnesium sulfate 
Manganese(II) chloride 
Messenger RNA 
Millisecond 
Sodium acetate 
Sodium chloride 
Native gel electrophoresis 
Sodium dihydrogen phosphate 
Disodium monohydrogen phosphate 
N-hydroxysuccinimide 
Optical density 
Overnight 
Open reading frame 
Origin of replication 
Phosphate buffered saline 
0.05%  (v/v) Tween-20 in PBS 
Polymerase chain reaction 
A negative logarithmic measure of hydrogen ion concentration 
Polymeric Ig receptor 
Polyvinylidene fluoride 
Rifampicin 
retinoic acid-inducible gene I 
Ribonucleic acid 
Revolutions per minute 
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RT 
SDS-PAGE 
Sh ble 
SVP 
TBE 
TEM 
TEMED 
TGF-β 
TLR 
UTR 
V 
v/v 
VLP 
w/v 
w/w 
YNB 
 
Room temperature 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
Streptoalloteichus hindustanus bleomycin resistance gene 
Subviral particle 
Tris- buffered saline electrophoresis buffer 
Transmission electron microscopy 
N,N,N′, N′-tetramethylene-ethylenediamine 
Transforming growth factor-beta 
Toll-like receptor 
untranslated region 
Volt 
Volume per volume 
Virus-like particle 
Weight per volume 
Weight per volume 
Yeast nitrogen base 
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VIII.2 Schematic presentation of PCR and cloning procedure for 
generation of tobacco expression vectors  
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Figure VII.1 Schematic diagrams describing the cloning strategy for IBD-VP2 constructs and the 
final generated tobacco expression vectors used in this thesis (not drawn to scale). 
Cloning strategy description: The cDNA of the mature IBD-VP2 sequence (strain IR01, GenBank 
accession number: AY704912) sequence fused to C-terminal His-tag were amplified using the primers 
VP2-forward and VP2-reverse-withHis6 containing BspHI and XbaI restriction recognition sites, 
respectively. Following direct cloning into NcoI and XbaI restriction sites of (A) the vector pTRAkc-
GFPapo containing the sequence for the leader sequence LPH of the murine antibody 24 heavy chain 
(Vaquero et al., 1999) or into (B) the vector pTRAkc-rbcs-cTP containing the Rbcs encoding for the 
chloroplast targeting signal peptide of Ribulose-1,5-bisphosphate carboxylase oxygenase (RuBisCO) 
small subunit from Solanum resulting in generation of the final expression vectors pTRAkc-VP2apo and 
pTRAkc-VP2chlo, respectively. (C) SOE (splicing by overlap extension) PCR was exploited using the 
CHS-elongation5’ and VP2-reverse-withHis6 primers for elongation and Solulin-for5’UT and VP2-
reverse-withHis6 for amplification of the chalcone synthase 5’ UT from Petroselinum fused to the VP2 
encoding sequence. The 1.4 kb resultant construct (CHS-VP2) was double digested with EcoRI and XbaI 
and cloned into the corresponding sites in the pTRAkc-GFPapo vector to generate pTRAkc-VP2cyto. (D) 
The His-tag was fused to the N-terminal end of VP2 using SOE-PCR using IBD-VP2 cDNA as template 
and CHS-elongation5’-withHis6 and VP2-reverse for elongation, and Solulin-for5’UT and VP2-reverse 
for amplification. The cytochrome b5 membrane anchor containing fragment (CytB5-MA) was amplified 
by PCR using CytB5 cDNA as template and CytB5memAnch.-for and vIL-10_XbaI-bw primer sets. 
Eventually, the two generated fragments were fused together using the generated overlapping region in a 
SOE-PCR and the joint sequence was amplified using the primers Solulin-for5’UT and vIL-10_XbaI-bw. 
Finally, the generated construct was double digested with EcoRI and XbaI and subsequently cloned into 
the corresponding sites of the pTRAkc-GFPapo vector. The final construct was named pTRAkc-VP2mem. 
Vector maps description: LB and RB are left and right border of the T-DNA; Pnos and pAnos: promoter 
and terminator of the nopaline synthase gene, respectively; nptII: coding sequence of the neomycin 
phosphotransferase gene; bla: coding sequence of the beta-lactamase gene; SAR: scaffold attachment 
region; P35S and pA35S: 35S promoter with doubled enhancer and terminator of the Cauliflower mosaic 
virus (CaMV) 35S gene, respectively; CHS5’UT: chalcone synthase 5’ untranslated region from 
Petroselinum; RK2 ori and ColE1 ori: plasmid origin of replication for Agrobacterium and E. coli 
respectively; LPH; plant codon optimized leader sequence derived from the murine heavy chain of the 
TMV-specific mAb24; rbcs-cTP: Rubisco small subunit chloroplast targeting signal; CytB5: cytochrome 
b5 membrane anchor; IBD-VP2: Codon sequence of the Infectious bursal disease virus VP2 corresponding 
to amino acids 1-441. 
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VIII.3 Schematic presentation of PCR and cloning procedure for 
generation of Pichia expression vectors 
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Figure VII.2 Schematic diagrams describing the cloning strategy for IBD-VP2 constructs and the 
final generated Pichia expression vectors used in this thesis (not drawn to scale).  
Cloning strategy description: IBD-VP2 encoding fragments were excised from the plant expression 
vectors pTRAkc-VP2apo and pTRAkc-VP2cyto using EcoRI and XbaI and cloned into the same 
restriction digestion sites of pPICZ_B, Pichia expression vector, resulting in the generation of pPICZ_B-
VP2sec and pPICZ_B-VP2cyto, respectively. As a result, VP2 fused to the C-terminal His-tag, was 
expressed under the control of the methanol-inducible alcohol oxidase 1 (AOX1) promoter and terminator, 
downstream of the CHS5’UT sequence with (pPICZ_B-VP2sec) and without (pPICZ_B-VP2cyto) the 
leader sequence LPH of the murine antibody 24 heavy chain (Vaquero et al., 1999). 
Vector maps description: 5’ AOX1 and AOX TT: alcohol oxidase 1 promoter und terminator, 
respectively; CHS5’UT: chalcone synthase 5’ untranslated region from Petroselinum; LPH; leader peptide 
of heavy chain (Murin originated); IBD-VP2: Codon sequence of Infectious bursal disease virus VP2 
corresponding to amino acids 1-441 (mature VP2). PTEF1: transcription elongation factor 1 gene 
promoter from S. cerevisiae that drives expression of the Sh ble gene in Pichia, conferring Zeocin 
resistance; PEM7: synthetic synthetic prokaryotic promoter that drives expression of Sh ble in E. coli, 
conferring Zeocin resistance; Sh ble: zeocin gene resistance; Cyc1 TT: cyc1 transcription termination; 
pUC origin: plasmid origin of replication for E. coli.    
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VIII.4 Protein sequence alignment of IBD-VP2 
 
IBD-VP2_AF109154      MTNLTDQTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFF 60 
IBD-VP2_AY704912      MTNLQDQTQQIVPFIRSLLMPTTGPASIPDDTLEKHTLRSETSTYNLTVGDTGSGLIVFF 60 
                      **** ******************************************************* 
 
IBD-VP2_AF109154      PGFPGSIVGAHYTLQSNGNYKFDQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYAL 120 
IBD-VP2_AY704912      PGFPGSIVGAHYTLQSNGNYKFDQMLLTAQNLPASYNYCRLVSRSLTVRSSTLPGGVYAL 120 
                      ************************************************************ 
 
IBD-VP2_AF109154      NGTINAVTFQGSLSDLTDVSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLGYVRL 180 
IBD-VP2_AY704912      NGTINAVTFQGSLSELTDVSYNGLMSATANINDKIGNVLVGEGVTVLSLPTSYDLGYVRL 180 
                      ************** ********************************************* 
 
IBD-VP2_AF109154      GDPIPAIGLDPKMVATCDSSDRPRVYTITAADDYQFSSQYQSGGVTITLFSANIDAITSL 240 
IBD-VP2_AY704912      GDPIPAIGLDPKMVATCDSSDRPRVYTITAADDYQFSSQYQAGGVTITLFSANIDAITSL 240 
                      ***************************************** ****************** 
 
IBD-VP2_AF109154      SIGGELVFHTSVHGLALDATIYLIGFDGTTVITRAVASDNGLTTGIDNLMPFNLVIPTNE 300 
IBD-VP2_AY704912      SIGGELVFQTSVQGLILGATIYLIGFDGTAVITRAVAADNGLTAGTDNLMPFNIVVPTSE 300 
                      ******** *** ** * *********** ******* ***** * ******* * ** * 
 
IBD-VP2_AF109154      ITQPITSIKLEIVTSKSGGQAGDQMSWSAMWSLAVTIHGGNYPGALRPVTLVAYERVATG 360 
IBD-VP2_AY704912      ITQPITSIKLEIVTSKSGGQAGDQMSWSASGSLAVTIHGGNYPGALRPVTLVAYERVAKG 360 
                      *****************************  *************************** * 
 
IBD-VP2_AF109154      SVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERERLGIKTVWPTREYT 420 
IBD-VP2_AY704912      SVVTVAGVSNFELIPNPELAKNLVTEYGRFDPGAMNYTKLILSERDRLGIKTVWPTREYT 420 
                      ********************************************* ************** 
 
IBD-VP2_AF109154      DFREYFMEVADLNSPLKIAGA 441 
IBD-VP2_AY704912      DFREYFMEVADLNSPLKIAGA 441 
                      ********************* 
 
Figure VII.3  Protein sequence alignment of IBD-VP2 sequence used in this thesis (AY704912) and 
the one used by Doong et al. (2007) (AF109154). The alignment was performed using Clustal 2.1 
algorithm. “*” = the residues in that column are identical in two sequences in the alignment. His249 and 
His253 (in red) which were replaced by Q in AY704912, facilitate purification by IMAC for generated 
IBD-SVP.  
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VIII.5 Monitoring of IBDV clinical signs among the vaccinated chickens 
after viral challenge.  
Table VII.1 Observations and the intensity of the clinical signs of infectious bursal disease were recorded 
during the time-course before euthanization. In case of no specific observation, the box was left empty. 
   Group Vaccine Observation at the first dpc 
1 250 mg Pichia yVP2cyto   
2 250 mg Pichia yVP2cyto+ Oral adjuvant 
 3 25 mg Pichia yVP2cyto 
 4 25 mg Pichia yVP2cyto+ Oral adjuvant 
 
5 50 µg IBD-SVPcyto few chickens with greyish-greenish 
but well formed feces 
6 50 µg IBD-SVPcyto+ Oral adjuvant  few chickens with greyish-greenish 
but well formed feces 
7 500 µg IBD-SVPcyto 
 8 500 µg IBD-SVPcyto+ Oral adjuvant 
 9 250 mg lyophilized inactivated wild type Pichia  
 10 20 µg of Purified IBD-SVPcyto+ Adjuvant 100 (i.m) 
 11 Challenge control 
 12 AviPro Gumboro vac.  (Oral control) 
 13 Vaccine control (without challenge)   
     
Group Observations at the second dpc 
 1 many chickens with slightly reduced clinical signs  
2 many chickens with slightly reduced clinical signs  
3 many chickens with slightly reduced clinical signs   
4 many chickens with slightly reduced clinical signs  
5 many chickens with slightly reduced clinical signs  
6 many chickens with slightly reduced clinical signs  
7 many chickens with slightly reduced clinical signs  
8 many chickens with slightly reduced clinical signs  
9 
many chickens with moderately reduced clinical signs, 1 chicken with severely 
reduced clinical signs  
10   
11 many chickens with moderately reduced clinical signs  
12  
 13    
 
 
 Group Observations at the third dpc 
1 all chickens with slight to moderate reduced clinical signs 
2 all chickens with slight to moderate reduced clinical signs 
3 all chickens with slight to moderate reduced clinical signs 
4 all chickens with slight to moderate reduced clinical signs 
5 2 chickens died, some chickens with severely reduced clinical signs 
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6 1 chicken died, some chickens with severely reduced clinical signs 
7 
 8 
 
9 
3 chickens died, 1 chicken with moderate to severe and 1 chicken with slightly reduced clinical 
condition 
10 
 
11 
1 chicken died, 2 chickens with moderately to severely and 1 chicken with slightly reduced 
clinical condition 
12 
 13   
 
Group Observations at the forth dpc 
1 2 chickens died 
2 1 chicken  with slightly reduced clinical condition 
3 
 4 1 chicken died 
5 1 chicken  with slightly and 1 chicken with severely reduced clinical condition 
6 2 chickens died 
7 1 chicken with slightly reduced clinical condition 
8 1 chicken with slightly reduced clinical condition 
9 1 chicken with slightly reduced clinical condition 
10 
 
11 
1 chicken died, 1 chicken  with  moderately and 1 chicken with slightly reduced clinical 
condition  
12 
 13   
  
Group Observations at the fifth dpc Observations at the sixth dpc 
1     
2 
  3 
 
1 chicken with reduced clinical condition 
4 
 
1 chicken with reduced clinical condition 
5 
 
1 chicken with reduced clinical condition 
6 
 
1 chicken with reduced clinical condition 
7 
  8 
  9 
  10 
  11 1 chicken died , 1 chicken with slightly reduced 
clinical condition 
1 chicken with slightly reduced clinical 
condition 
12 
  13     
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VIII.6 Serological VP2 antibody titers 
Table VII.2 Serological VP2 antibody titer in immunized chickens after challenge with IBDV measured 
by the IDEXX IBD-XR kit, protection status, virus detection in the bursa, histopathological damage 
evaluation and the morphological observation of the bursa fabricious damage score extracted from 
chickens 7 dpc. Chickens with IDEXX index value over 396 are resistant to IBD (Rong et al., 2007). D= 
detected, ND= not detected. (-): no specific observation. 
 
G
ro
up
 
B
ir
d 
N
o.
 
anti-VP2 
titer 
measured 
by 
IDEXX 
IBD-XR 
Ab test 
kit 
Protection 
Detection 
of IBDV 
in the 
bursa 
Bursa 
lesion 
score 
Bursa damage 
1 1 8488   D 1 - 
1 2 10132 
 
D 2 - 
1 3 18 died D 2 
mildly swollen, edema around bursa, 
hemorrhages in bursa 
1 4 2400 
 
ND 1 - 
1 5 0 died D 2 mildly swollen 
2 6 2079 
 
D 1 - 
2 7 5866 
 
D 1 - 
2 8 8782 
 
D 1 - 
2 9 2166 
 
D 1 - 
2 10 2327 
 
D 1 - 
3 11 11480 
 
D 1 - 
3 12 2327 
 
D 1 - 
3 13 9669 
 
D 2 accumulated pus 
3 14 5408 
 
D 1 - 
3 15 13078 
 
D 2 accumulated pus, hemorrhages 
4 16 6954 
 
D 1 - 
4 17 201 died D 2 mildly swollen 
4 18 10147 
 
D 1 - 
4 19 4495 
 
ND 1 - 
4 20 11034 
 
D 1 - 
5 21 57 died D 3 
severely swollen, edema around bursa, cherry 
red 
5 22 448 
 
ND 0 - 
5 23 7985 
 
D 3 - 
5 24 11226 
 
D 2 - 
5 25 127 died D 3 severely swollen, cherry red 
6 26 13905 
 
D 2 - 
6 27 252 died D 2 
moderately swollen, edema around bursa, 
hemorrhages in bursa 
6 28 0 died D 3 moderately swollen, cherry red 
6 29 8342 
 
D 1 - 
6 30 0 died D 3 moderately swollen, hemorrhages in bursa 
7 31 7434 
 
D 1 - 
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G
ro
up
 
B
ir
d 
N
o.
 
anti-VP2 
titer 
measured 
by 
IDEXX 
IBD-XR 
Ab test 
kit 
Protection 
Detection 
of IBDV 
in the 
bursa 
Bursa 
lesion 
score 
Bursa damage 
7 32 10704 
 
D 2 - 
7 33 7400 
 
D 2 accumulated pus 
7 34 7842 
 
D 1 - 
7 35 4105 
 
D 1 - 
8 36 8953 
 
D 1 - 
8 37 1549 
 
ND 0 - 
8 38 9298 
 
D 3 accumulated pus, hemorrhages 
8 39 6827 
 
ND 1 - 
8 40 6657 
 
ND 0 - 
9 41 253 died D 0 edema around bursa 
9 42 0 died D 3 moderately swollen, cherry red 
9 43 6776 
 
ND 1 - 
9 44 13204 
 
D 1 - 
9 45 0 died D 3 severely swollen, cherry red 
10 46 2246 
 
ND 0 - 
10 47 1875 
 
ND 0 - 
10 48 1533 
 
ND 0 - 
10 49 681 
 
ND 0 - 
10 50 4895 
 
ND 0 - 
11 51 172 died D 3 - 
11 52 9914 
 
ND 1 - 
11 53 0 died D 3 mildly swollen 
11 54 66 died D 3 mildly swollen, hemorrhages 
11 55 11250 
 
D 1 - 
12 56 4522 
 
ND 0 - 
12 57 1207 
 
ND 0 - 
12 58 4883 
 
ND 0 - 
12 59 2587 
 
ND 0 - 
12 60 10657 
 
ND 0 - 
13 61 
  
ND 0 - 
13 62 
  
ND 0 - 
13 63 
  
ND 0 - 
13 64 
  
ND 0 - 
13 65     ND 0 - 
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VIII.7 Figure legends 
 
Figure I.1  The schematic feature of mucosal immune system in the gut. 
Figure I.2  Schematic configuration of IBDV and its genome. 
Figure I.3  Three VP2 proteins assemble together and form a trimer, the structural unit of the virus. 
Figure I.4  Hydrophobicity plot of IBD-VP2 provided by CLC Main workbench 6.5 using Kyte-
Doolittle hydrophobicity scale. 
Figure I.5  (A) Protein structure of VP2; (B) The trimeric VP2 structure from the top view 
Figure I.6  Schematic overview of the work presented in this dissertation. 
Figure II.1  Weight development in specific pathogen free (SPF) chickens.  
Figure III.1  Schematic drawing of the generated pTRAkc plant expression vectors for IBD-VP2 
expression in tobacco. 
Figure III.2  Comparison of VP2 accumulation in various cell compartments using immunoblot. 
Figure III.3  Determination of VP2 content accumulated in different cell compartments of transiently 
transformed N. tabacum cv. Petite Havana SR1 leaves. 
Figure III.4  SDS-PAGE analysis of VP2 purified by IMAC form transiently transformed tobacco 
leaves using pTRAkc-VP2apo and pTRAkc-VP2cyto. 
Figure III.5  SDS-PAGE analysis to check the VP2 purity.  
Figure III.6  Prediction of potential N-glycosylation sites of IBD-VP2 protein predicted by the 
NetNGlyc 1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc/).  
Figure III.7  SDS-PAGE for glycosylation analysis of the tobacco-produced VP2 followed by (A) 
Coomassie brilliant blue staining and (B) glycan detection by immunoblot.  
Figure III.8  SDS-PAGE analysis of the deglycosylated tobacco-produced affinity-purified VP2apo 
using peptide N-Glycosidase F (PGNase F). 
Figure III.9  Liquid chromatography-mass spectrometry (LC-MS) of the three N-glycosylation sites of 
plant-produced and affinity-purified VP2apo. 
Figure III.10  Chromatographic profile obtained by separation of purified (III.1.4) VP2cyto (red) and 
VP2apo (blue) in two separate runs using a Superdex 200 column.  
Figure III.11  ELISA analysis for the VP2 content of the tobacco-produced VP2cyto separated by 
sucrose gradient ultracentrifuge (10-60%).  
Figure III.12 Chromatographic profile obtained by separation of VP2cyto before (blue) and after 
incubation with urea (brown) in two separate runs using a Superdex 200 column.  
Figure III.13  Schematic diagram shows mice immunization and blood sampling plan. 
Figure III.14  Determination of polyclonal IgG antibody titers in the sera of five mice immunized with 
(A) VP2apo or (B) VP2cyto, respectively, by indirect ELISA.  
Figure III.15  Schematic presentation of the final yeast pPICZ_B based expression vectors. 
Figure III.16  Dotblot analyses for screening of yVP2sec or yVP2cyto in producing P. pastoris cultures.  
Figure III.17  Time-course study for production level evaluation of Pichia-produced (A) yVP2sec and 
(B) yVP2cyto accumulated in the medium and inside the cell, respectively. 
Figure III.18  SDS-PAGE analysis of yVP2sec and yVP2cyto obtained from selected Pichia colonies 
(III.2.2) after 96 h expression induction, followed by (A and C) Coomassie brilliant blue 
staining and (B and D) immunoblot.  
Figure III.19  First step purification of yVP2cyto using pH-shift from 6 to 4.  
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Figure III.20 Separation of Pichia-produced IBD-SVPcyto from not-fully assembled VP2 using size 
exclusion chromatography and further electron microscopy studies. 
Figure  VIII.21  Analyses the purity of the purified yVP2.  
Figure III.22  Lectin blot analysis of yVP2 produced in Pichia.  
Figure III.23  Analysis of deglycosylated VP2 using peptide N-glycosidase F (PGNase F) and lection 
blot. 
Figure III.24  Liquid chromatography-mass spectrometry (LC-MS) of the three N-glycosylation sites of 
Pichia-produced and affinity-purified yVP2sec-m. 
Figure III.25  Analysis of stability and integrity for IBD-SVPcyto after Pichia cell inactivation using 
SDS-PAGE and SEC.  
Figure III.26  Immunization of the chickens randomly allocated between 13 immunization groups. 
Figure III.27  Weight of the chickens was monitored as a health index during immunization. 
Figure III.28 Serum IgA and intestinal IgA response in chickens immunized with freeze-dried 
inactivated cell-capsulated and purified IBD-SVPcyto after viral challenge.  
Figure III.29  Immunization of chickens with freeze-dried inactivated cell-capsulated and purified 
IBD-SVPcyto  
Figure III.30  Stability of IBD-SVPcyto in ethanol–water and DMSO–water mixtures determined by 
NAGE (A), A280 spectroscopy (B), DLS (C) and TEM (D).  
Figure III.31 Stability of IBD-SVPcyto at different temperatures determined by NAGE (A), A280 
spectroscopy (B), DLS (C) and TEM (D).  
Figure III.32  Stability of IBD-SVPcyto in different pH environments determined by NAGE (A), A280 
spectroscopy (B), DLS (C) and TEM (D).  
Figure III.33  Structural analysis of IBD-SVPcyto.  
Figure III.34  Labeling of amine groups on the surface of IBD-SVPcyto using biotinamidohexanoic acid 
N-hydroxysuccinimide ester. 
Figure III.35  Biochemical analysis of biotinylated IBD-SVPcyto by western blot (A), SEC (B), TEM 
after amine conjugation (C) and TEM after carboxyl conjugation (D).  
Figure III.36  Labeling carboxyl groups on the surface of IBD-SVP. 
 
Figure VII.1  Schematic diagrams describing the cloning strategy for IBD-VP2 constructs and the final 
generated tobacco expression vectors used in this thesis. 
Figure VII.2  Schematic diagrams describing the cloning strategy for IBD-VP2 constructs and the final 
generated Pichia expression vectors used in this thesis.  
Figure VII.3  Protein sequence alignment of IBD-VP2 sequence used in this thesis (AY704912) and the 
one used by Doong et al. (2007) (AF109154).  
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VIII.8 Tables 
 
Table I.1  Recombinant expression systems that have been used for production of subunit vaccines 
for chickens against IBDV by expression of IBD-VP2. 
Table  VIII.1  Primers used for generation of DNA fragments by PCR.  
Table  VIII.2  SOE-PCR primers for introducing extra DNA fragments into constructs or joining two 
separate constructs. 
Table  VIII.3  Primers used for DNA sequencing. 
Table II.4  Phosphorothioate CpG ODN used as adjuvant in oral immunization of chickens. 
Table  VIII.5  Names, suppliers and genotypes of E. coli strains used throughout the work. 
Table  VIII.6  PCR master mix. 
Table II.7  Experimental design for immunization of chickens. 
Table III.1  Glycan compositions and their ratio in the three N-glycan sites (1, 2 and 3) of plant-
produced and affinity-purified VP2 by liquid chromatography-mass spectrometry (LC-
MS). 
Table III.2  Glycan composition and their ratio at the three N-glycan sites (1, 2 and 3) of purified 
yVP2sec using IMAC form the medium (III.2.3) studied by liquid chromatography-mass 
spectrometry (LC-MS). 
Table III.4  The frequency of IgM, IgY and IDEXX IBD seropositive chickens before and after viral 
challenge and the protection rate.  
Table III.5  The virus clearance ability by the immune system of the immunized birds was evaluated 7 
dpc.  
Table VII.1  Observation and the intensity of the clinical signs of infectious bursal disease were 
recorded during the time-course before euthanization. 
Table V VIII.2  Serological VP2 antibody titer in immunized chickens after challenge with IBDV 
measured by the IDEXX IBD-XR kit, protection status, virus detection in the bursa, 
histopathological damage evaluation and the morphological observation of the bursa 
fabricious damage score extracted from chickens 7 dpc. 
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